SPIRIN A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Aspirin: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83746-5 1. Aspirin-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on aspirin. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON ASPIRIN ..................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Aspirin ........................................................................................ 11 E-Journals: PubMed Central ....................................................................................................... 65 The National Library of Medicine: PubMed ................................................................................ 69 CHAPTER 2. NUTRITION AND ASPIRIN ......................................................................................... 115 Overview.................................................................................................................................... 115 Finding Nutrition Studies on Aspirin....................................................................................... 115 Federal Resources on Nutrition ................................................................................................. 122 Additional Web Resources ......................................................................................................... 123 CHAPTER 3. ALTERNATIVE MEDICINE AND ASPIRIN ................................................................... 129 Overview.................................................................................................................................... 129 National Center for Complementary and Alternative Medicine................................................ 129 Additional Web Resources ......................................................................................................... 139 General References ..................................................................................................................... 153 CHAPTER 4. DISSERTATIONS ON ASPIRIN ..................................................................................... 155 Overview.................................................................................................................................... 155 Dissertations on Aspirin............................................................................................................ 155 Keeping Current ........................................................................................................................ 156 CHAPTER 5. CLINICAL TRIALS AND ASPIRIN ............................................................................... 157 Overview.................................................................................................................................... 157 Recent Trials on Aspirin............................................................................................................ 157 Keeping Current on Clinical Trials ........................................................................................... 161 CHAPTER 6. PATENTS ON ASPIRIN................................................................................................ 163 Overview.................................................................................................................................... 163 Patents on Aspirin ..................................................................................................................... 163 Patent Applications on Aspirin ................................................................................................. 188 Keeping Current ........................................................................................................................ 209 CHAPTER 7. BOOKS ON ASPIRIN ................................................................................................... 211 Overview.................................................................................................................................... 211 Book Summaries: Federal Agencies............................................................................................ 211 Book Summaries: Online Booksellers......................................................................................... 215 The National Library of Medicine Book Index ........................................................................... 218 Chapters on Aspirin................................................................................................................... 220 CHAPTER 8. MULTIMEDIA ON ASPIRIN ........................................................................................ 229 Overview.................................................................................................................................... 229 Bibliography: Multimedia on Aspirin........................................................................................ 229 CHAPTER 9. PERIODICALS AND NEWS ON ASPIRIN ..................................................................... 231 Overview.................................................................................................................................... 231 News Services and Press Releases.............................................................................................. 231 Newsletter Articles .................................................................................................................... 235 Academic Periodicals covering Aspirin ..................................................................................... 239 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 241 Overview.................................................................................................................................... 241 U.S. Pharmacopeia..................................................................................................................... 241 Commercial Databases ............................................................................................................... 244 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 247 Overview.................................................................................................................................... 247 NIH Guidelines.......................................................................................................................... 247
viii Contents
NIH Databases........................................................................................................................... 249 Other Commercial Databases..................................................................................................... 252 The Genome Project and Aspirin ............................................................................................... 252 APPENDIX B. PATIENT RESOURCES ............................................................................................... 257 Overview.................................................................................................................................... 257 Patient Guideline Sources.......................................................................................................... 257 Finding Associations.................................................................................................................. 261 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 263 Overview.................................................................................................................................... 263 Preparation................................................................................................................................. 263 Finding a Local Medical Library................................................................................................ 263 Medical Libraries in the U.S. and Canada ................................................................................. 263 ONLINE GLOSSARIES................................................................................................................ 269 Online Dictionary Directories ................................................................................................... 270 ASPIRIN DICTIONARY .............................................................................................................. 273 INDEX .............................................................................................................................................. 371
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with aspirin is indexed in search engines, such as www.google.com or others, a nonsystematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about aspirin, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to aspirin, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on aspirin. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to aspirin, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on aspirin. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON ASPIRIN Overview In this chapter, we will show you how to locate peer-reviewed references and studies on aspirin.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and aspirin, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “aspirin” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Helicobacter Pylori Infection as a Risk Factor for Gastrointestinal Symptoms in Patients Using Aspirin to Prevent Ishaemic Heart Disease Source: Alimentary Pharmacology and Therapeutics. 15(7): 1055-1059. July 2001. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Aspirin use in the secondary prevention of ischemic heart disease may provoke gastrointestinal (GI) discomfort. This article reports on a study undertaken to register GI symptoms and complications in patients with cardiovascular disease using aspirin and to relate these symptoms to infection with H. pylori. Blood samples were obtained from 398 consecutive patients in the Coronary Care Unit at a hospital in the
4
Aspirin
Netherlands; samples were analyzed for serum antibody levels to H. pylori infection. Questionnaires were sent 2 weeks after discharge to assess GI symptoms. Questionnaires were returned by 314 patients (79 percent). A total of 183 out of 314 patients (46 percent) reported GI symptoms. Of the 238 patients using 80 to 100 milligrams of aspirin daily, 145 (61 percent) recorded GI symptoms. Besides aspirin, the use of calcium antagonists was correlated with GI symptoms. Of the 128 patients using calcium antagonists, 84 (66 percent) reported GI symptoms. The prevalence of GI symptoms in H. pylori positive and negative patients using aspirin was 48 percent and 52 percent respectively. The authors conclude that 2 weeks after discharge, almost 50 percent of the patients with cardiovascular disease experienced GI symptoms, especially patients using aspirin or calcium antagonists. Patients seropositive for H. pylori and using aspirin or calcium antagonists did not have more GI discomfort compared to non infected patients. 2 tables. 16 references. •
Aspirin Use and Counseling About Aspirin Among Patients with Diabetes Source: Diabetes Care. 25(6): 963-970. June 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: Despite being a safe, effective therapy for lowering cardiovascular risk, only 20 percent of patients with diabetes were using aspirin in the early 1990s. This article reports on a study that examined current physician practices and the use of aspirin therapy by individuals with diabetes. A random sample of diabetes patients (almost exclusively male) receiving care in the Department of Veterans Affairs health care system were surveyed during January through March 2000. The association between aspirin counseling, aspirin use, and reported coronary vascular disease (CVD) and classical CVD risk factors were examined. A majority (71 percent) of the respondents reported being counseled about aspirin use, and 66 percent were taking daily aspirin. Individuals with known CVD were more likely to be counseled. The factor most strongly associated with aspirin use was having been counseled about aspirin therapy by a doctor. The authors estimate that for this population, increasing daily aspirin use to 90 percent could prevent an additional 11,000 myocardial infarctions (heart attacks) and potentially save more than 8,000 lives. The authors conclude that it is imperative that clinicians include counseling about aspirin therapy as a care priority for all their patients with diabetes, as this simple intervention may prevent many cardiovascular events and deaths. 1 figure. 2 tables. 34 references.
•
Risk of Upper Gastrointestinal Bleeding in Patients Taking Low-Dose Aspirin for the Prevention of Cardiovascular Diseases Source: Alimentary Pharmacology and Therapeutics. 16(11): 1945-1953. November 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Most patients with vascular-occlusive diseases benefit from low-dose aspirin (75 to 325 milligrams per day). However, they have an increased risk of upper gastrointestinal bleeding (UGIB). This article reports on a study undertaken to analyze the incidence and factors influencing the occurrence of UGIB in patients taking low-dose aspirin for the prevention of cardiovascular diseases outside clinical trials. The authors studied 903 consecutive patients discharged on low-dose aspirin from the Cardiology Department of a general hospital. Data were collected from medical charts and
Studies
5
structured telephone interviews. Of the 903 patients, 41 (4.5 percent) presented with UGIB required hospitalization during follow up (45 months, plus or minus 22 months). The incidence of UGIB was uniform during follow up (1.2 UGIB per 100 patient years). Analyses showed that a history of peptic ulcer or UGIB and aspirin dose was associated with higher risk of UGIB. On the other hand, antisecretory and nitrovasodilator drugs were associated with a decreased risk of UGIB. The authors conclude that cardiovascular patients on long term low-dose aspirin have a stable risk of major UGIB, which is higher than published controlled clinical trials. Antisecretory and nitrovasodilator drugs protect from UGIB, whereas previous peptic ulcer or UGIB and higher doses of aspirin increase the risk. 4 figures. 4 tables. 31 references. •
Aspirin Therapy in Diabetes Source: Diabetes Care. 25(Supplement 1): S78-S79. January 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: People with diabetes have a two to fourfold increase in the risk of dying from the complications of cardiovascular (heart) disease and both men and women are at increased risk. Research studies of men and women with diabetes support the view that low-dose aspirin therapy should be prescribed as a secondary prevention strategy, if no contraindications exist. Substantial evidence suggests that low dose aspirin therapy should also be used as a primary prevention strategy in men and women with diabetes who are at high risk for cardiovascular events. This article presents the American Diabetes Association position statement on aspirin therapy in people with diabetes. Topics include efficacy, safety, dosage, special considerations, and specific clinical recommendations. 4 references.
•
Effect of Aspirin on the Periodontal Parameter Bleeding on Probing Source: Journal of Periodontology. 73(8): 871-876. August 2002. Contact: Available from American Academy of Periodontology. Suite 800, 737 North Michigan Avenue, Chicago, IL 60611-2690. (312) 573-3220. Fax (312) 573-3225. Summary: The absence or presence of bleeding on probing (BOP) is a sign of periodontal health or disease, but the presence of BOP is not an accurate predictor of disease progression. Aspirin is increasingly used in the prevention of cerebrovascular and cardiovascular diseases and is a non-disease factor that may affect bleeding indices (given its anticlotting activity). This article reports on a double-blind placebo-controlled randomized clinical trial that was undertaken to study the effect of short-term daily aspirin ingestion on the clinical parameter BOP. A total of 46 periodontally healthy subjects were included in the study: 16 received placebo, 15 low-dose aspirin (81 milligrams), and 15 regular dose (325 milligrams) aspirin. A statistically significant difference in BOP was found in patients with greater than 20 percent of bleeding sites during the visit prior to placebo or aspirin exposure (n = 11). The group treated with 325 milligrams of aspirin exhibited a moderate yet statistically significant increase in BOP (12.4 percent) compared to the placebo group (there was no significant difference between the 81 milligram aspirin group and placebo). The tendency to bleed was not statistically significant in the group which exhibited less than 20 percent (n = 30) of bleeding sites during the visit prior to exposure. The authors summarize that aspirin intake of 325 milligrams daily for 7 days moderately increased the appearance of bleeding on probing in a population that had greater than 20 percent BOP sites. 2 figures. 4 tables. 15 references.
6
Aspirin
•
Dental Erosion and Aspirin Headache Powders: A Clinical Report Source: Journal of Prosthodontics. 9(2): 95-98. June 2000. Contact: Available from W.B. Saunders Company. Periodicals Department, P.O. Box 628239, Orlando, FL 32862-8239. Summary: The causes of tooth erosion are varied, but all are associated with a chemical attack on the teeth and a resulting loss of tooth structure. Etiologic (causative) factors related to erosion cited in the literature include bulimia (an eating disorder that involves vomiting), eating acidic foods, soft drink consumption, acid reflux (return of stomach gastric acid to the esophagus and mouth), and swimming, among others. This clinical report suggests that chronic use of headache powders can also be a factor leading to tooth erosion. Erosion occurs when tooth structure is dissolved by chemical action not related to bacterial plaque. The authors describe a case report in which a 38 year old female patient presented with a chief complaint of cold sensitivity in her mandibular teeth. The patient suffered from frequent headaches and had a 3 year history of headache powder use, using as many as 6 doses per day of an over the counter product. Each dose contained 520 mg aspirin, 260 mg acetaminophen, and 32.5 mg caffeine. The patient placed the undissolved headache powder under her tongue (sublingually) to increase the rate of absorption, as a result bathing the mandibular (lower jaw) teeth in an acidic solution of dissolving aspirin. Oral examination revealed severe erosion on the occlusal surfaces of the mandibular molars and premolars and moderate erosion of the mandibular anterior teeth. Less erosion was evident on the maxillary (upper jaw) teeth. The mandibular teeth were prepared for full coronal restorations, followed by placement of acrylic provisionals; after a one month trial period, permanent ceramic restorations were utilized. The patient was cautioned about the potential for tooth erosion caused by aspirin products and was referred to a physician for treatment of the rebound headaches. 4 figures. 29 references.
•
Aspirin Use Among Adults with Diabetes: Estimates from the Third National Health and Nutrition Examination Survey Source: Diabetes Care. 24(2): 197-201. February 2001. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article describes a study that examined the prevalence of regular aspirin use among adults in the United States with diagnosed diabetes. The study used data from the Third National Health and Nutrition Examination Survey. Among the survey participants were 1,503 adults with self reported diabetes. Participants were classified as regular aspirin users if they reported taking aspirin 15 or more times in the month before the interview. Cardiovascular disease (CVD) conditions were self reported heart attack and stroke and symptoms of angina and claudication. CVD risk factors included smoking, hypertension, obesity, albuminuria, lipid abnormalities, and family history of heart attack. An estimated 27 percent of adults with diabetes had CVD, and an additional 71 percent had one or more CVD risk factors. Aspirin was used regularly by 37 percent of those with CVD and by 13 percent of those with risk factors only. CVD, race or ethnicity, and age were significantly associated with regular aspirin use among people with diabetes who could be considered candidates for aspirin therapy per the American Diabetes Association recommendation. The odds of regular aspirin use were 4.3 times as great for people with CVD as for those with zero or one CVD risk factor, but having a larger number of CVD risk factors was not significantly associated with increased odds of aspirin use. Non-Hispanic whites were 2.5 times as likely to use
Studies
7
aspirin regularly as African Americans, Mexican Americans, and others. The odds of regular aspirin use were greater for people aged 40 to 59 years than for those less than 40 years old. Insulin use, duration of diabetes, glycosylated hemoglobin, and health insurance coverage were not associated with aspirin use and were not included in the final model. The article concludes that nearly every adult in the United States with diabetes has at least one risk factor for CVD and thus may be considered a potential candidate for aspirin therapy. Major efforts are needed to increase aspirin use. 4 tables. 34 references. (AA-M). •
Life-Saving Power of Aspirin! An Aspirin a Day Helps Keep Heart Attack Away Source: Diabetes Forecast. 52(12): 56-58. December 1999. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article discusses the life saving power of aspirin. One aspirin per day can protect people who have diabetes from cardiovascular disease. Although this complication of diabetes claims more lives than any other, most people who have diabetes and who could benefit from taking aspirin do not take it. Diabetes has been associated with a condition known as sticky platelets. These platelets adhere to blood vessel walls more easily and aggregate more readily, which may be one reason why people who have diabetes are more prone to cardiovascular disease. The American Diabetes Association recommends that most people who have diabetes regularly use an antiplatelet drug to decrease the stickiness of platelets. Aspirin, which is the most readily available and commonly used antiplatelet drug, works by preventing platelets from making the chemical signals that trigger platelet activation and aggregation. Dosing depends on the individual. However, aspirin is not recommended for people who have had an allergic reaction to aspirin in the past, who have stomach ulcers, who have active liver disease, and who are taking antiplatelet drugs. In addition, aspirin does have some side effects, including stomach upset and easy bruising. 3 figures.
•
Dr. Quick's Aspirin Fix Source: Diabetes Forecast. 54(10): 38-40. October 2001. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article discusses the role of aspirin in blood clotting. Aspirin interferes with a small but very important component of blood called platelets. Research has shown that platelets have an essential role in blood clotting because they stick to cut or damaged tissue and attract other platelets to the site of injury. Although this process can be lifesaving when a person is severely cut or injured, when the clotting occurs inside the arteries leading to the heart or the brain, a heart attack or stroke can result. People who have diabetes are at a higher risk for these types of dangerous clots, and aspirin can prevent them from forming. Aspirin attaches itself to an enzyme on platelets and inactivates it. This enzyme is needed to produce the substance that allows platelets to constrict blood vessels and to clump together to plug holes in blood vessels. High blood glucose levels increase the concentration of the substance in platelets that causes them to clump. Thus, people who have diabetes may be at the same risk for a vascular event as someone who has already had such an event. Therefore, the American Diabetes Association recommends that all people with diabetes who are older than 30 take an 81 milligram coated aspirin every day unless there are specific reasons not to.
8
Aspirin
•
Aspirin: Big Benefits in a Small Package? Source: Diabetes Self-Management. 11(4): 50-52, 54. July-August 1994. Contact: Available from R.A. Rapaport Publishing, Inc. 150 West 22nd Street, New York, NY 10011. (800) 234-0923. Summary: This article discusses the uses of aspirin in people with diabetes. The author notes that an international group of researchers has determined that people with diabetes, as well as women, the elderly, and people with high blood pressure should be added to the group of people who can benefit from taking aspirin after surviving a heart attack or stroke as a preventive measure. Topics include how aspirin works; preventing recurrence; side effects of aspirin, including stomach problems, hemorrhage, ringing in the ears, allergy, Reye's syndrome, and blood glucose problems; preventing cardiovascular disease and stroke; using aspirin to treat heart attacks in progress; the relationship between aspirin and other health problems, including colon cancer and migraines; and determining appropriate aspirin dosage levels.
•
Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report 14 Source: JAMA. Journal of American Medical Association. 268(10): 1292-1300. September 9, 1992. Summary: This article presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS). Patients (n=3711) were enrolled in 22 clinical centers between April 1980 and July 1985. Men and women between the ages of 18 and 70 years with a clinical diagnosis of diabetes mellitus were eligible. Patients were randomly assigned to aspirin or placebo (two 325-mg tablets once per day). Results show that the effects of aspirin on any of the cardiovascular events considered in the ETDRS were not substantially different from the effects observed in other studies that included mainly nondiabetic persons. The ETDRS results support recommending aspirin for persons with diabetes at increased risk of cardiovascular disease. 2 figures. 7 tables. 35 references. (AA-M).
•
Aspirin a Day Keeps the Cardiologist Away Source: Diabetes Forecast. 51(1): 29-30. January 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article provides information for people with diabetes mellitus about aspirin therapy as a step towards preventing heart disease. Heart disease is the leading cause of death among people with diabetes. The American Diabetes Association recommends daily aspirin therapy for people with type 1 and type 2 diabetes who are at high risk for developing heart disease. Aspirin is recommended for the prevention of initial heart attacks, and, in the case of people who already have evidence of large vessel disease, for the prevention of subsequent problems. People with diabetes who are considered to be at high risk for heart disease are those who have a family history of coronary heart disease, smoke cigarettes, have hypertension (high blood pressure), are obese, have albuminuria, or have high lipid levels. Since taking aspirin can be harmful to some people, the article advises that everyone should consult a health care professional before starting aspirin therapy. For those who can benefit from aspirin
Studies
9
therapy, the dosage can be as little as one baby aspirin (81 mg) to as much as one regular, adult aspirin (325 mg) per day. (AA-M). •
Risk of Kidney Failure Associated With the Use of Acetaminophen, Aspirin, and Nonsteroidal Antiinflammatory Drugs Source: New England Journal of Medicine. 331(25): 1675-1679. December 22, 1994. Summary: This article reports on a case-control study of 716 patients treated for endstage renal disease (ESRD) and 361 control subjects to determine the risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs (NSAIDs). The study participants were interviewed by telephone about their past use of these medications. For each analgesic drug, the average use (in pills per year) and the cumulative intake (in pills) were examined for any association with ESRD. Heavier acetaminophen use was associated with an increased risk of ESRD in a dose-dependent fashion. When persons who took an average of 0 to 104 pills per year were used for reference, the odds ratio of ESRD was 1.4 for those who took 105 to 365 pills per year; and 2.1 for those who took 366 or more pills per year, after adjustment for race, sex, age, and intake of other analgesic drugs. Approximately 8 to 10 percent of the overall incidence of ESRD was attributable to acetaminophen use. 5 tables. 17 references.
•
Effects of Aspirin on Vitreous/Preretinal Hemorrhage in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report No. 20 Source: Archives of Ophthalmology. 113(1): 52-55. January 1995. Summary: This article reports on a study undertaken to assess whether the use of aspirin exacerbates the severity or duration of vitreous/preretinal hemorrhages in patients with diabetic retinopathy. Patients (n=3711) were randomly assigned to either an aspirin (650 mg/d) or a placebo group. One eye of each patient was randomly assigned to early photocoagulation and the other to deferral of photocoagulation. Based on gradings of fundus photographs, there were no statistical differences in the severity of vitreous/preretinal hemorrhages or their rate of resolution between the groups. The authors conclude that, as previously reported, the use of aspirin did not increase the occurrence of vitreous/preretinal hemorrhages in patients enrolled in this study. Thus, there are no ocular contraindications to the use of aspirin in persons with diabetes who require it for treatment of cardiovascular disease or for other medical indications. 1 figure. 2 tables. 19 references. (AA-M).
•
Aspirin for Vascular Dementia (Cochrane Review) Source: The Cockrane Library. 3: 1-9. 2001. Summary: This article reviews the literature on the effectiveness of aspirin for vascular dementia. The search strategy included major computerized databases, websites, handsearching of selected journals, and personal contact with specialists in the field. All randomized controlled trials investigating the effect of aspirin in vascular dementia were considered. In the initial search, 11 publications were identified as potentially relevant. All of these were discarded: five were not trials, five were not relevant, and one had methodological flaws. A subsequent search yielded nine further publications, six of which were discarded. The remaining three are ongoing trials which can be reviewed at a later date. Because no eligible studies were found that could be included in the review, the authors conclude that there is currently no evidence to support the use of aspirin for patients with vascular dementia. 3 tables, 9 references.
10
Aspirin
•
Aspirin Therapy in Diabetes Is Underutilized (editorial) Source: Diabetes Care. 24(2): 195-196. February 2001. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This editorial comments on a study that investigated the use of low dose aspirin therapy as a secondary prevention strategy in people with diabetes. Results from primary and secondary prevention trials in people who have diabetes support the recommendation that adults older than 30 who are at high risk for vascular disease should be treated with 81 to 325 milligrams of enteric coated aspirin daily. The study reviewed data from the Third National Health and Nutrition Examination Study and found that only 20 percent of the participants gave a history of regular aspirin use despite being eligible for aspirin therapy. An issue that many have influenced the results is the lack of appreciation of the evidence on the effectiveness of aspirin as a prevention strategy. In addition, much of the early collaborative trial data was obtained primarily from men. The editorial also reviews other studies on aspirin use among people who have diabetes and concludes that low dose aspirin therapy is a simple inexpensive medication with potential medical benefits that outweigh its risks in people who have type 2 diabetes. 14 references.
•
Aspirin: The Modern Wonder Drug? Source: Diabetes Forecast. 45(7): 31, 33-34. July 1992. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This patient education article provides readers with information about aspirin and its uses for people with diabetes. Topics covered include a history of aspirin, including its discovery; dosage and administration; aspirin in combination with other medications; the side effects of aspirin, including bleeding; the impact of aspirin on blood glucose levels; aspirin as a prophylactic for heart disease; aspirin for people with diabetic retinopathy; and how to obtain more information about the uses of aspirin.
•
Aspirin Therapy in Diabetes (technical review) Source: Diabetes Care. 20(11): 1767-1771. November 1997. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This review article provides the technical basis for the American Diabetes Association's position statement on aspirin therapy in diabetes, which was approved in 1997. People with diabetes have a twofold to fourfold increase in the risk of dying from complications of cardiovascular disease. Atherosclerosis and vascular thrombosis are major contributors. This article reviews results from primary and secondary prevention trials and comments on the safety, dosage, and special considerations regarding aspirin therapy. Topics include platelet function in diabetes; the pharmacology of aspirin's action on platelets; the efficacy of aspirin therapy as found in the U.S. Physicians' Health Study, the Early Treatment Diabetic Retinopathy Study (ETDRS), and in secondary prevention trials; the safety of aspirin therapy and contraindications to beginning therapy; effective dosage; and additional issues including gender, age, compliance, and substitutes for aspirin therapy. 1 table. 31 references. (AA-M).
Studies
11
Federally Funded Research on Aspirin The U.S. Government supports a variety of research studies relating to aspirin. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to aspirin. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore aspirin. The following is typical of the type of information found when searching the CRISP database for aspirin: •
Project Title: A POPULATION-BASED POLICY MODEL FOR COLORECTAL CANCER Principal Investigator & Institution: Kuntz, Karen M.; Associate Professor; Health Policy and Management; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: The purpose of this project is to further develop a population- based policy model that is specific for the prevention, detection, and treatment of colorectal cancer in the United States. The model will be a dynamic Monte Carlo simulation of the U.S. population that will include all of the modifiable and non-modifiable risk factors that have been found in epidemiological studies to be associated with the incidence of colorectal cancer: smoking history, body mass index, physical activity, red meat consumption, fruit and vegetable consumption, aspirin use, multivitamin use (as a proxy for folate intake), alcohol consumption, postmenopausal hormone use, and family history of colorectal cancer, as well as demographic variables (age, gender, race). Risk equations will be derived primarily from the Nurses' Health Study and the Health Professionals Follow-up Study; risk factor distributions over time in the U.S. population will be obtained primarily from the NHANES I, II, and III. The model will track the underlying progression and location of adenomatous polyps and undiagnosed cancer, thus enabling a screening test to detect and remove an adenomatous polyp, or to possibly detect a cancer at an earlier stage. Once a cancer is detected and staged (either by a screening test or by symptoms), all relevant colorectal cancer treatment strategies will be incorporated, allowing for the evaluation of current or hypothetical interventions. The model will be used to analyze the potential contributors to the observed cancer trends and to predict the potential impact on national trends of risk factor interventions, screening, and colorectal cancer treatment. Throughout this project, the research team will collaborate with the National Cancer Institute to incorporate national data sources and to focus research questions. The research team will also be
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
12
Aspirin
involved with other modeling groups for purposes of calibration, validation, and the comparison of model results. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE Principal Investigator & Institution: Curhan, Gary C.; Associate Professor of Medicine; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 15-AUG-1998; Project End 31-JUL-2003 Summary: Analgesic-associated nephropathy is potentially fatal and costly yet completely preventable as a cause of renal dysfunction. Retrospective studies have reported an increased risk of renal dysfunction associated with consumption of large amounts of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these analgesics are widely available and used, their association with renal dysfunction is particularly important. The primary objective of this study is to examine, prospectively, the association between chronic consumption of acetaminophen, aspirin and NSAIDs, and the risk of chronic renal dysfunction, defined as an increase in serum creatinine or a decrease in calculated creatinine clearance during the 5-year study period. From participants in two large female cohorts, the Nurses' Health Studies I and II (NHSI, NHSII), 3 groups of women will be identified, each comprised of 1150 participants (half from each cohort), who reported frequent use of acetaminophen, aspirin, or NSAIDs, and a fourth group of 1150 women who reported no use of these analgesics. Detailed information on dosage and duration of analgesic use will be obtained through supplementary questionnaires, to be mailed in the 01, 03, and 05 years, which have been shown to be reproducible. 4600 nurses will be enrolled at the outset and, after excluding women with prevalent renal disease and those who drop out, an expected 4000 will complete the study in the 05 year. The outcomes are: change in serum creatinine and calculated creatine clearance, measured at baseline and years 03 and 05 from all subjects. Mixed effects regression will be used to analyze the slope of renal function in the unexposed and exposed groups during the 5 year study period. For approximately 2000 subjects in NHSI, stored blood from 1989 will be used to perform the same analyses over a 13 year period. This study will provide: prospective data on change in renal function associated with chronic analgesic use; threshold levels of safe cumulative dose and duration of these analgesics; and population-based incidence rates and attributable risks of analgesic-associated chronic renal dysfunction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANGIOTENSINOGEN VARIANTS AND ADVERSE PREGNANCY OUTCOMES Principal Investigator & Institution: Ward, Kenneth; Senior Scientist; ObstetricsGynecology; University of Utah 200 S University St Salt Lake City, Ut 84112 Timing: Fiscal Year 2001; Project Start 20-AUG-1995; Project End 31-JUL-2003 Summary: (Adapted from Investigator's Abstract) Early in normal gestation, there is a decrease in maternal vascular resistance accompanied by a 20% of 100% expansion of maternal blood volume. At the same time, the uterine arteries undergo profound remodeling and dilation -- termed "physiologic change" -- to provide adequate blood flow to the developing conceptus. Failed volume expansion and failed or abnormal physiologic change are associated with a variety of common pregnancy complications, including preeclampsia, intrauterine growth retardation (IUGR), and preterm labor. Molecular variants of the angiotensinogen gene, which increase angiotensinogen
Studies
13
expression in certain local systems, predispose women to develop preeclampsia and related pregnancy complications. This competing renewal proposes to test the hypothesis that disease-associated angiotensinogen alleles promote abnormal spiral artery remodeling and inhibit maternal plasma volume expansion. Three interrelated approaches are proposed: 1) an affected sister-pair linkage analysis of polymorphisms in angiotensinogen and other relevant genes, 2) gene expression and quantitative histology studies of spiral artery remodeling using an existing large collection of human pregnancy tissues, and 3) transgenic mouse and human studies to evaluate the newlydescribed paracrine tubular renin angiotensinogen system's role in maternal blood volume expansion. The investigators state that this work may lead to predictive and diagnostic tests that indicate a woman's increased risk for complications early in pregnancy, allowing improved monitoring, earlier diagnosis, and new opportunities for treatment. They further state that the ultimate goal of this research is the development of improved preventive measures and effective treatments for these common pregnancy disorders. Through an understanding of particular genetic subsets of preeclampsia, they note that they may find that once promising therapies, such as low-dose aspirin, do have a role in some patients. Finally, they note that new biologic pathways may be discovered that suggest novel therapeutic strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTICOAGULATION POST-FONTAN/CLOSURE OF ASDS Principal Investigator & Institution: Mccrindle, Brian W.; Hospital for Sick Chldrn (Toronto) 555 University Ave Toronto, Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant) Patient-related research in heart problems in children has been of limited quality, because of lack of collaboration and emphasis on information provided in medical charts. Important problems remain controversial and unsolved. The Fontan operation is designed for patients who have only one pumping chamber, and guides blood from the major veins returning to the heart directly into the lung arteries, with the pumping chamber reserved to pump blood into the arteries of the body. Afterwards, blood flows differently and more slowly in the veins and lungs, and clots may form, which can cause strokes. The proposed study aims to determine the risk of clots and the best way to prevent them. The study will consist of a review medical charts on a large number of patients who have had Fontan to help determine the risk of clots. For patients who will have Fontan, they will be enrolled in a study where they will be randomly assigned to different types of medications to prevent clots, which will be compared. For patients who have already had the Fontan, they will be enrolled in a similar study where they will randomly assigned to either aspirin or a medication called warfarin. In both the studies, the patients will have regular check-ups and tests for a two year period to see if clots occur and which type of medicine best prevents the clots. Atrial septal defects, or holes between the two collecting chambers of the heart, can lead to heart failure and heart rhythmn problems. They can be closed with surgery, or by placing a special patch or device with a catheter. The proposed study aims to determine whether closure is better with surgery or the catheter method, and whether there are any differences in closure with different types of catheter devices. The study will review medical charts of children who have had closure of these holes, and compare surgery and catheter methods. A second part of the study will enroll children with holes which need to be closed, and randomly assign them to either surgery or the catheter method. For patients assigned to the catheter method, they will be further randomly assigned to one of two types of catheter devices. Comparisons will be made between surgery and
14
Aspirin
the two catheter methods regarding the completeness of closure and complications. A further analysis will look at patient preferences and the costs for these different types of procedures, to help determine the best way to close these holes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTI-INFLAMMATORY INFLAMMATION
LIPIDS
IN
ACUTE
MUCOSAL
Principal Investigator & Institution: Gronert, Karsten; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-DEC-2004 Summary: (provided by applicant) Inflammatory bowel diseases (IBD) that are associate with a dramatic increase in colorectal cancer occur throughout the world with an annual incidence of approximately 12/100,000 people. Aberrant activation of neutrophils and a profound increase in lipid and peptide mediators are cardinal signs of these inflammatory diseases as well as for ischemia reperfusion injury, a known complication of surgical procedures. How acute inflammatory responses switch from vital host defense to aberrant inflammation and neutrophil mediated tissue injury remains to be completely elucidated. Therefore, endogenous mechanisms that disrupt proinflammatory circuits are of interest. Aspirin and omega-3 polyunsaturated fatty acids (PUFA) are therapeutic agents that demonstrate benefits in inflammatory diseases as well as prevention of colon cancer. However, their mechanisms of action still needs to be clearly defined but targets the formation of lipid mediators namely eicosanoids. Both therapeutic agents trigger the formation of novel classes of anti-inflammatory lipids, namely 15R-lipoxins and omega-3 PUFA derived 15R-and 18R-series eicosanoids. This study shall test the hypothesis that acute inflammation induces a regulated and temporal generation of anti-inflammatory lipid signals and that omega-3 fatty acid and aspirin augment these protective lipid mediator circuits. The specific aims of this application will employ a combined approach of structural elucidation, molecular biology and transgenics to delineate three main aspect of the role of lipid signals in neutrophil mediated intestinal injury: i) Establish the temporal relationship of pro- and anti-inflammatory eicosanoids. ii) Determine the impact of aspirin and omega-3 PUFA on eicosanoid profiles and elucidate novel protective lipid mediators. iii) Determine if novel aspirin and omega-3 PUFA triggered lipid mediators are protective against aberrant PMN activation and if changes in expression of receptors for lipid mediators are markers for aberrant intestinal inflammation. The broad and long-term objectives of this application are to elucidate endogenous pathways that block PMN mediated injury to promote resolution of inflammation. Results from this project may provide novel anti-inflammatory tools for controlling inflammatory diseases such as Ulcerative Colitis and Chron's Disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIOXIDANTS AND FEMALE HORMONES IN THE ETIOLOGY OF RA Principal Investigator & Institution: Karlson, Elizabeth W.; Assistant Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 31-AUG-2003 Summary: The candidate is an Instructor in Medicine in the Department of Medicine, Division of Rheumatology, Immunology and Allergy at the Brigham and Women's Hospital and Harvard Medical School. Her research area is the epidemiology of
Studies
15
rheumatic diseases, and the social and biological determinants of outcome in rheumatic diseases. Dr. Matthew Liang, Director, Multipurpose Arthritis and Musculoskeletal Diseases Center (MAMDC), Professor of Medicine at Harvard Medical School and Professor of Health Policy and Management at Harvard School of Public Health, will be her sponsor and co-mentor along with Drs. Frank Speizer, Charles Hennekens, Walter Willett and Meir Stampfer from the Channing Laboratory and Division of Preventive Medicine. The research training program consists of the two studies described below, Research Seminars in the MAMDC, Channing Laboratory and Division of Preventive Medicine, courses at the Harvard School of Public Health, and close review by an Advisory Committee. The goal of the proposed studies is to define the role of dietary and hormonal risk factors in the development of rheumatoid arthritis (RA) in women. Specifically, it will test the potential protective role of antioxidants and N-3 fatty acids on the risk of RA, whether postmenopausal estrogen reduces risk and whether menopause increases risk of RA. The study utilizes information from two separate, complementary cohorts, the Nurses' Health Study, a prospective cohort of 121,700 women aged 30-55 years at baseline, followed since 1976, and the Women's Health Study, a randomized, double-blind, placebo-controlled trial of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer among 39,876 female health professionals, aged 45 years and older. RA will be confirmed by a screening questionnaire regarding rheumatic symptoms and review of medical records. The study will identify potentially modifiable risk factors for primary prevention of RA. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASPIRIN IN THE PREVENTION OF COLON POLYPS Principal Investigator & Institution: Sandler, Robert S.; Professor of Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ASPIRIN PROPHYLAXIS IN SICKLE CELL DISEASE Principal Investigator & Institution: Lerner, Norma; Pediatrics; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-MAY-2006 Summary: (provided by the applicant): Neurologic complications secondary to cerebrovascular damage are prevalent in children with homozygous Sickle Cell Disease. These patients experience both clinically-overt cerebrovascular accidents and "silent infarctions," demonstrated by Magnetic Resonance Imaging (MRI). They are also at risk for neurocognitive abnormalities. We hypothesize that daily, low-dose, aspirin therapy will safely diminish the incidence and progression of cognitive deficits, as well as the pre-disposition to overt and silent stroke in children with homozygous Sickle Cell Disease. In order to optimize the design of a future trial to test this hypothesis, we propose a randomized, placebo-controlled, double-blind pilot study. The trial's primary objective is to evaluate the safety and tolerability of daily low-dose aspirin in children with Sickle Cell Disease. The secondary objectives are: 1. To establish the level of compliance with aspirin administration. 2. To identify the most useful assessments in a battery of age-appropriate neurocognitive tests. 3. To assess the feasibility of MRI and Magnetic Resonance Angiography (MRA) studies, and the utility of classification systems for use in group comparisons. 5. To establish trends in Transcranial Doppler
16
Aspirin
(TCD) ultrasound velocities over time, and the validity of using trends in group comparisons. 6. To obtain preliminary data regarding the effect of aspirin on the incidence of cognitive deficit, imaging abnormalities, overt stroke, painful crises, and Acute Chest Syndrome. 7. To establish the feasibility of recruiting patients. A minimum of 60 patients will be enrolled. Subjects will include children between the ages of 3 and 10 years, with documented homozygous Sickle Cell Disease who are currently followed at the Galisano Children's Hospital (University of Rochester Medical Center, Rochester, New York), and at Saint Luke's-Roosevelt Hospital Center (Columbia University, New York, New York). Subjects will be randomized to one of two treatment groups, daily aspirin (1-2.5 mg./kg./day), or placebo. Patients will receive therapy for 18 months. There will be careful laboratory and clinical monitoring every 3 months, and more frequently as needed. Group comparisons regarding pre- and post-treatment clinical complications, neurocognitive testing, MRI, MRA, and TCD studies will be made. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASPIRIN, HELICOBACTER PYLORI, AND PEPTIC ULCER DISEASE Principal Investigator & Institution: Lew, Edward A.; Medicine; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2004 Summary: Aspirin and other non-steroidal anti-inflammatory drugs are widely used to treat pain and inflammation, and at low doses, aspirin is also increasingly being used for cardiovascular prophylaxis. However, these drugs have substantial gastrointestinal toxicity and a significant number of patients develop peptic ulcers and GI bleeding. Although infection with Helicobacter pylori is another major risk factor for ulcers, the relationships between aspirin and H. pylori in the development of ulcers remain highly controversial. It is unclear, for example, whether there is an addictive or synergistic interaction between these factors in conferring ulcer risk such that aspirin interacts with H. pylori to increase ulcer complications. Aspirin impairs mucosal protective mechanisms by decreasing prostaglandin production, whereas H. pylori promotes mucosal injury through cytokines and inflammation to form ulcers. Past studies have provided conflicting data on the ulcer risks associated with both factors but they have been limited by recall bias of aspirin use, selection bias, and small sample sizes with short follow-up. The primary goals of the proposed research are to determine the risk of peptic ulcers associated with the joint effects of low dose aspirin and H. pylori infection, the ulcer risk associated with low dose aspirin and a specific virulent strain of H. pylori, known as cagA+ H. pylori, and the risk of GI bleeding associated with low dose aspirin and H. pylori (especially cagA+ H. pylori strains) as compared to those without infection. We will have 80% power to detect a difference of 1.56 in the odds ratio, when comparing the association of aspirin use and ulcer formation in H. pylori positive and negative subjects. As the US population grows older, the chronic use of aspirin for cardiovascular prophylaxis and the subsequent development of ulcers are likely to increase, involving health care costs. The proposed study will provide important information to make an informed decision about aspirin related GI complications and whether H. pylori infected patients are at risk for ulcers and GI bleeding while on aspirin. These results may help identify high-risk patients and lead to strategies that will reduce ulcer complications among aspirin users. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
17
Project Title: ASPIRIN, UGT1A6 GENOTYPE, AND COLON GENE EXPRESSION Principal Investigator & Institution: Potter, John D.; Member & Program Head; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 13-MAY-2002; Project End 31-MAR-2006 Summary: (provided by applicant): Colorectal cancers are thought to arise as the result of a series of molecular changes that transform normal epithelial cells into a colorectal carcinoma, with an adenomatous polyp as an intermediate step in this process. One way to reduce mortality from this cancer involves the use of oral agents that prevent neoplasms from developing in the large bowel. Regular use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the incidence of colon adenomas as well as carcinomas by approximately 50 percent. Enzymes prominently involved in metabolizing aspirin are UDP-glucuronosyltransferases (UGT). UGT1A6 is a polymorphic UGT and its variant alleles metabolize aspirin less efficiently. We showed that in NSAIDs users, and aspirin users in particular, the risk for colon neoplasia is reduced only in individuals who are UGT1A6 heterozygous and homozygous variant, but not homozygous wild-type. Aspirin and its metabolite, salicylic acid, can inhibit growth through the inhibition of cyclooxygenases (catalysts of prostaglandin synthesis), the promotion of apoptosis, and other as yet unidentified pathways. The goal of this project is to determine the effect of UGT1A6 genotype on aspirin metabolism and on aspirin-induced changes in colonic gene expression and protein markers of apoptosis (Bax and Bcl-2). We propose to study: 1) urinary excretion of aspirin metabolites in 380 healthy individuals with different UGT1A6 genotypes in a cross-sectional study and 2) changes in colon gene expression induced by aspirin supplementation in a randomized, placebo-controlled trial of 40 individuals who are either homozygous wild-type or homozygous variant for UGT1A6. We hypothesize that in slow metabolizers the proportion of glucuronidated metabolites is smaller and that a smaller proportion of the aspirin dose is excreted within a specific time. Alterations in colonic gene expression will be determined using cDNA microarray analysis of biopsy RNA from the sigmoid colon and rectum and Bax and Bcl-2 expression in the colonic crypts will be measured by immunohistochemistry. We hypothesize that expression of e.g. growth-promoting genes will be reduced and apoptotic genes increased during aspirin use and that this reduction may be stronger in slow metabolizers than fast metabolizers. This project will also allow the identification of other genes whose expression is affected by aspirin supplementation. Ultimately, information obtained from this project will be useful in developing chemopreventive drugs that specifically target pathways involved in colon neoplasia. By targeting relevant pathways, side effects caused by the use of NSAIDs or specific Cox-2 inhibitors may be avoided. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ATRIAL FIBRILLATION INCIDENCE, RISK FACTORS AND GENETICS Principal Investigator & Institution: Heckbert, Susan R.; Associate Professor; Epidemiology; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2006 Summary: (provided by applicant): The goal of this research is to assess the safety of commonly used medications in relation to the risk of incident atrial fibrillation (AF), and to assess the association of several genetic polymorphisms with stroke risk after AF onset. Several lines of evidence suggest that both beta-blockers and ACE inhibitors may prevent or inhibit the atrial electrical remodeling that allows AF to become established
18
Aspirin
and maintained. Withdrawal of these medications may be associated with increased risk of AF in individuals at risk. Genetic polymorphisms that promote thrombosis are associated with an increased risk of venous thrombosis, and in some studies, with arterial thrombosis including stroke or myocardial infarction. Although several recently published trials indicate that warfarin or aspirin treatment of patients with AF decreases the risk of stroke, little is known about the risk of stroke as a complication of AF in relation to genetic variants that affect clotting. The proposed project will build on successful population-based studies of myocardial infarction and stroke at Group Health Cooperative (GHC), a large non-profit health maintenance organization. Detailed information from the GHC computerized pharmacy database on the timing of medication use among approximately 1500 incident AF cases and 1750 controls with medically treated hypertension will permit us to assess the risk of incident AF associated with the use or recent stopping of beta-blockers or ACE inhibitors. This project will collect DNA samples on a population-based inception cohort of approximately 855 AF patients, and will examine the risk of stroke in relation to genetic variants known to affect coagulation. The main tasks of the proposed project are: 1) identification of cases with incident AF and controls; 2) review of outpatient and inpatient medical records to assess eligibility and collect information on risk factors and medical history; 3) classification of medication use over time; 4) for AF patients, telephone interview and collection of blood samples; 5) blood specimen processing, DNA extraction, and genotyping; and 6) data analysis of the associations of medication use and genotype with AF onset and stroke complications. This project will contribute important information about drug safety and will incorporate advances in molecular biology to study AF and its complications, problems of considerable public health importance in the elderly. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOLOGY OF SINGLE ACTIVITY PGH SYNTHASES Principal Investigator & Institution: Funk, Colin D.; Professor of Pharmacology; Pharmacology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: adapted from applicant's abstract): Prostaglandin H synthase-1 (PGHS-1) is the key enzyme in the biosynthesis of prostaglandins, homeostatic lipid mediators in the cardiovascular, gastrointestinal, renal and other organ systems. PGHS-2, on the other hand, is a separate gene product, is highly regulated, inducible and is regarded as the form involved in cancer and inflammation. While the simplistic viewpoint of "housekeeping" PGHS-l vs "inducible, pro-inflammatory" PGHS-2 is practical, data is emerging that is not entirely consistent with this hypothesis. PGHS isozymes are bifunctional, with a cyclooxygenase (COX) activity and a functionally linked peroxidase (POX) activity. Non-steroidal antiinflammatory drugs (NSAIDs) act by inhibition of the COX activity, leaving POX activity intact. Substantial data, primarily from in vitro model systems, has implicated the POX component of PGHS in the metabolic activation of xenobiotics and other non-prostaglandin related activities. The main objective of this proposal is to delineate the distinct functions of the COX and POX activities of the PGHS isozymes in carcinogenesis and inflammation using mice with induced mutations created by gene targeting in embryonic stem cells. In Aim 1, COX gene-disrupted mice will be generated by mutation of the aspirin-binding site (serine 530 to asparagine or glutamine), while POX gene-disrupted mice will be created via mutation of the proximal heme ligand (histidine 388 to tyrosine) in Aim 3. The involvement of PGHS POX in the metabolic activation of the nitrofuran compound FANFT, a potent urinary bladder
Studies
19
carcinogen, will be analyzed by examination of tumor formation in the mutant mice. Also, the effects of separate COX and POX ablation on skin carcinogenesis using the two-stage DMBA/phorbol ester initiation/promotion protocol and models of inflammation will be assessed in Aims 2 and 4. The COX-disrupted mice, in essence, are perfect in vivo models for complete and selective PGHS-1 arid PGHS-2 inhibition and will be invaluable for studying non-PGHS dependent actions of NSAIDs. Results obtained from this proposal should have broad implications for understanding mechanisms of human cancer and inflammatory disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CASE CONTROL STUDY OF STATIN USE AND LARGE BOWEL CANCER Principal Investigator & Institution: Coogan, Patrica F.; Epidemiology and Biostatistics; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 18-SEP-2000; Project End 31-AUG-2005 Summary: (Adapted from applicant's abstract): Cancer of the large bowel is a leading cause of cancer morbidity and mortality in the United States. Our previous epidemiologic studies played a key role in documenting an inverse association between the use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDS) and the incidence of large bowel cancer. Those studies were inspired by laboratory data suggesting that NSAIDs may reduce colon carcinogenesis. Now a growing body of laboratory data indicates that the commonly used, relatively new class of cholesterollowering drugs, the "statins" may have a similar chemopreventive potential: statins inhibit the growth of colon cancer cells in vitro and in vivo. There is also some evidence that statins may enhance the chemopreventive effect of NSAIDS. The statins (e.g., lovastatin, simvastatin) were first marketed in 1987, and are now among the most commonly prescribed drugs in the United States. At this time there is little epidemiologic data concerning their potential protective effect against large bowel cancer. Two randomized trials of statin use as preventives of coronary heart disease had nonsignificant deficits of large bowel cancer in the treated groups. We propose to conduct a population-based case-control study in Massachusetts of the relation of statin use to the risk of large bowel cancer. We will identify 2050 incident cases aged 50-74 through participating hospitals and 2050 age, sex, and precinct matched community controls from Massachusetts town lists. Cases and controls will be interviewed to obtain information on demographic factors, risk factors for large bowel cancer, detailed histories of statin and NSAID use, and data useful for addressing potential biases. The study is large enough to assess the influence of characteristics of statin use (timing, duration, dose) on the risk of large bowel cancer and to assess consistency of findings across subgroups of age, sex, and cancer site. The joint effect of statins and NSAIDs will also be assessed. The proposed study will provide informative epidemiologic data on a potential chemopreventive of large bowel cancer. Because the incidence of the disease and prevalence of statin use by U.S. men and women are high, an inverse association would be of considerable public health importance. Moreover, it would shed light on a mechanism of colon carcinogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELLULAR INFLAMMATION
MECHANISMS
OF
ENDOGENOUS
ANTI-
Principal Investigator & Institution: Devchand, Pallavi R.; Instructor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115
20
Aspirin
Timing: Fiscal Year 2001; Project Start 01-MAR-2001; Project End 30-NOV-2003 Summary: (Taken from the applicant=s abstract): About 1% of the US population (2.1 million people) have rheumatoid arthritis(RA). The most common RA is a late-onset disease, beginning at middle age with increased frequency in adulthood. While the exact causes for the different types of RA vary, the symptoms in each (swelling, redness, heat and pain) are reminiscent of the cardinal signs of inflammation. The social and financial impact of RA on both individual and nation are substantial, and due primarily to the debilitating symptoms of the disease (daily joint injury and inflammation). One approach to relieving the discomfort of this disease, is to treat the symptoms, i.e. an antiinflammatory treatment. Our knowledge of the cellular mechanisms involved in the resolution of acute inflammatory reactions that are neutrophil-driven is limited. Lipoxin A4 is a potent lipid-signaling molecule that mediates protective actions. This eicosanoid provides a model system for the evaluation of key targets in anti-inflammatory pathways. This research proposal is intended to test the hypothesis that in vivo, ALXR is a ligand-activated cell-surface receptor that tranduces the anti-inflammatory LXA4 signal, in part via a nuclear receptor pathway, to regulate the dynamics of an acute inflammatory reaction. A combined approach using transgenics, eicosanoid chemistry and molecular and cell biology techniques will be used to evaluate three main aspects of LXA. signaling in mature myeloid cells: 1.) To establish, in vivo, that the Lipoxin A4 receptor (ALXR) is a primary site of action for LXA4 and aspirin-triggered lipoxins. 2.) Identify nuclear events associated with LXA4 signaling and understand how these events counter-regulate pro-inflammatory transcription factors; and 3.) Use a woundhealing animal model to understand how ALXR modulates the dynamics of an acute inflammatory reaction towards resolution. The control of leukocytes is important not only for therapeutic use in disorders associated with uncontrolled inflammation (e.g., R A), but also has potential as a preventative measure against second organ injury during routine surgical procedures. Knowledge of endogenous anti-inflammatory lipid mediators and their sites of action could provide a platform for new therapeutic interventions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL PHARMACOLOGY OF ACETAMINOPHEN AND SALICYLATE Principal Investigator & Institution: Oates, John A.; Professor and Chairman; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 01-DEC-1977; Project End 30-JUN-2006 Summary: (provided by applicant) In contrast to the cyclooxygenase inhibitors in the nonsteroidal anti-inflammatory class, acetaminophen exerts a more narrow spectrum of pharmacologic effects, acting primarily as an antipyretic and an analgesic agent with much less effect on inflammation, the platelet, and the gastrointestinal tract. Acetaminophen is known to inhibit prostaglandin production in the central nervous system and endothelial cells. We have found that the inhibition of prostaglandin biosynthesis by acetaminophen in endothelial cells was more marked when these cells were stimulated with the pyrogen, IL-l alpha, which induces both cyclooxygenase-2 and PGE2 synthase in the endothelial cell, with a resultant increase in prostacyclin and even more marked increase in the biosynthesis of PGE2. In human studies we have found that endotoxin markedly increases prostacyclin biosynthesis. From these preliminary data we postulate that acetaminophen will inhibit the biosynthesis of the prostaglandin pyrogen, PGE2, and pyrexia induced by endotoxin, and will assess this in a study with human volunteers. It is also hypothesized that during endotoxemia, acetaminophen will
Studies
21
inhibit prostacyclin biosynthesis to a greater degree than in the control state. The effect of reducing production of this potent inhibitor of platelet aggregation on the enhanced activation of platelets in vivo during endotoxemia will be Sodium salicylate in high doses has anti-inflammatory properties. It is a weak inhibitor of purified cyclooxygenase in vitro, but has been shown to reduce prostaglandin biosynthesis in some cells. The mechanism of its antipyretic effect is unknown. We plan to determine whether an antipyretic dose of salicylate will inhibit prostaglandin biosynthesis in endotoxininduced pyrexia, and also to assess this in relationship to the doses that exert an antiinflammatory effect. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CATALYSIS
COBALT(II)-RADICAL
PAIR
DYNAMICS
IN
B12
ENZYME
Principal Investigator & Institution: Warncke, Kurt; Associate Professor; Physics; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 15-MAR-1998; Project End 31-DEC-2002 Summary: An emergent class of enzymes that harness the extreme reactivity of electrondeficient free radical species to carry out some of the most difficult chemical reactions in biology has been recently identified. The regio- and stereo-selectivity achieved by these enzymes defies long- held ideas that radical reactions are non-specific. This class includes the following: ribonucleotide reductases, which catalyze the first unique step in DNA biosynthesis, prostaglandin H-synthase, the target of aspirin and other nonsteroidal anti-inflammatory drugs, and the family of B12 coenzyme-dependent enzymes, which catalyze metabolite covalent bond rearrangements. The common primary step in the catalysis is metallocenter- or metal-assisted generation of an electron-deficient organic radical. This initiator radical abstracts a hydrogen atom from the substrate to form a substrate-based radical, opening a new reaction channel that facilitates rearrangement to a product radical. A challenging issue is how the radical is stabilized against recombination with the metal. There are analogies with the charge separation reactions in photosynthetic and respiratory bioenergetic complexes, for which the rudimentary performance principles have been established. However, unlike simple electron-hole separation by electron tunneling among weakly interacting redox sites, metal-radical separations involve large- scale movement of heavy nuclei and relatively strong electronic interactions. Elucidating the basic principles of how protein and cofactors guide radical stabilization and ensuing substrate radical rearrangement will be sustained focuses of the proposed studies. The adenosylcobalamin-dependent systems, and ethanolamine deaminase specifically, have been selected for scrutiny because homolytic cleavage of the cobalt-carbon bond to form the CoII metalloradical and 5'adenosyl initiator radical can be triggered by a visible laser pulse, allowing the coherent preparation of the radical pair state under catalytic conditions. The radical pair separation and substrate radical rearrangement will be tracked by time-resolved techniques of pulsed-EPR spectroscopy. Dynamic electron spin-spin and electronnuclear hyperfine interactions will be measured and used to construct a detailed molecular mechanism. The insights and techniques developed will promote identification of transient radical intermediates in other enzyme reactions, indicate designs for programmed site-specific radicals reactions in vivo, and assist therapeutic efforts to combat biologically-destructive free radicals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
22
Aspirin
•
Project Title: COX2 DEVELOPMENT
EXPRESSION
IN
GENITOURINARY
CANCER
AND
Principal Investigator & Institution: Breyer, Matthew D.; Professor; Medicine; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-JUL-2002 Summary: Cyclooxygenase (COX) play a critical role in cellular metabolism, mediating the conversion of arachidonate to a family of bioactive prostaglandins. The discovery of COX2, a second, mitogen inducible isoform, occurred almost simultaneously with realization that patients taking cyclooxygenase inhibitors including aspirin and other non-steroid anti-inflammatory drug (NSAIDs) had nearly a 40% risk reduction of clon and other cancers. Recent studies confirm that COX2 is aberrantly increased in specific epithelium cancer cell sub-populations including colonic prostate, aberrantly increased in specific epithelial cancer cell sub-populations including colonic, prostate, bladder. COX2 inhibitors significantly slow growth of these tumors in a variety of experimental models. Additionally, the observation that COX2 knockout mice and mice exposed to COX2 selective NSAIDs in utero exhibit sever renal dysgenesis suggests a specific and critical role for COX2 in the development and maintenance of normal renal development and genitourinary function. Expression of COX2 in the genitourinary tract is among the highest of any normal tissue. Expression of COX2 in the genitourinary tract is among the highest of any normal tissue. The factors contributing to the particular importance of COX2 in the normal genitourinary tract and in the growth and progression of epithelial cancers are uncharacterized. The aim of the proposed studies is to 1) develop a mouse expressing a GFP reporter driven by the COX2 promoter to facilitate the isolation of viable COX2 expressing cells from developing mouse and mice with genitourinary cancers. Specific Aim #2 is to develop cell lines from the developing genitourinary tract and murine neoplastic tissue which will allow genetic and functional distinction of COX2 positive and OX2 negative cells. The is9olation of these cells should provide a means of identifying those factors responsible for aberrant up-regulation of COX2 in cancers, and normal programmed expression of COX2 along the GU tract. Isolation of these cells will allow characterization of the prostanoid profile synthesized by COX2 over- expressing cells which should clarify how COX2 inhibitors progression of cancer in the bladder prostate, and other tissues. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIET, HORMONE REPLACEMENT THERAPY AND BREAST CANCER Principal Investigator & Institution: Zhang, Shumin; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 12-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): This is a resubmission of I K07 CA096619-01 "Diet, Hormone Replacement Therapy and Breast Cancer". Candidate: Shumin Zhang received her MD at the Harbin Medical University in 1986 and her ScD in epidemiology and nutrition at the Harvard School of Public Health in 1998. She then completed her postdoctoral training in 2000, and now is an Assistant Professor of Medicine at the Harvard Medical School (HMS). She applies for this Career Development Award to acquire the methodological and theoretical research skills needed to become an independent scientist in cancer and nutritional epidemiology. Sponsor and Environment: JoAnn Manson, MD, DrPH, is the Chief of the Division of Preventive Medicine at the Brigham and Women's Hospital, Professor of Medicine at the HMS and Co Principal investigator
Studies
23
(Co-Principal Investigator) of the Women's Health Study ONHS). Julie Buring, ScD, is the Deputy Director of the Division, Professor of Ambulatory Care and Prevention at the HMS and Principal Investigator of the WHS. They have trained numerous investigators in the fields of diet, lifestyle and chronic diseases, areas in which they have published extensively. Research: We plan to conduct a prospective analysis within the WHS, an ongoing clinical trial of vitamin E and low-dose aspirin in the primary prevention of cancer and cardiovascular disease among 39,876 women. We will test 4 dietary hypotheses that moderate alcohol intake increases risk of breast cancer, whereas high intake of folate and fiber reduces risk; and caffeine intake is not associated with risk. We will link fiber intake to plasma endogenous sex steroid hormones in a subsample of the WHS. We will also test 4 hormone replacement therapy (HRT) hypotheses that tong-term use of estrogen plus progestin increases risk of breast cancer more than estrogen alone; estrogen plus cyclic progestin increases risk more than estrogen plus continuous progestin; low-dose estrogens confer lower risk than highdose; and use of estrogen is more strongly associated with risk among women drinking alcohol. The ongoing WHS will provide updated and repeated measures of HRT, comprehensive dietary assessment at baseline, and important covariates for breast cancer in addition to follow-up of the cohort and documentation of breast cancer cases (expected N = 1550). The findings from this project could have direct clinical application for efforts to reduce risk of breast cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY IDENTIFICATION OF ADVERSE REACTIONS TO HERBS Principal Investigator & Institution: Bent, Stephen W.; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2003; Project Start 16-DEC-2002; Project End 30-NOV-2007 Summary: (provided by applicant): Herbal products have gained widespread popularity in the United States, with up to one-quarter of adults reporting use of an herb to treat a medical illness within the past year. Although herbs are commonly perceived as safe and "natural," numerous serious side effects have been reported, including myocardial infarction, stroke, liver failure, end-stage renal disease, and death. Unfortunately, surveillance systems to detect side effects of herbal products are extremely limited. Most serious reactions to herbs (including Chinese herb nephropathy and kava-kava related hepatitis) have been identified through case reporting, an inefficient system of monitoring that captures only a small percentage of all adverse events and only after large numbers of patients have been exposed. Current monitoring systems can be described as "passive," since action is only taken after enough case reports accumulate to raise concern of a possible dangerous adverse reaction. This career development program will provide the applicant with mentored training and research experience to examine the ability of "active" systems to detect adverse reactions to herbs at an early phase, before severe clinical outcomes occur. After completing an extensive curriculum in pharmacognosy, pharmacoepidemiology, and the analysis of complex cohort data, Dr. Bent will conduct four research projects that address two specific aims. The first specific aim is to determine if secondary data analysis is able to detect associations between specific herbs and laboratory and clinical outcomes that may represent adverse reactions. This will be addressed by three studies that examine 1) associations in a completed randomized controlled trial, 2) associations in an existing patient database, and 3) a comparison of the sensitivity and specificity of the two methods. The second specific aim is to determine the ability of a prospective cohort study to detect associations between specific herbs and laboratory/clinical outcomes that may represent
24
Aspirin
adverse events. A cohort of patients at high risk for herb-drug interactions (patients on long-term anticoagulation) will be established to determine if herbal product use is associated with poor control of anticoagulation or related adverse clinical outcomes. Ultimately, this research strives to identify improved methods for the early detection of adverse events, providing patients with a safer environment to achieve the potential benefits of herbal products. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ECONOMICS AND QUALITY OF LIFE IN THE OCCLUDED ARTERY TRI Principal Investigator & Institution: Mark, Daniel B.; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: This revised application proposes to establish an Economics and Quality of Life Coordinating Center for the Open Artery Trial, (OAT), a multi-center, randomized trial of late (3-21 days) percutaneous revascularization versus standard medical therapy in 3200 asymptomatic high-risk acute myocardial infarction (MI) survivors and who are found at diagnostic catheterization to have an occluded infarct-related artery. All patients will receive standard medical therapy (including aspirin, beta blockers, ACE inhibitors). Qualifying patient will be randomized in equal proportions to either percutaneous revascularization of the occluded infarct related artery or medical therapy alone. Patients will be recruited into the trial over a 2 year period, with a subsequent minimum follow-up period of 2.25 years. The primary endpoint of the trial is a composite of all cause mortality, non-fatal MI and hospitalization for class IV heart failure. Cost, cost effectiveness and health-related quality of life are secondary endpoints. In collaboration with the Clinical Coordinating Center and the Statistical and Data Coordinating Center, the Economics and Quality of Life Coordinating Center will perform the following major functions: 1) obtain baseline economic status and quality of life data from all patients enrolled at each participating study site at the time of randomization; 2) collect detailed health resource consumption data from the index hospitalization; 3) assess detailed economic, functional status and quality of life outcomes during follow-up telephone contacts by study site coordinators at 4 months, 1 year and 2.25 years after enrollment; 4) assess angina- and heart failure-related functional status by telephone contacts every 4 months during study follow-up; 5) identify all major medical encounters that occur during follow-up and collect detailed health care resource consumption data and cost data for each; 5) compare cost and quality of life outcomes for the two treatment arms according to intention-to-treat; 7) estimate the incremental cost effectiveness ratio for the experimental arm and perform extensive sensitivity analyses. If efficacy is demonstrated for the primary study endpoint, then the economic and quality of life data collected as part of this proposal will clearly be pivotal in determining how the results of this study are viewed and whether the findings of the trial receive widespread implementation. We propose to use state-of-the-art methods for measuring cost and quality of life and for estimating cost effectiveness. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EPIDEMIOLOGIC STUDIES OF LUNG CANCER RISKS IN NSAID USERS Principal Investigator & Institution: Zheng, Wei; Professor; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917
Studies
25
Timing: Fiscal Year 2001; Project Start 28-JUN-2001; Project End 31-DEC-2006 Summary: (provided by applicant): Cumulative evidence from in vitro and animal studies suggests that the enzyme cyclooxygenase-2 (COX-2) is important in the development and progression of lung cancer. Epidemiologic studies evaluating the association between the use of aspirin (an inhibitor of COX-2) and the risk of lung cancer have been conflicting, and no study has been conducted to evaluate non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs). Using pre-recorded drug prescription databases of the Tennessee Medicaid program and North Jutland County of Denmark, we propose to conduct two studies in these populations to examine the effect of NSAID use on the risk of lung cancer. The first is a retrospective cohort study of over 10,000 enrollees of the Tennessee Medicaid Program who were diagnosed with chronic obstructive pulmonary diseases (COPD) during the period of 1980 to 2002. The second is a population-based, retrospective cohort study of over 150,000 users of NSAIDs in the general population of North Jutland County during the period of 1991 to 2002. Within the Danish cohort will be a nested case-control study of 350 cases and 700 controls, in which relevant information will be obtained on over the counter (OTC) analgesic use, as well as cigarette smoking and other potential confounding factors. The two studies proposed here complement each other and provide for an international comparison of NSAIDs as possible lung cancer chemoprevention agents. Because the data on NSAID use have already been collected, the studies will be very cost-efficient. More importantly, the use of pre-recorded pharmacy records minimizes potential errors in exposure assessment and provides a major advantage over existing cohort studies in evaluating the potential chemopreventive effect of NSAIDs. Given the high incidence and mortality of lung cancer and high prevalence of NSAID use, the results from our studies may have important public health implications in lung cancer prevention, and could set the stage for future randomized trials of COX-2 inhibitors in cancer prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EVALUATION OF ANTIOXIDANT SUPPL IN FOCAL CNS ISCHEMIA Principal Investigator & Institution: Clark, Wayne M.; Neurology; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 31-MAY-2004 Summary: (provided by applicant): Stroke is a major cause of death and disability in the United States. Evidence suggests that even if blood flow is initially restored additional "reperfusion injury" processes can occur that can potentiate brain injury and reduce existing blood flow. Some of the mediators of this "reperfusion injury" appear to be due to an inflammatory responsive involving free radical generation, activated leukocytes, and platelet activated factor. Various commercially available "antioxidant supplements" appear to produce clinical benefit in several diseases. These supplements including Ginkgo biloba extract (EGb) and alpha lipoic acid (LA) have multitude of biologic effects including reducing free radical generation, inhibiting PAF and leukocyte activation (inhibit NFalphaB), and improving cerebral blood flow. Antioxidants have shown benefits in multiple disease models involving reperfusion injury but have yet to be fully evaluated in reperfusion injury related to stroke. This project will investigate the treatment potential and protective mechanisms of selected antioxidants using an animal model that closely approximates clinical stroke. The specific aims of the study are as follows: Aim 1: To confirm and characterize the neuroprotective efficacy of EGb in focal CNS ischemia, determine the effects of EGb on the inflammatory response and CBF, and
26
Aspirin
evaluate safety interventions with other medications used in stroke. Aim 2: To confirm and characterize the neuroprotective efficacy of LA and dihydro lipoic (DHLA) in focal CNS ischemia and determine their effects on the inflammatory response and CBF. This study will use the middle cerebral artery filament occlusion (MCAO) model in the mouse and will utilize a combination of ischemic damage (lesion size) and neurologic functional measurements to determine efficacy. Potential mechanisms of efficacy for each antioxidant will be assessed including effects on in vivo cerebral blood flow (laser doppler measurement of blood flow) and the inflammatory response (molecular and flow cytometry). The information obtained from this project will be critical in planning future clinical stroke trials involving these agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FOLATE, DNA METHYLATION AND CARCINOGENESIS IN THE BOWEL Principal Investigator & Institution: Baron, John A.; Professor of Medicine; Medicine; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2001; Project Start 30-SEP-1993; Project End 30-NOV-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FUNCTIONAL ANALYSIS OF VASCULAR NTPDASES Principal Investigator & Institution: Robson, Simon C.; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-JUL-2004 Summary: CD39 is the prototype ATP/ nucleoside triphosphate diphosphohydrolase (ATPDase/NTPDase; EC 3.6.1.5) member of a family of E-type ectonucleotidases. CD39 modulates purinergic receptor-mediated signaling, following the hydrolysis of ATP and ADP, but also facilitates generation of adenosine for intracellular transport from extracellular adenine nucleotides. Although CD39 appears to be regulated and widely expressed within the vasculature, the functional significance of ectoenzyme expression by the endothelium is unclear. Ectonucleotidases could be involved in the regulation of vascular inflammatory reactions by influencing platelet microthrombi formation, endothelial cell activation or apoptosis and systemic purine homeostasis. To study the functional significance of the vascular NTPDase, the investigators have developed antisense reagents, recombinant adenoviruses and generated CD39-deficient and null mice by homologous recombination. These mutant mice have been shown to be fully viable but have a bleeding diathesis. Platelet hypofunction, secondary to selective purinergic P2Y1 receptor desensitization, can be demonstrated. In keeping with the predicted loss of this vascular thromboregulatory mechanism, fibrin deposition has been observed within the vasculature at multiple sites; the mutant mice also respond adversely to vascular insults and their cardiac xenotransplants rapidly fail. The role of CD39 in modulating differing endothelial cell purinoreceptor mediated effects in vitro and consequent thrombotic reactions in vivo will be further examined in this proposal. Vascular responsiveness to systemic platelet activation, ischemia-reperfusion injury and xenograft rejection will be evaluated in selected vascularized murine tissues overexpressing NTPDase biochemical activtity and in mutant mice deficient in CD39. Reconstitution experiments, using soluble NTPDases, will be performed in parallel. Purinergic mechanisms by which CD39 influences platelet and cellular activation appear to differ from those associated with endothelial constitutive nitric oxide synthase
Studies
27
(eNOS), a second aspirin-insensitive thromboregulatory system. These pathways may be additive or synergistic and will be studied by in vitro systems and by modulating NO-activity in CD39 mice. The generation of mice deficient in both eNOS and CD39 will also be undertaken. These double knock-outs may be viable; however, a lethal phenotype will be also informative. These experiments should indicate the involvement of the vascular NTPDase/CD39, and also elucidate interactions with NOS systems, in certain vascular inflammatory disorders observed in human disease states. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENES, ANTICARINOGENS AND COLON NEOPLASMS Principal Investigator & Institution: Lin, Henry J.; Professor; Harbor-Ucla Research & Educ Inst 1124 W Carson St Torrance, Ca 90502 Timing: Fiscal Year 2001; Project Start 30-SEP-1996; Project End 31-JUL-2006 Summary: (provided by applicant): The long-term goal is to use genetics and epidemiology to identify targets for prevention of colon cancer. The application is on prostaglandin biosynthesis as a promising target, because aspirin prevents some cases of colon cancer. The hypothesis is that genetic variation in prostaglandin production may mimic aspirin effects and shed light on preventive mechanisms. Work will focus on naturally-occurring mutations in people and targeted mutations in mice in a nuclear prostaglandin pathway defined by: cytosolic phospholipase A prostaglandin H synthase 2 (PTGS2/Cox-2), hematopoietic prostaglandin D synthase (H-PGDS), and peroxisome proliferator-activated receptor gamma. The project builds on discovery among 10 percent of African Americans of a PTGS2/Cox-2 mutation (Val5llAla) near the active site of the enzyme. Specific aims are to: (1) conduct case-control analyses on prevalence of colorectal adenomas and cancer in relation to genetic variants in PTGS2/Cox-2 and H-PGDS; (2) assess human interindividual variation in PTGS2/Cox-2 activity in relation to the Va151 1 Ala enzyme variant; (3) develop in vitro expression assays for novel variants identified in H-PGDS; and (4) develop a knockout mouse model of variation in H-Pgds to complement human epidemiologic studies. Three case-control studies will be used to assess effects of genetic variation on colon neoplasms: a Kaiser sigmoidoscopy study of adenomas (1,700 subjects); a Univ. of North Carolina colonoscopy study of adenomas (800 subjects); and African American cancer cases and controls (roughly 400) from the Multiethnic Cohort Study. Results may lead to better understanding of protective mechanisms involving aspirin and nonsteroidal anti-inflammatory drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENOME-WIDE SEARCH FOR CVD GENE-ENVIRONMENT INTERACTIONS Principal Investigator & Institution: Shuldiner, Alan R.; Professor of Medicine; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2006 Summary: (provided by applicant): The overall objective of this proposal is to localize chromosomal loci (and ultimately genes) that interact with specific environmental exposures to modify risk factors for CVD using state-of-the-art molecular and statistical genetic approaches in the Old Order Amish, a unique closed founder population who are relatively genetically homogeneous, and have very large family sizes and well documented genealogies. Since February 1995, Dr. Shuldiner and his coworkers have recruited and studied over 2500 Amish individuals, 1,000 of whom are participants of Amish Family Calcification Study (AFCS), a study designed to examine independent
28
Aspirin
and joint genetic influences on osteoporosis and coronary artery disease. Extensive phenotypic characterization of AFCS participants include blood pressure, body composition, bone mineral density, lipids, and coronary artery calcification by electron beam CT. DNA already has been collected on all AFCS subjects and a 5-cM genome scan (approximately 800 short tandem repeat (STR) markers) will be completed by Summer 2002. The Specific Aims of this proposal are: (1) To perform four focused short-term interventions and to measure CVD responses in subjects of AFCS including high fat meal and changes in endothelial function as assessed by flow-mediated vasodilation (FMD) studies; cold presser stress and changes in FMD and blood pressure; a high salt and low salt diets and changes in blood pressure; and aspirin therapy and measures of platelet function; (2) To characterize the genetic epidemiology of the CVD related response to each short-term intervention; (3) To identify specific chromosomal loci that influence CVD related responses to the four interventions by performing genome-wide linkage analysis (4) To identify and localize chromosomal regions and genes influencing CVD related responses by exploiting the extended linkage disequilibrium in this relatively young founder population to perform LD mapping with densely distributed single nucleotide polymorphisms (SNPs) within linked regions; and (5) To determine if chromosomal regions linked to, or associated with, variation in CVD trait responses are also linked to, or associated with, variation in coronary artery or aortic calcification. Discovery of context-dependent CVD genes will provide (i) critical insights into molecular mechanisms and new molecular targets for therapeutics; (ii) clinically useful information that will allow physicians to individualize pharmacological and nonpharmacological therapy, and (iii) blood tests for the early detection of susceptibility individuals so that targeted preventative interventions can be instituted. These advances will impact substantially on the quality of life of millions of older Americans with CVD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENOTYPIC DETERMINANTS OF ASPIRIN RESPONSE IN HIGHRISK Principal Investigator & Institution: Becker, Lewis C.; Robert L. Levy, Professor of Cardiology; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2006 Summary: (provided by applicant): Low dose aspirin (ASA) is cost effective and efficacious for the prevention and treatment of coronary heart disease (CHD). The benefit of ASA is thought to be related to the irreversible acetylation of platelet cyclooxygenase-1 (COX-1), resulting in a reduction in platelet aggregation and plateletmediated inflammation. Considerable inter-individual variation exists in the effect of ASA on platelet function, and this variability may be related to genetic variations across individuals. This study will characterize the inhibitory effect of ASA on agonist-induced platelet aggregation, thromboxane and ATP release, aggregation under shear conditions, and surface expression of P-selectin and CD40 ligand in 3200 subjects from 400 multi-generational families, half African American and half white. Participants will be high-risk siblings of patients with premature CHD (previously identified in the Johns Hopkins Sibling Study), along with their adult offspring. Platelet function and plasma inflammatory markers (C-reactive protein, interleukin-1 Beta, interleukin-6, monocyte chemotactic protein-1, and matrix metalloproteinase-9) will be measured at baseline and after 14 days of ASA, 81 mg/day, to characterize ASA-response phenotypes. From a list of candidate genes involved in the known biochemical pathways of platelet aggregation and platelet-mediated inflammation, 20 genes will be initially selected for genotyping of 15-20 single nucleotide polymorphisms (SNPs) per gene, based on biological importnace
Studies
29
and the presence of sufficient known SNPs in coding and/or regulatory regions. After the first 1600 participants have been phenotyped, a complementary genome wide scan of short tandem repeat (STR) markers and fine mapping of up to 5 regions of interest will be done using SNP clusters. Based on linkage analysis, the list of candidate genes will be re-prioritized and additional genotyping will be performed. Analyses will be performed to determine whether ASA responsiveness is heritable and whether it is associated with specific variations in candidate genes or defined haplotypes. The results should lead to a better understanding of the variability among individuals in ASA responsiveness, including possible racial differences, and should enable genotype tailoring of preventive therapy for CHD in high-risk individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHENOTYPES
GLUCURONIDATION
IN
HUMANS--GENOTYPES
AND
Principal Investigator & Institution: Lampe, Johanna W.; Associate Member; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2005 Summary: (provided by applicant): Glucuronidation is an important detoxification process that plays a critical rote in the defense against chemical induced carcinogenesis. drug toxicities, and hormonal imbalances. UDP-glucuronosyltransferases (UGTs) catalyze the transfer of the glucuronyl group from uridine 5'-disphosphoglucuronic acid to endogenous molecules, such as bilirubin and steroid hormones, and exogenous substrates, such as drugs, plant-food Constituents, environmental pollutants, and carcinogens. The resulting glucuronyl products are more polar, generally water-soluble, less toxic, and more easily excreted than the substrate molecules. Polymorphisms in several UGT isoforms influence glucuronidation of xenobiotic compounds, as well as bile acids and some steroid hormones. The opposite reaction, the hydrolysis of such glucuronide moieties by human beta-glucuronidase (f3-G) can restore biologic activity of xenobiotics and steroid hormones. Thus, the impact of beta-G as part of the glucuronidation cycle should also be considered. We postulate that the induction of UGTs and the inhibition of beta-G are plausible mechanisms by which a diet high in vegetables and fruit (V&F) may reduce risk of various diseases. We propose to examine the effects of V&F consumption on UGT and beta-G activities, considering the potential interaction with genetic polymorphisms in several relevant UGTs. The specific aims of this proposal are: 1) To determine whether UGT activity, as measured by acetaminophen and aspirin glucuronide formation and serum bilirubin concentrations, differs by UGT genotypes for the following isozyme polymorphisms: UGTIAI*28, UGT/A6*2, and UGT2B15(D85Y); 2) To measure the effect of feeding specific V&F under controlled dietary conditions on UGT and beta-G activity; and 3) To determine whether the effects of these plant foods on UGT activity differ by UGTgenotypes (UGTJA1*28, UGTIA6*2, UGT2BI5(D85Y)). The project will be implemented in two parts: 1) a cross-sectional study and 2) a feeding study. For the cross-sectional study, we will recruit 300 non-smokers, aged 20-40 years, and who are not taking any medication. We will genotype them for UGTIAI*28, (UGTIA6*2, and UGT2B15(D85Y), measure acetaminophen, aspirin metabolite, and bilirubin conjugation, and serum beta-G activity, and assess diet using a food frequency questionnaire and 3-day food records. For the feeding study, we will recruit a subset of the 300 (30 men and 30 women), based on their UGT genotypes, to take part in two, 14-day feeding periods. We will examine the effect of a high-V&F diet compared to a basal (low-phytochemical) diet on UGT and
30
Aspirin
beta-G activities. The randomized cross-over design will allow us to test efficiently for diet effects within individuals, as well as for gene-by-diet and sex-by-diet interactions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GREATER PHOENIX COMMUNITY CLINICAL ONCOLOGY PROGRAM Principal Investigator & Institution: King, David K.; Banner Good Samaritan Medical Center Phoenix, Az 85006 Timing: Fiscal Year 2001; Project Start 01-SEP-1983; Project End 31-MAY-2003 Summary: The Greater Phoenix Community Clinical Oncology Program (GPCCOP)is a consortium of five hospitals with 67 investigations led by principal investigator David K. King, M.D. Dr. King and many of the investigators have been associated with the CCOP since its initial planning stage in 1982. The continuing long-term goals and specific aims of the GPCCOP include: 1) increased clinical research activities; 2) access to additional clinical trials; 3) further development of cancer control research initiatives and patient accrual; 4) maintenance of quality data management; 5) pharmacy resources to coordinate and manage drug distribution; 6) involvement of primary care physicians in state-of-the- art cancer management and education; and 7) continued development of data management systems to support NCI evaluations. GPCCOP's organizational structure requires the involvement of the Co- Principal Investigators and hospital administrators from each of the participating institutions in the planning and policymaking decisions of the CCOP. The physicians, nurses and administrative staff have active roles in guiding the GPCCOP toward attainment of its goals. This experienced team has demonstrated their commitment and ability to accrue patients to both therapeutic and cancer control protocols while maintaining high levels of quality control and timely submissions. GPCCOP's data management systems were recognized by SWOG in 1991 with the Outstanding Achievement Award. Additional investigators, specializing in medical and radiation oncology, have been recruited to the GPCCOP to ensure the availability of total patient care for the 3000 average new patients seen each year. By adding investigators from the Tucson area and adding the GOG as a research base, a higher level of participation is expected. The above resources, the placement of 347 patients on treatment protocols and 1097 patients on cancer control trials during the period 1989 to present demonstrate GPCCOP's preparedness to continue its active participation in NCI's Community Oncology Program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GROWTH FACTORS AND COLON CANCER Principal Investigator & Institution: Slattery, Martha L.; Professor; Family and Preventive Medicine; University of Utah 200 S University St Salt Lake City, Ut 84112 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-AUG-2005 Summary: Cell growth and proliferation are central to carcinogenesis. Scientific evidence that growth hormones, and genetic variants that influence these growth hormones, are importantly related to colorectal cancer is increasing. Furthermore, insulin and insulin-like growth factors (IGF), growth hormones that appear to be important for colorectal cancer, are influenced by previously identified risk factors for colorectal cancer such as body size and physical activity. In this study we will use existing lifestyle and metabolic exposure data; known tumor mutational status of microsatellite instability and K-ras mutations; and available germline DNA from an incident colorectal cancer case-control study of approximately 3000 cases and 3000
Studies
31
controls to study how genetic variants that influence growth hormones and cell growth and proliferation relate to development of colorectal cancer and subsequent survival after diagnosis. The study focuses on genetic and environmental interaction. Specific genes examined are molecular variants of genes along insulin pathway, including the IGF1 gene, insulin- like growth factor binding protein-3 (IGFBP3), the insulin receptor substrate gene 1 (IRS-1), the insulin receptor substrate gene-2 (IRS-2); the peroxisome proliferator-activated receptor gamma gene (PPARgamma), apolipoprotein E gene (ApoE), and the vitamin D receptor gene (VDR). We hypothesize that these variants are associated with altered risk of colorectal cancer in conjunction with genetic, diet, and lifestyle factors. Specially, we hypothesize that molecular variants of IGF1, IGFBP3, IRS1, IRS-2, PPARgamma, ApoE, and VDR interact with dietary such as calcium, vitamin D, sugar, and glycemic index; sunshine exposure, physical activity, aspirin use, and body size to alter risk of colorectal cancer; that molecular variants of IGF1, IGFBP3, IRS-1, IRS2, PPARgamma, ApoE, and VDR are associated with specific types of mutations in tumors including microsatellite instability and K-ras mutations; and that molecular variants of IGF1, IGFBP3, IRS-1, IRS-2, PPARgamma, ApoE, and VDR are associated with survival after diagnosis. To test the hypothesis that these variants interact with dietary and other factors, it is necessary to have a large sample size, such as the one available. Molecular variants of these genes that are involved in the insulin and growth factor disease pathway will be determined. Statistical analyses will use logistic regression and survival methods. This study builds on a unique existing resource to study genetic and environmental associations with colorectal cancer. It will provide insight into colon cancer etiology and therefore avenues to disease prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: H+ NEUTRALIZATION AND C1- HOMEOSTASIS IN GASTRIC MUCOSA Principal Investigator & Institution: Soybel, David I.; Associate Professor of Surgery; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-FEB-1992; Project End 31-JAN-2003 Summary: (Adapted from investigator's abstract) This application represents a continuation of the principal investigator's FIRST Award. The long-term goal of this project is to evaluate, at the cellular level, the mechanisms that protect gastric mucosa from the damaging effects of luminal acid. Until recently, it was accepted that a Cl/HCO3- exchanger, located in the basolateral cell membrane, is responsible for regulation of intracellular Cl- levels (aiCl) and intracellular pH (pHi) in surface cells and oxyntic cells. We recently found evidence to suggest that a basolateral Na-K-Cl cotransport process plays a dominant and previously unsuspected role in preserving intracellular Cl- levels of the surface cells and in regulating HCl secretion by oxyntic cells. These findings have altered the previous model and led to the following hypotheses: 1) a basolateral, HCO3--independent, Na-K-Cl cotransporter is the dominant mechanism for regulating aiCl of oxyntic cells and surface cells in Necturus gastric fundus during stimulation of acid secretion; 2) a complementary, Cl-independent mechanism of basolateral HCO3-extrusion is also present in the oxyntic cell and contributes significantly to the "alkaline tide" generated by high rates of acid secretion; 3) expression of basolateral transporters that are dominant in preserving aiCl and pHi in the oxyntic cells is regulated by the gastric neurohumoral milieu; 4) secretory activity of the oxyntic glands plays a major role in regulating cell pH and ion composition of the neighboring surface epithelial cells during high rates of acid secretion and during exposure to ulcerogenic conditions; and 5) the ammonium (NH4+)
32
Aspirin
ion that is produced by the pathogen H. pylori may gain access to the cell via the Na-KCl cotransporter, leading to disturbances in both aiCl and pHi. Studies proposed in this application will address these hypotheses using intracellular microelectrode and fluorescence techniques for measuring pH and ion composition, and molecular methods for evaluating expression of membrane transporters. The specific aims of this application are organized into four parts. First, we will evaluate the relationship of the basolateral Cl--transporting processes and their implications for regulation of HCO3transport and other protective functions in both surface cells and oxyntic cells in the mucosa of the gastric fundus of Necturus. Second, we will examine, in both amphibian and mammalian models, the effects of secretory agonists such as gastrin, histamine, carbachol in stimulating synthesis and expression of the basolateral HCO3- and Cltransport systems in surface cells and oxyntic cells of gastric mucosa. Third, we will evaluate the effects of ulcerogens such as aspirin or indomethacin on activity and expression of basolateral Cl- transport systems in both surface cells and oxyntic cells. Finally, we will explore the interaction between ammonium (NH4+), which is produced by the bacterium Helicobacter pylori, and cell pH and Cl- homeostasis. Using these techniques, we hope to provide detailed information regarding activity and expression of transport processes that preserve ion composition and pH in gastric mucosal cells during acid secretion or exposure to ulcerogenic conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEART ATTACKS AND TRAFFIC POLLUTION Principal Investigator & Institution: Schwartz, Joel D.; Director of Research & Development; Environmental Health; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2002; Project Start 26-SEP-2002; Project End 31-JUL-2007 Summary: (provided by applicant ): Since the late 1980's, numerous studies have found particulate air pollutant concentrations to be responsible for excess mortality. More recent studies have clarified that most of these deaths are sudden deaths. We have recently shown that particles from traffic are more specifically associated with acute cardiovascular effects. We have also shown the pre-existing diabetes was an important modifier of the particle effect. All of these studies have looked at immediate effects. Two prospective cohort studies have indicated that long-term exposure to particles is also associated with noticeable reductions in life expectancies. To replicate the association between chronic exposure and deaths, and examine the specific role of traffic particles we will conduct a case-control study of myocardial infarctions, using data from the Worcester Heart Attack Study. We will use a GIS system to code the latitude and longitude of home and work locations of cases and controls, and fit models relating concentrations of elemental carbon (a tracer for traffic particles) to population density, distance from roadways, and traffic counts in the Worcester MSA. From this, we will assign exposures to each subject. Controls will be sampled from town census books, which are conducted annually in Massachusetts. Controls will be matched by age, sex, and 10 year age group. Socio-economic data will be merged from the block group of the subjects, and questionnaire data will assess smoking history, alcohol consumption, aspirin and other medication use, educational level, height, weight, age, race, exercise, and air conditioner use. We will also ask about the presence of medical conditions, such as diabetes, that may be modifiers of the effect of pollution. Nonlinearities in covariates will be assessed and controlled for using penalized splines, in conditional logistic regressions. A preliminary analysis will use retrospective data, and not obtain
Studies
33
questionnaire data. Effect modification by diabetes, prior MI, COPD, smoking, and angina will be tested using interaction terms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HORMONE REPLACEMENT THERAPY AND PROTHROMBOTIC VARIANTS Principal Investigator & Institution: Psaty, Bruce M.; Professor, Medicine and Epidemiology; Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2006 Summary: (provided by applicant) Estrogens are prothrombotic. Recently, the Heart and Estrogen/progestin Replacement Study (HERS), renewed interest in the adverse effects of hormone replacement therapy (HRT). In HERS, HRT was no better than placebo at preventing coronary events. In post hoc analyses, treatment was associated with early harm and late benefit. In an AHA-funded case-control study, we identified a potential interaction between HRT and the prothrombin G20210A variant on the risk of first myocardial infarction (MI) in post-menopausal women with hypertension. Aims: The primary purpose is to examine the potential interactions of hormone replacement therapy with other procoagulant variants on the risk of cardiovascular events, and the main variants of interest are: (la) factor XIIIA Val34Leu; (ib) platelet glycoprotein (PGP) Jib Ile843Ser; (ic) PGP IIIa Leu33Pro; and (id) PGP Ia C807T. The secondary aims include the assessment of other drug-gene, risk-factor-gene or gene-gene interactions on risk: (2a) the interaction between PGP IIb Ser843, PGP lila Leu33Pro and PGP Ia C807T and traditional cardiovascular risk factors such as smoking and obesity on the risk of MI and stroke; (2b) the interaction between three coagulation factor XIII polymorphisms and PAl-1 4G/5G on the risk of stroke in women; and (2c) the interaction between aspirin use and glycoprotein IIIa Leu33Pro on the risk of MI and stroke. Methods: The setting is Group Health Cooperative (GHC). GHC computerized files will be used to identify postmenopausal females, aged 30 to 79 yrs, with incident MI or stroke during 1/200012/2004. Population-based controls, sampled from the GHC enrollment files, will be frequency matched to cases by age, calendar year, and treated hypertension. Data collection will include medical-record review, telephone interview of consenting subjects, and venous-blood collection. Standard methods will be used to assay variant alleles. The GHC computerized pharmacy records will serve as the primary source of information about the use of HRT. Data analysis will involve restriction, stratification, and logistic regression. Case-control and case-only analyses are planned. By including subjects recruited in previous and on-going studies, the proposed project will also enable us to test new hypotheses efficiently in a total of 600 MI cases, 420 stroke cases and 1800 controls. Power for primary and secondary aims is excellent. Information from this project may help physicians counsel women about HRT to maximize either effectiveness, or safety, or both. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HORMONES AND BIOMARKERS PREDICTING STROKE IN WOMEN Principal Investigator & Institution: Wassertheil-Smoller, Sylvia W.; Professor; Epidemiology & Population Health; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 30-JUN-2006
34
Aspirin
Summary: (provided by applicant) The Women's Health Initiative clinical trial of estrogen plus progestin for the prevention of cardiovascular disease in healthy, postmenopausal women, which was recently stopped due to adverse effects, as well as other secondary prevention clinical trials, have found increased risk of stroke in users of estrogen plus progestin. We wish to investigate possible mechanisms for such an increase by studying biomarkers of hemostasis /inflammation as risk factors for ischemic stroke and as mediators of stroke related effects of hormone replacement therapy and other risk factors, including hypertension and lifestyle variables. The goal of the proposed study is to determine whether blood-based biomarkers related to systemic inflammation, and/or atherothrombosis/hemostasis/coagulation may be important risk factors for ischemic stroke and subtypes of ischemic stroke among older women. We will conduct a population based nested case-control study of 1050 ischemic stroke cases and 1050 matched controls among participants in the Observational Study component of the Women's Health Initiative (WHI-OS). The WHI-OS, conducted in a multi-ethnic cohort in 40 centers throughout the United States, is a prospective study of 93,676 postmenopausal women, followed for 8 to 12 years, with extensive baseline and follow-up data including blood and DNA specimens collected and stored at baseline. Multivariate modeling techniques will be used to investigate the associations of selected biomarkers, hypertension, hormone use and lifestyle variables, with risk of ischemic stroke and specific stroke subtypes as classified by central adjudicators. We will also determine whether the effects on stroke risk of established risk factors (hypertension, smoking, diabetes) and use of specific medications (statins, aspirin, non-steroidal antiinflammatory agents, estrogen and progesterone) will be modified in the presence of markers of inflammation and/or of atherothrombosis/hemostasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IATRONGENIC CAUSES OF CANCER Principal Investigator & Institution: Ross, Ronald K.; Professor; Preventive Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 01-APR-1979; Project End 31-JAN-2004 Summary: This proposal requests continued support for a Program Project Grant (PPG) to conduct epidemiologic and biostatistical research on iatrogenic causes of cancer by investigators at the Kenneth Norris Jr. (University of Southern California) Comprehensive Cancer Center. This PPG is currently in its 16th year of continuous funding. The professional staff of this Program consists of 11 epidemiologists and statisticians with major research interests in iatrogenic exposures and cancer. The Scientific Program of the current application consists of 3 case-control studies. The successful conduct of these 3 projects depends on 5 core resources. The 4 projects include the following: (1) A continuation of an ongoing case-control study of the relationship of hormone replacement therapy and breast cancer risk in postmenopausal women. An expanded study will allow more detailed and precise evaluation of duration and latency effects, the evaluation of interactions and adequate adjustment for confounding factors; (2) A continuation of an ongoing case- control study of analgesics and diuretics and renal cell carcinoma. Preliminary results suggest that acetaminophen is associated with a greater increment in risk than aspirin, but the strong correlation between different formulations requires larger sample sizes to determine independent effects; and A continuation of an ongoing case-control study of diagnostic radiation and acute myelogenous leukemia. Preliminary data suggest a dose response relationship between trunk x-rays and risk but results are not statistically significant. The major core resource for this PPG is the Cancer Surveillance Program, a rapid ascertainment
Studies
35
population-based tumor registry. Other core resources include a Medical Record Retrieval Core for validating self-reported prescription medications, diagnostic and therapeutic radiation, a Control Identification Core for identifying neighborhood controls for case-control studies, a Statistical Core for developing strategies for analyzing the types of studies described above and an Administrative Core for overseeing the scientific direction of the PPG and handling its fiscal administration. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL Principal Investigator & Institution: Shoelson, Steven E.; Senior Investigator; Joslin Diabetes Center Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 21-SEP-1996; Project End 31-AUG-2005 Summary: (Adapted from the applicant's abstract) This application is based on new data from the applicant's laboratory indicating that the protein kinase IKKb may act to inhibit the insulin signaling pathway. This function is presumably a result of IKKb-mediated phosphorylation of one or more elements in the pathway whereby insulin receptor tyrosine kinase and its substrates are linked to glucose transport. Data presented in the application show decreased phosphorylation of IRS proteins in response to insulin when cells are transfected with IKKb, and also very significant effects of aspirin to reverse decreased IRS phosphorylation due to TNF and protein serine phosphatase inhibitors. Further, the applicant shows data indicating that poor glucose tolerance in insulin resistant mouse models such as ob/ob mice are ameliorated by aspirin treatment, which blocks IKKb. Based on these findings, the applicant proposes to test the hypothesis that the IKK signaling cascade is activated by conditions associated with insulin resistance and that inhibition of IKKb reverses insulin resistance by sensitizing the IR/IRS/ PI 3kinase signaling cascade. Specific aims include attempts to determine upstream and downstream elements in the IKK pathway in respect to various models of insulin resistance. The mode of interaction of IKK with the IR/IRS proteins will also be approached. Other experiments will use animal models of insulin resistance to address the pharmacological profile for IKKb inhibition in vivo using various salicylates, and to directly determine the target of salicylate-mediated insulin sensitization. Finally, clinical studies are proposed to determine whether IKKb inhibition reverses insulin resistance in humans with impaired glucose tolerance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMPROVING ANTI-THROMBOTIC USE IN STROKE PREVENTION Principal Investigator & Institution: Beyth, Rebecca J.; Assistant Professor of Medicine; Medicine; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: (provided by the applicant): Atrial fibrillation is a common disorder and an important risk factor for stroke. Evidence from controlled clinical trials shows that adjusted-dose warfarin decreases the risk of stroke by two-thirds. Clinical practice guidelines recommend that most atrial fibrillation patients receive life-long anticoagulation; only about one-third of atrial fibrillation patients receive it. This study is a randomized controlled trial of an intervention (the RBC) to increase the appropriate use of anti-thrombotic therapy (warfarin and aspirin) for stroke prevention in patients with chronic atrial fibrillation. The intervention is a tailored patient-specific risk-benefit consult (RBC) that incorporates the risks and benefits of anti-thrombotic therapy for stroke prevention using the American College of Chest Physicians guidelines and the
36
Aspirin
Outpatient Bleeding Risk Index, a validated risk assessment for major bleeding. The intervention is aimed at primary care providers practicing in different clinical settings. Evidence-based specific recommendations about the use of anti-thrombotic therapy, as well as the quality of anti-thrombotic management will be formulated for each atrial fibrillation patient in the intervention physician's panel. The control and the intervention physicians will also receive performance feedback in the form of an Achievable Benchmark of Care (ABC) that informs them of the percentage of their patient panel with atrial fibrillation that is receiving anti-thrombotic therapy in relation to the other physicians (intervention or control) in their group. The primary outcome is the change, pre-to post-intervention, in the proportion of eligible patients with chronic atrial fibrillation who are prescribed anti-thrombotics. This will be measured by the proportion of the eligible patients in each physician's panel for whom anti-thrombotics are currently prescribed at baseline, 6-months, and 12-months. Secondary safety outcomes are the proportion of individuals in the physician's panel with stroke, the proportion of anticoagulated patients with major bleeds, and the proportion of total treatment time during which the International Normalized Ratio is below, above and within therapeutic range. This study will test a novel and generalizable approach to increasing the appropriate use of anti-thrombotic therapy in patients with atrial fibrillation in a community setting and the findings will provide valuable insight into stroke prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMPROVING UTILIATION OF ISCHEMIC STROKE RESEARCH Principal Investigator & Institution: Borbas, Catherine; Executive Director; Minneapolis Medical Research Fdn, Inc. 600 Hfa Bldg Minneapolis, Mn 55404 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2003 Summary: Although few therapies exist for directly decreasing neural tissue damage caused by stroke, much can be done to improve (or worsen) patient outcome. Despite extensive research evidence including randomized control trials and meta-analyses that demonstrate the efficacy of specific acute ischemic stroke therapies and processes of care (i.e. appropriate and timely provision of rt-PA, aspirin, antihypertensives, antiembolics, antithrombotics, mobilization, physical and occupational therapy, and patient and family education), there is evidence to suggest that these therapies are underutilized. The American Heart Association and the American Academy of Neurology have developed and actively disseminated ischemic stroke guidelines regarding these drug therapies and processes of care. The overall goal of this project is to build on our previous AHRQ funded research to assess the effectiveness of a replicable and an innovative model for accelerating the application of evidence-based treatment guidelines for acute ischemic stroke. We will use a randomized controlled design in a voluntary consortium of hospitals (N=24) in Minnesota to test a hospital based intervention involving feedback of both hospital specific clinical performance data and information on relevant personal and interpersonal characteristics of staff and organizational capacity shown to be predisposing and enabling factors associated with organizational change. At the experimental hospitals, we will work with both informal clinical opinion leaders and members of the formal leadership (i.e. CEO, Nursing Director) to use this information to improve performance in the targeted areas. At the control hospitals, we will provide a minimalist intervention involving informal opinion leaders but not hospital leadership. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
37
Project Title: IN VIVO ROLE OF NF-KB/REL FACTORS IN IMMUNE RESPONSES Principal Investigator & Institution: Sha, William C.; Assistant Professor; Molecular and Cell Biology; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2001; Project Start 01-JAN-1998; Project End 31-DEC-2002 Summary: (Adapted from the Investigator's abstract): NF-kappaB/Rel transcription factors are a family of five proteins which function as dimer complexes in the regulation of genes involved in innate and specific immunity. This study will examine how these transcription factors regulate in vivo immune responses. Our experimental approach will utilize gene-targeted mice for individual family members in combination with two unique experimental approaches. The first approach uses a histochemical marker that directly monitors in vivo NF-kappaB/Rel activation. This marker was created by targeted introduction of a lacZ reporter gene into the I-kappa-B-alpha locus. The second approach uses retroviral vectors tagged with a green fluorescent protein to reconstitute primary B-cells with specific forms of NF-kappaB/Rel proteins. Retroviral reconstitution will be used to determine how individual complexes regulate class switching and immunoglobulin secretion in B-cells. Defining the natural physiological roles of these factors will directly contribute to understanding why certain members are protooncogenes, and how their disregulation can lead to oncogenic activation in human cancer. Determining how these factors regulate immune responses will also produce a better understanding of the in vivo action of clinically relevant drugs, such as aspirin and glucocorticoids, that have been identified as inhibitors of this transcription factor family. Specific Aim 1 will determine when and where NF-kappaB/Rel complexes are activated in vivo during the natural history of an immune response to a T-cell dependent antigen. Specific Aim 2 will examine in vivo how the absence of individual NF-kappaB/Rel factors disrupts effective immune responses and determine the cellular basis for defective responses. Aim 3 will define roles of specific NF-kappaB/Rel complexes in primary B-cells in regulating immunoglobulin secretion and class switching. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INSULIN RESISTANCE IN TISSUE SPECIFIC IKKB TRANSGENICS Principal Investigator & Institution: Lee, Jongsoon; Joslin Diabetes Center Boston, Ma 02215 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2004 Summary: (provided by applicant): Our studies in insulin resistant cells and animals, and type 2 diabetic patients showed that the IkappaB kinase, IKKbeta, plays a central role in acquired insulin resistance. In 3T3-L1 adipocytes and Fao hepatoma cells, activation of IKKbeta by treatment of TNF or by transfection of upstream kinase, NIK, or constitutively active IKK, induced cellular insulin resistance-decreased insulinstimulated Tyr phosphorylation of IR and IRSs. Inhibition of IKKbeta by specific inhibitors- high doses of salicylates (NaS) or aspirin (ASA)- or by transfection of dominant negative IKKbeta reversed TNF-induced insulin resistance. Treatment of high doses of NaS or ASA to type 2 diabetes patients or obese and insulin resistant animals reversed insulin resistance as judged by glucose tolerance test (GTT), insulin tolerance test (ITT) and hyperinsulinemic, euglycemic clamp studies. Hyperglycemia, hyperinsulinemia, and dyslipidemia are normalized by ASA treatment. Insulin signaling studies conducted with tissues isolated from the rodents show that insulinstimulated Tyr phosphorylation of IR and IRS are increased due to decrease in inhibitory Ser/Thr phosphorylation of IRSs. Heterozygous deletion (IkkBeta +/-) in
38
Aspirin
mice reduced fasting glucose and insulin concentrations, and protected against the development of insulin resistance during high-fat feeding and in obese Lep-ob/ob mice. We also found that obese animals have higher IKK kinase activity than control animals. To study which tissue(s) are important for IKK-mediated insulin resistance and for the reversal of insulin resistance by salicylates, we generated mice expressing constitutively active IKKbeta in fat, muscle and liver with the hypothesis that increasing IKKbeta activity in animal tissues may itself induce insulin resistance. We now have colonies of all three tissue transgenic mice and found that fat- and liver-specific transgenic mice have developed insulin resistance as early as 4 week-old. We will characterize these mice to determine which tissue is responsible for IKKbeta-induced insulin resistance and how activation of IKKbeta in one tissue can induce whole body insulin resistance. These experiments will validate IKKbeta as a major mediator of insulin resistance and as a useful target for the discovery of new drugs to treat type 2 diabetes and insulin resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IONDT FOLLOW-UP STUDY Principal Investigator & Institution: Kelman, Shalom E.; Ophthalmology; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2001; Project Start 19-FEB-1992; Project End 31-JAN-2003 Summary: The Ischemic Optic Neuropathy Decompression Trial (IONDT), the first multicenter, prospective randomized controlled trial of newly diagnosed patients with non-artertic anterior ischemic optic neuropathy (NAION), found that optic nerve decompression surgery (ONDS), when compared to careful foIlowup, is not effective and may be harmful to a patient's visual acuity. Randomized patients have been followed for 1 to 3 years (median = 1.51 years) since onset of symptoms. Patients with NAION whose vision was better than 20164 were not randomized to treatment but were followed as a natural history cohort for the same length of time. The goal of the IONDT Followup Study is to follow all patients enrolled in the IONDT to learn more about the natural history of NAION, specifically: incidence of NAION in the second eye; changes in visual acuity over time in the study and fellow eyes; incidence of systemic disease; health-related quality of life (QOL); medication use, including aspirin; and risk factors for ocular and systemic events occurring after enrollment. An additional goal of the Followup Study will be to analyze all visual fields and fundus photographs accumulated during the IONDT and IONDT Followup Study. IONDT patients will be followed at all 24 participating Clinical Centers an additional four years at annual visits related both to the effect of ONDS and the natural history of NAION. Examinations will consist of ophthalmic examinations, measurement of visual acuity and visual field. In the event of NAION occurring in the second eye, a special visit will be scheduled at the Clinical Center, which will be similar to annual visits with the addition of fundus photographs. At three month intervals between annual visits, a coordinator located at the Coordinating Center will telephone patients to maintain high rates of patient followup, ensure that annual visits take place, and determine whether any ophthalmic or medical events have occurred between annual visits. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LIPID MEDIATORS IN NEUTROPHIL RESPONSES Principal Investigator & Institution: Van Dyke, Thomas E.; Professor; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118
Studies
39
Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: The goal of this proposal is to determine the exact roles of lipid mediators (i.e. diacylglycerols [DAG's] and Presqualene Diphosphate [PSDP] in periodontal inflammation, and to develop novel molecular strategies to pharmacologically interrupt the inflammatory cascade. We will focus on Localized Juvenile Periodontitis (LJP), which presents neutrophils with a classically "primed" phenotype, i.e. hyperresponsiveness in superoxide production during cell stimulation. Previous work by this group (see Project 1) has revealed that a new class of compounds, the so called aspirin triggered lipoxins that are potent natural inhibitors of inflammation in various models, and block superoxide production in neutrophils. These compounds are thought to exert their effects, at least in part, by increasing the cellular levels of PSDP. To accomplish our goals, we will characterize the biochemical basis for the primed state in LJP neutrophils and elucidate the molecular mechanism(s) responsible for PSDP inhibition of superoxide production by determining: 1. the chemical nature and the source of the elevated diacylglycerol (DAG) in LJP neutrophils; 2. the biochemical basis for the reduce activity of DAG kinase in neutrophils from LJP, including preparation of specific anti- peptide antibodies to the various isoforms and subtypes of DAG kinase to identify the species present in neutrophils, determining if the pronounced diminution of DAG kinase in neutrophils from LJP is due to the absence of one or more isoforms of this kinase, characterizing the isoform of DAG kinase that associates with Rac and Cdc42 in normal neutrophils, and determining if this situation is altered in LJP; 3. the mechanism(s) by which PSDP inhibits superoxide production in PMN stimulated permeabilized neutrophils, including inhibition of the phosphorylation of p47-phox, p67-phox or p40phox, blocking assembly of the NADPH oxidase complex by inhibiting translocation of p47-phox, p67-phox and/or Rac to the plasmalemma, blocking activation of Rac (and other small GTPases) by inhibiting nucleotide exchange, finally comparing these experiments in normal neutrophils to those from LJP; and 4. characterizing the phosphatase that catalyses the conversion of PSDP to PSMP, including the subcellular location and substrate specificity of the PSDP-phosphatase (i.e. will this enzyme also catalyze dephosphorylation of phospatidate and sphingosine-1-P?), the kinetic (Km, Vmax) and physical properties (molecular weight, isoelectric point) of the enzyme, and the PSDP-phosphatase activity during cell stimulation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LONGITUDINAL OPHTHALMOLOGY
STATISTICAL
METHODS
FOR
Principal Investigator & Institution: Davidow, Amy L.; Prev Med and Community Health; Univ of Med/Dent Nj Newark Newark, Nj 07103 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2003 Summary: (Applicant's Abstract) The proposed project is a two year study to develop inferential and study design aspects of a linear statistical model appropriate to the analysis of longitudinal ophthalmologic data and to apply the improved model in a reanalysis of a data set obtained from the Early Treatment Diabetic Retinopathy Study (ETDRS). The relevant statistical model is the repeated-measures random effects/AR(l) model for continuous data due to Heitjan and Sharma. This model incorporates crosscorrelation between eyes and longitudinal correlation among measurements obtained from a single eye. The re-analysis of the ETDRS data set will consider the effects of aspirin on visual acuity measured continuously. A previously published analysis (ETDRS Report Number 8) analyzed a categorical version of visual acuity, ignoring longitudinal correlation and handling cross-correlation between eyes by analyzing eyes
40
Aspirin
separately. The repeated measures random effects /AR(l) model has already been utilized by Heitjan and Sharma in a published study of intraocular pressure, using the expected information to perform statistical inference. Simulation studies have shown that it performs well in the balanced data case. Our first objective is to develop better inferential methods so as to 1) handle unbalanced (i.e., missing) data such as that arising when only one eye of two has the disease of interest and/or when the number of followup visits varies with subject, 2) control for the use of a possibly mis-specified variance structure, and 3) compensate for the use of estimated variance parameters in the standard error of the fixed effects, a procedure that may result in an underestimation of the standard error. This objective will be accomplished by the following: 1) replacing the expected information with the observed information, the observed information being a more reliable method of performing statistical inference in the presence of missing data, 2) using the robust (sandwich) variance estimator, a method that can control for a possibly mis-specified variance structure, and 3) approximating the degrees of freedom so as to control for the possibility of underestimated standard errors. Methodological advances will be incorporated into a computer package to be made available on the World Wide Web. Our second objective is to carry out power and sample size calculations for several different longitudinal ophthalmologic study designs, under various assumptions about the prevalence of bi-ocular versus uni-ocular disease, differential treatment allocation, loss-to-follow-up, and expected adherence to study treatment(s). The implications of treatments applied at the eye-level (e.g., photocoagulation) as well as systemically applied treatments (e.g., aspirin) on sample size, frequency of evaluation, and power will be considered. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS FOR CHEMOPREVENTION OF COLORECTAL CANCER Principal Investigator & Institution: Dubois, Raymond N.; Professor; Medicine; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 07-APR-1999; Project End 31-JAN-2004 Summary: OVERALL (Applicant's Description) The overall goal of this Program Project Grant is to determine the molecular mechanisms involved in the chemoprevention of colorectal cancer by non- steroidal anti-inflammatory drugs (NSAIDs). In this regard, we will specifically test the hypothesis that the cyclooxygenase (COX) pathway and/or its eicosanoid products play a role in colorectal carcinogenesis. Colorectal cancer is the second leading cause of cancer related deaths in the United States. This year alone, approximately 55,000 Americans will die from this disease. Recent clinical research has revealed a 40-50% reduction in mortality from colorectal cancer in persons who take aspirin and other NSAIDs on a regular basis. Cyclooxygenase enzymes are known targets for NSAIDS. Two isoforms of cyclooxygenase have been characterized and they are referred to as Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) in this proposal. Previous work conducted by investigators involved in this program grant has demonstrated that there is a 2-50 fold increase in COX-2 expression in 85% of human colorectal adenocarcinomas and in 45-50% of adenomas. The goals of this program are to test the hypothesis that COX or its eicosanoid products play a role in colorectal carcinogenesis and to determine the molecular mechanisms by which NSAIDs prevent colorectal cancer. Here we provide an overview of the projects proposed to test this hypothesis and highlight how planned interactions among the investigators will aid significantly in the success of this program project. In addition, the role of COX-2 and prostaglandins in the pathogenesis of colorectal cancer is discussed, so as to provide a
Studies
41
rationale for undertaking the projects that are proposed. There are four projects and three cores included in this revised Program Grant application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR EPIDEMIOLOGY OF MI AND STROKE IN OLDER ADULTS Principal Investigator & Institution: Reiner, Alexander P.; Epidemiology; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): This project represents a collaborative effort among investigators of the Cardiovascular Health Research Unit, Department of Genome Sciences at the University of Washington (UW), and the multi-center Cardiovascular Health Study (CHS), including the CHS Blood Laboratory at the University of Vermont. The proposal links advances in thrombosis and inflammation biology, large-scale human genomics, and population and statistical genetics, with the unique resources of CHS, a large, bi-racial cohort of older adults. In older men and women without clinically apparent vascular disease, carotid intimal-medial thickness or IMT (a measure of subclinical atherosclerosis), C-reactive protein (a sensitive marker of inflammation), and D-dimer (a global marker of activation of the hemostatic system) predict subsequent clinical events such as MI and stroke. While the therapeutic benefits of thrombolytic therapy and aspirin suggest a major role for clotting and inflammation in the etiology of coronary disease and stroke, the genetic determinants of these risk factors, which are also influenced by traditional lifestyle risk factors such as smoking and obesity, remains largely unexplored in older adults. The setting for this study is the Cardiovascular Health Study, a cohort study of 5888 older adults designed to assess risk factors for stroke and coronary disease. Data on traditional risk factors, on measures of subclinical disease, and cardiovascular events are available to the proposed ancillary study. By integrating recent clinical and experimental data on age-related and vascular bedspecific regulation of blood coagulation, and incorporating complete human genomic DNA sequence variation data from the NHLBI-funded UW Program for Genomic Applications, we propose to evaluate thoroughly the association of thrombosis and inflammation genes with (1) carotid IMT, CRP, and D-dimer levels measured at baseline and (2) incident MI and stroke in adults >65 years old followed for up to 12 years. The strengths of the proposal include a focus on several sets of biologically related genes, the selection of common SNPs based on the complete linkage disequilibrium or common haplotype structure of each candidate gene, and a flexible analytic approach that allows assessment of single-locus and multi-locus genotypes, haplotypes, as well as geneenvironment and gene-gene interaction. We expect this multi-disciplinary approach to enable the detection of genetic variants that influence CVD susceptibility or modify the response to conventional cardiovascular risk factors. Understanding the molecular background of these common but complex athero-thrombotic disorders may help identify older individuals at high cardiovascular risk because of genetic or environmental differences in the inflammatory or thrombotic response to advanced atherosclerosis and provide new directions for prevention and treatment of MI and stroke. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
42
Aspirin
•
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Mabie, Bill C.; Obstetrics and Gynecology; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2001; Project Start 05-MAY-1996; Project End 31-MAR-2002 Summary: The Department of Obstetrics and Gynecology at the University of Tennessee, Memphis has been part of the Maternal-Fetal Medicine Network since April 1986. With this application, we hope to participate in a large multicenter network designed to develop and conduct clinical trials in the field of Maternal-Fetal Medicine, which could not be undertaken in a single center. In comparison to our previous application, we have recently expanded our resources and facilities to include patients at all major hospitals in the city. The obstetric population will now total approximately 13,000 women of various ethnic and economic groups. We are particularly interested in pursuing trials which require large sample size in order to adequately address specific questions and those regarding rare events of obstetric interest. The Principal Investigator, Dr. Baha Sibai, and the Alternate Principal Investigator, Dr. Brian Mercer, as well as the faculty in the Division of Maternal-Fetal Medicine continue to be active in Network administrative activities, and the design and conduct of protocols. The Principal Investigator currently participates on the Concurrent Research Committee, the Ad Hoc Committee on Preterm Studies, and the "High-Risk" Aspirin Protocol, the Interim Progesterone, and the Preliminary Terbutaline subcommittees. The Alternate Principal Investigator chairs the "Premature Rupture of Membranes" protocol and the Chart Review Subcommittee. He serves on the Capitation Subcommittee, Preterm PROM Pathology Subcommittee, Preterm Prediction Protocol Subcommittee, Obstetrical Determinants of Neonatal Survival Protocol Subcommittee, Neural Tube Defect Protocol Subcommittee and the Preliminary MgSO4 Subcommittee. He has recently submitted for consideration a clinical trial regarding tocolytic, corticosteroid and antimicrobial therapy after PROM. We are applying to continue as a clinical research center within the Network and agree to join protocols in existence and participate in the design of protocols in cooperation with other centers selected by the NICHD. The University of Tennessee, Memphis, and the Department of Obstetrics and Gynecology are committed to collaborative Maternal-Fetal research as documented by listed publications and the enclosed letters of commitment. The Division of Maternal-Fetal Medicine agrees to cooperate with the policy of capitation of research costs for each individual protocol, in addition to a base budget. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NATURAL VITAMIN E FORMS AS ANTI-INFLAMMATORY DRUGS Principal Investigator & Institution: Ames, Bruce N.; Professor; Children's Hospital & Res Ctr at Oakland Research Center at Oakland Oakland, Ca 94609 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Chronic inflammation constitutes one of the major etiologies of degenerative diseases including cancer, and cardiovascular and neurodegenerative diseases; chronic inflammation also contributes to rheumatoid arthritis, asthma and hepatitis. These diseases are among the leading causes of death and disability in the world. During inflammation, several pro-inflammatory mediators including prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), as well as cytokines, such as TNF-alpha, play central roles in regulating inflammatory response and inflammationmediated damage. Vitamin E comprises eight structurally related molecules, alpha-
Studies
43
,beta-, gamma-, delta-tocopherol, and alpha-,beta-, gamma-, delta -tocotrienol. Among them, only alpha -tocopherol (alphaT) has been extensively studied. Recent studies indicate that other forms of vitamin E have unique properties, which are not shared by alphaT, but are important to human disease prevention and therapy. GammaTocopherol (gammaT) and its metabolite, but not aT, exhibit anti-inflammatory effects by inhibiting cyclooxygenase (COX)- catalyzed formation of PGE2. In a rat inflammation model, gammaT inhibits not only PGE2, but also LTB4, and TNF-alpha. These results suggest that gammaT may be superior to some commonly used non-steroid antiinflammatory drugs (NSAIDs), such as COX inhibitors, most of which only inhibit the COX-mediated pathway. Preliminary studies also indicate that delta- tocopherol and gamma-tocotrienol, compared with gammaT, are even stronger inhibitors of the COXcatalyzed formation of PGE2. These observations led to the current hypothesis that certain forms of vitamin E and their combinations have unique pharmaceutical utility as anti-inflammatory drugs, or as supplements that complement and improve current treatments for inflammatory diseases. This hypothesis will be tested by pursuit of the following Specific Aims in cell culture and animal experiments: 1. Investigate in vitro anti-inflammatory properties of individual vitamin E forms and their combinations; 2. Investigate and compare in vivo anti-inflammatory activities of individual vitamin E forms and their combinations; and 3. Investigate the potentially improved effects of combining certain forms of vitamin E and NSAIDs, such as aspirin, in a rat inflammation model. Our studies may lead to the discovery of novel and better therapy for treating and preventing inflammatory diseases, and provide the scientific rationale, the experimental evidence and the biochemical basis for future human studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NF-KB SIGNAL TRANSDUCTION IN BRAIN INJURY Principal Investigator & Institution: Pennypacker, Keith R.; Associate Professor; Pharmacology and Therapeutics; University of South Florida 4202 E Fowler Ave Tampa, Fl 33620 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2004 Summary: (adapted from applicant's abstract): Nuclear factor-kB (NF-kB), a transcription factor, is a component of anti-apoptotic signal transduction in immunederived cells initiated by tumor necrosis factor receptor-1 stimulation. NF-kB is activated in the brain after injury and many genes, such as growth factors and cytokines, associated with regeneration and repair are target genes for this transcription factor. While the function of NF-kB in brain injury has been controversial, the investigator's laboratory has discovered increased expression NF-kB p50 in neurons surviving brain injury. They have observed an extended time-course (one to two weeks after injury) of p50 and p65 expression and elevated NFkB DNA binding activity suggesting that NF-kB signal transduction is involved in regulating genes related to regeneration and repair. They propose that brain injury leads to activation of NF-kB in neurons surviving injury and that this activation induces the transcription of growth factors that play a decisive role in promoting cell survival. They plan to examine NF-kB expression and activity in the rat hippocampus in response to injury caused by excitotoxicity (kainite), ischemia (middle cerebral arterial occlusion) and neurotoxicity (trimethyltin) to observe whether activation of NF-kB is a common event in injury to the brain. Transgenic mice containing a kB responsive promoter will be used to determine kB activation in the in vivo brain. The role of NF-kB in neuronal survival in hippocampus after injury will be discerned by blocking NF-kB transcription using p50 (p105) gene knockout mice and aspirin treatment. Hippocampal neuronal counts will be determined by unbiased cell counting
44
Aspirin
to determine if inhibition of NF-kB activation increases neuronal death. Nerve growth factor, an important gene in the brain's repair and recovery, has been shown to be a target gene of NF-kB-driven transcription in brain cell cultures but this has not been demonstrated in in vivo brain injury models. They will determine whether nerve growth factor is a target for NF-kB-driven transcription in brain injury using colocalization studies in these brain injury models and inhibiting NF-kB activation using p50 (p105) gene knockout mice and aspirin treatment. These studies will define the role of NF-kB in the process of brain injury and subsequent repair and regeneration processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NO CHEMOPREVENTION
RELEASING
ASPIRIN
AND
COLON
CANCER
Principal Investigator & Institution: Rigas, Basil A.; Scientist; Institute for Cancer Prevention 1 Dana Rd Valhalla, Ny 10595 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2006 Summary: (provided by applicant):Chemoprevention has the potential to be a major component of the control of colon cancer, one of the commonest malignancies. Although traditional non-steroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer, their side effects are a major obstacle to their large-scale application to prevent colon cancer. The novel nitric oxide (NO)-releasing NSAIDs (NO-NSAIDs), consisting of a NSAID molecule and a NO-releasing moiety linked to it via a chemical spacer, have been synthesized to overcome NSAID toxicity. Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions. That NO-ASAs have superior effectiveness and safety makes them promising chemopreventive agents and constitutes a compelling argument to study their mechanism of action in colon carcinogenesis. The proposed studies will evaluate two hypotheses: a) NO-ASA compounds share with traditional NSAIDs some of their known mechanisms of action, such as their effects on cell kinetics and on the eicosanoid and NO pathways, all relevant to chemoprevention, and b) Since NO-ASA derivatives are markedly more effective than unmodified ASA, the additions to the ASA molecule to generate NO-ASA impart on it new properties, which make it more effective. Our specific aims are 1) Determine in cultured colon cancer cells the effect of NO-ASA derivatives on cell kinetics (proliferation, apoptosis) and cell cycle; on the eicosanoid pathway (effect on the catalytic activity of COX; COX-1 and -2 expression and regulation; evidence for effects beyond COX); and on the nitric oxide pathway (expression of NOS isoforms; NOS catalytic activity). 2) Determine in an animal model of colon cancer the contribution of the NO-ASA-induced changes to colon carcinogenesis. Based on results from Specific Aim #1, we will select the most promising of the three NO-ASA derivatives and assess its chemopreventive efficacy against azoxymethane-induced colon carcinogenesis in F344 rats. The effect of this compound on cell kinetics and on the two metabolic pathways will be assessed and correlated with chemopreventive efficacy. 3) Assess the contribution of the key structural components of the NO-ASA molecule to their chemopreventive actions. We will study the effects of synthetic molecules representing the structural components of each one of the three NOASA compounds. They include: ASA+spacer (NO- ASA without the -NO2 group) to test the contribution of NO; spacer (the part linking ASA to -NO2) to test its individual contribution; and a NO-donor which releases NO, to further test the role of NO. The
Studies
45
long-term goal of these studies is to develop mechanism-driven safe and effective strategies for colon cancer prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NORTHWEST COMMUNITY CLINICAL ONCOLOGY PROGRAM Principal Investigator & Institution: Colman, Lauren K.; Medical Director; Multicare Health System 315 Sw Ml King Way Tacoma, Wa 98405 Timing: Fiscal Year 2002; Project Start 15-SEP-1983; Project End 31-MAY-2003 Summary: (Applicant's Description) The Northwest Community Clinical Oncology Program has been in existence sine 1983, and is now applying for competitive renewal. The Northwest CCOP consists of 42 participating physicians, including medical and radiation oncologists, and 11 hospital facilities located in Southwestern Washington and Norther Oregon. The Northwest CCOP utilizes five research bases, to include the Southwest Oncology Group, M.D. Anderson Cancer Center, University of Rochester Cancer Center, the National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group. The objective of the Northwest CCOP is to provide community physicians the opportunity of continued participation in a wide variety of clinical trials sponsored by these research bases, to include not only treatment but cancer prevention and control trials. Through this mechanism, the latest and most up-to-date cancer treatment regimens can be provided to patients. It is anticipated that further increase in accrual to clinical trials will be possible throughout the next five years. The funds obtained through a successful application will be used to support the administration of these activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOVEL ANTI-INFLAMATORY LIPID MEDIATORS Principal Investigator & Institution: Petasis, Nicos A.; Professor of Chemistry; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: The long-term goal of this project is the development of novel regulators of leukocyte function to serve as anti-inflammatory molecules based on the modulation of the mode of action of some new types of lipid-derived mediators (LM). Our recent collaborative work with Dr. Serhan (Project 1) has led to the identification and biological investigation of several new LM that have novel and promising activities, including several biostable analogues of the lipoxins (LX), the aspirin-triggered (ATL) and presqualene disphosphate (PSDP). A typical feature of the above LM is that they are topically active and that they have multi-faceted biological activity, which involves a number of other cell-signaling molecules related to inflammation. Following recent studies that suggested the potential involvement of these LM in periodontal diseases, this project seeks to develop a series of new molecules that would elucidate their role. Thus, this project will pursue the design and synthesis of: (1) new structural analogues of LX and ATL, and (2) new structural analogues of PSDP. In addition to synthetic and conformational studies of these molecules, this project will pursue several new synthetic approaches that may facilitate their synthesis. The synthetic molecules will be used in bioassays in Projects 1-3 of this program and structure-activity relationships will be established for each of the targeted LM. Finally, selected compounds will be scaled-up for in vivo animal model studies in Core D (Demonstration Core). Overall, this project will lead to the elucidation of the physiological and pathophysiological role of several topically active LM, particularly in host defense and inflammation. Therefore, this
46
Aspirin
research may result in development of new molecules with novel anti-inflammatory properties with therapeutic potential in regulation of tissue-mediated injury, as in periodontal disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL OXYGENATIONS OF ARACHIDONIC ACID Principal Investigator & Institution: Brash, Alan R.; Professor; Pharmacology; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 01-MAY-1997; Project End 31-AUG-2005 Summary: The formation of bioactive eicosanoids is initiated by stereoselective oxygenation of the substrate, arachidonic acid, by lipoxygenase (LOX) and cyclooxygenase (COX) enzymes. The products mediate important physiological activities and are key modulators of the inflammatory response. Individual enzymes of the LOX family catalyze oxygenation of arachidonate with distinct positional specificity and stereo specificity. In an earlier cycle of this grant we discovered novel human LOX enzymes with 15 S-LOX (named I 5-LOX-2) and 1 2R-LOX specificities. We will use these and related LOX enzymes to examine the structural basis for their differences in reaction with arachidonic acid. This is a practically important goal for the future rational design of specific inhibitors. Currently a 5-LOX inhibitor is used therapeutically to treat asthma, but other LOX inhibitors are too non-specific for practical applications. The COX enzymes are the targets of aspirin and other widely used antiinflammatory medications, and to fully understand their mechanism of action will require an understanding of how the selective oxygenation reactions with arachidonic acid are controlled. We propose a novel hypothesis that will challenge current ideas of oxygen channeling within the cyclooxygenase active site and lead, we believe, to a new concept that will be applicable also to lipoxygenase catalysis. Our hypothesis is that enzymeinduced localization of the substrate free radical will, by well precedented chemistry, direct the targeted reactions with molecular oxygen. To test this idea with COX enzymes we will examine the stereo fidelity of the C-13 hydrogen abstraction in the conversion of arachidonic acid to distinct products. We will also examine the control of oxygenation at the C-Il position using novel fatty acid substrates, and at C-15 by changing the specificity of the enzyme. As a third arm of this project we will investigate the physiological roles of I 5-LOX-2, the enzyme we discovered and that we have shown to have highly selected expression in certain epithelial tissues. In addition to characterizing the expression of human LOX-2, we aim to develop new animal models of 15-LOX-2 physiology in tissues of the rat. This is prompted by our finding that the mouse homologue of l5-LOX-2, an 8-LOX, has completely different reaction specificity and patterns of expression. We have preliminary evidence that the rat enzyme is a closer structural relative to human l5-LOX-2 will be a suitable animal model for physiological studies. Finally, in the theme of novel oxygenations we will characterize novel lipoxygenase activities in animal models of vascular tone and cell proliferation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NSAIDS AND OTHER MEDICATIONS IN PROSTATE CANCER ETIOLOGY Principal Investigator & Institution: Stanford, Janet L.; Head, Prostate Cancer Research Program; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2001; Project Start 21-AUG-2001; Project End 30-JUN-2006
Studies
47
Summary: Prostate cancer is the most common malignancy in men, yet its etiology remains obscure. A central theme of the carcinogenic process is uncontrolled cell growth, which is a disturbance in the balance between cell proliferation and cell death. Factors that stimulate cell proliferation enhance the opportunity for accumulation of random genetic errors and emergence of a malignant phenotype. Factors that block apoptosis, which would normally remove DNA-damaged cells from the cycle, may promote continued growth of malignant cells. There is compelling evidence that certain medications may act as risk or protective factors for prostate cancer through a common biological pathway involving altered rates of prostatic cell growth or death. To study the relationships between these frequently used medications and prostate cancer, we propose a population-based case-control study of 1000 cases and 1000 controls, aged 4074 years, that will test the following hypotheses: 1. Use of nonsteroidal antiinflammatory drugs is associated with a reduced risk of prostate cancer; 2. Use of statins is associated with a reduced risk of prostate cancer; 3. Use of calcium-channel blockers is associated with an increased risk of prostate cancer; and 4. Use of histamine H2-receptor antagonists is associated with an increased risk of prostate cancer. We also will assess genetic polymorphism in the CYP2C9 gene, which is involved in drug metabolism. Logistic regression models will be used to estimate relative risks of prostate cancer associated with use of each type of medication, adjusting for potential confounding factors. Tumor stage and grade will be used to assess whether associations vary by disease aggressiveness. Given the rising frequency of exposure to some of these medications, the information from this study will be timely and is urgently needed. Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NUTRITIONAL AND BIOCHEMICAL/GENETIC MARKERS OF CANCER Principal Investigator & Institution: Stampfer, Meir J.; Professor and Chair; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-JUN-1986; Project End 31-JUL-2003 Summary: The application proposed to continue and extend the analysis of blood samples that were collected at baseline as part of the Physicians' Health Study (PHS), a randomized trial of aspirin and beta-carotene among 22,071 U.S. male physicians, aged 40-84 years. Blood samples were collected prior to randomization, mostly in 1982, from 14,916 participants, free from prior myocardial infarction (MI), stroke, or cancer (excluding non- melanoma skin cancer), and were stored at -82C. Using a nested casecontrol design, the plan is to continue to analyze the specimens for nutritional and biochemical/genetic markers of risk, with a specific focus on prostate and colorectal cancers. The studies are directed toward exploring the hypothesis that dietary and genetic factors, which increase intracellular folate, reduce risk of colon cancer. Measurements of biochemical markers (plasma, folate, vitamins B6 and B12), genetic polymorphisms for key enzymes, and dietary variables will be carried out. For both prostate and colorectal cancer, vitamin D levels and metabolism (including polymorphisms of the vitamin D receptor) will be assessed. Additional experiments will test the hypotheses that high levels of insulin-like growth factor (IGF) and low levels of selenium are associated with risk of colorectal and prostate cancer. These analyses are based in the PHS, for which follow-up of disease endpoints is already supported. Furthermore, there was a long period of beta-carotene supplementation for half the cohort, providing the opportunity to assess several interactions. The accrual of cases
48
Aspirin
over a long duration since the blood was drawn will permit an assessment of latency. The completeness of follow-up and the many assays already performed can be used to complement any further studies. Several important and intriguing results have already emerged from the study. The nested case-control approach and the multiple analyses have provided an efficient means to increase the scientific value of PHS and test a number of hypotheses of potential public health importance, using blood samples that were collected at considerable expense and stored with great care. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OCCLUDED ARTERY TRIAL DATA COORDINATING CENTER Principal Investigator & Institution: Knatterud, Genell L.; President; Maryland Medical Research Institute, Inc 600 Wyndhurst Ave Baltimore, Md 21210 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Current pharmacologic strategies fail to achieve effective reperfusion in 30 percent or more of acute myocardial infarction (MI) patients, and many patients with occluded infarct-related arteries (IRAs) do not meet current criteria for use of these agents. Early angioplasty, an effective reperfusion method, is available to a small proportion of potentially eligible acute MI patients in the U. S. Hence, a substantial number of acute MI patients pass the time when reperfusion therapy has well documented benefit (12-24 hours) with a persistently closed IRAs. Several lines of experimental and clinical evidence suggest that late reperfusion of these patients could provide clinically significant reductions in mortality and morbidity. Hypothesis. Opening an occluded IRA 3-21 days after an acute MI in high-risk asymptomatic patients (ejection fraction less than 50 percent or proximal occlusion of a large coronary artery) will reduce the composite end point of mortality, recurrent MI, and hospitalization for NYHA Class IV congestive heart failure (CHF) over an average 3year follow-up. Study aims. In the Open Artery Trial (OAT) 3,200 patients will be randomly allocated in equal proportions to the two treatments over two years. One treatment will consist of conventional medical management (including aspirin, beta blockers, ACE inhibitors, and risk factor modification). The experimental treatment will consist of conventional medical therapy plus percutaneous coronary intervention and coronary stenting. The primary specific aim is to compare the composite outcome of allcause mortality, non-fatal MI and hospitalization for Class IV CHF based on an average 3-year follow-up among patients assigned to the two treatments. Three secondary specific aims are to compare: 1) the individual components of the study composite primary end point in the two treatments; 2) the medical costs of the two treatments; and 3) health-related quality of life in the two treatments. Role of Data Coordinating Center. This application is made for support of a Data Coordinating Center (DCC) at the Maryland Medical Research Institute. The DCC is responsible for statistical design and power calculations, random treatment assignments, data management, support for the Mortality and Morbidity Classification Committee, rapid communication and generation of performance data for review with the Study Chair and Co-Chair of the Clinical Coordinating Center and data analysis to assess treatment effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER Principal Investigator & Institution: Hochman, Judith S.; Professor of Medicine; St. Luke's-Roosevelt Inst for Hlth Scis Health Sciences New York, Ny 10019 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004
Studies
49
Summary: Background. The benefits of establishing early coronary reperfusion in acute myocardial infarction (MI) have now been unequivocally established. However, current pharmacological strategies fail to achieve effective reperfusion in 30% or more of patients, and many patients with occluded infarct arteries do not meet current criteria for use of these agents. Early angioplasty, an effective reperfusion method, is available to a small proportion of potentially eligible US acute MI patients. Hence, a substantial number of acute MI patients pass the time when reperfusion therapy has any documented benefit (12-24 hours) with a persistently closed infarct vessel. Several lines of experimental and clinical evidence suggest that late reperfusion of these patients could provide clinically significant reductions in mortality and morbidity. Hypothesis: The central hypothesis of the Open Artery Trial is that opening an occluded infarct artery 3-21 days after an acute MI in high-risk asymptomatic patients (ejection fraction less than 50% or proximal occlusion of a large coronary artery) will reduce the composite endpoint of mortality, recurrent MI, and hospitalization for NYHA class IV congestive hear failure (CHF) over an average three year follow-up. Specific aims. The study will be a prospective clinical trial with 3,200 patients randomly allocated in equal proportions to two tretments arms over two years. One treatment will consist of conventional medical management (including aspirin, beta blockers, ACE inhibitors, and risk factor modification). The experimental treatment will consist of conventional medical therapy plus percutaneous coronary intervention and coronary stenting. Clinical outcomes will be compared using an intention-to-treat analysis. We have one primary specific aim: 1) To compare the composite outcome of all-cause mortality, nonfetal MI and hospitalization of NYHA class IV CHF based on an average three year follow-up among patients assigned to the two treatments. We have three secondary specific aims: 1) To compare the individual components of the study composite primary endpoint in the two treatment arms. 2) To compare the medical costs of the two treatments and assess the cost effectiveness of percutaneous revascularization in the study population. 3) To compare health-related quality of life in the two treatment groups. Operations. The Luke's-Roosevelt Hospital in New York City. The Data Coordinating Center (DCC) is at the Maryland Medical Research Institute. The Economics and Quality of Life Coordinating Center is at Duke University. The Angiographic Core Laboratory is at the University of British Columbia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PAROXETINE--TREATMENT REACTIVITY WITH MAJOR DEPRESSION
OF
EXAGGERATED
PLATELET
Principal Investigator & Institution: Nemeroff, Charles B.; Reunette W. Harris Professor and Chair; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: This study is an amendment to SPID 3251 to add two weeks of open-label combined treatment with paroxetine, aspirin and clopidogrel to further elucidate the mechanism whereby the antidepressant, paroxetine, diminishes activation of the GPIIb/IIIa receptor in patients with major depression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHARMACOGENETIC ANTIPLATELET STRATEGIES IN CHD PATIENTS Principal Investigator & Institution: Cooke, Glen E.; Internal Medicine; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210
50
Aspirin
Timing: Fiscal Year 2003; Project Start 22-JAN-2003; Project End 31-DEC-2007 Summary: (provided by the applicant):Coronary heart disease (CHD) remains the most important cause of mortality. Myocardial infarction and unstable angina result from formation of a platelet thrombus, a process that requires the binding of extracellular adhesive ligands to the GPIIb-IIIa receptor on the surface of platelets. Percutaneous transluminal coronary angioplasty (PTCA/stenting) also results in disruption of vessel integrity at the location of an atherosclerotic plaque and during and after these procedures (up to thirty days, currently), there is an absolute requirement for antithrombotic therapy. The GPIlb-IIIa receptor is known to be polymorphic and the presence of the PLA2 allele has been associated with an increased prevalence of ischemic syndromes, especially in younger individuals. Recently, the PLA2 polymorphism has emerged as an important risk for sudden coronary death in patients less than 60 with myocardial infarction and adverse events in patients undergoing coronary stenting. Numerous studies have reported varying results with regard to this novel risk factor. It is fair to say that, as a result of divergent results generated by these subsequent studies, two camps have emerged: those who believe that PLA2 is a risk factor for arterial thrombosis, and those who do not. Our ability to interpretepidemiological data is limited by the lack of understanding of the effect of the PLA2 polymorphism on platelet biology and thrombosis. We have previously demonstrated that a differential effect of aspirin (ASA) on platelet aggregation occurs in platelets that demonstrate the PLA2 polymorphism, which may in part, explain the divergent results of PLA and CHD in numerous studies. We have conducted a study to characterize the impact of PLA2 on platelet response to agonists, in patients with CHD, randomized to receive ASA, (325mg/day), clopidogrel (75mg/day) or a combination of ASA and clopidogrel. We have shown that PLA functions as an important modifier for the platelet response to ASA, clopidogrel or their combination in CHD patients. ASA+clopidogrel appears superior than ASA alone in reducing platelet aggregation. Our data suggest that responses to clopidogrel and ASA, both, are PLA sensitive. The synergy between ASA and clopidogrel in PLA 1/A2 patients is interesting and could involve ASA inhibition of COX-1. However, when administered at 325mg per day, a contribution of COX-2 inhibition to this synergistic effect is possible. The overall hypothesis of this proposal is that genetics, and specifically the PLA2 polymorphism, can be used to determine optimum antiplatelet therapy in patients with CHD. This will be tested in patients with CHD, post-stent, by randomizing them to receive either ASA, clopidogrel, or ASA and clopidogrel and assessing clinical and platelet functional endpoints as a function of PLA. In addition, to expand our understanding to novel mechanisms of antiplatelet therapy we will also assess the potential benefit of COX-2 inhibition with a specific COX-2 inhibitor, rofecoxib. Such information will be paramount in the targeting of antiplatelet therapies and will be based on genomlc information (pharmacogenetics). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHOSPHOLIPASE ACTIVATION IN ASPIRIN INTOLERANT ASTHMA Principal Investigator & Institution: Langmack, Esther L.; National Jewish Medical & Res Ctr and Research Center Denver, Co 80206 Timing: Fiscal Year 2001; Project Start 01-AUG-1998; Project End 31-JUL-2003 Summary: (Adapted from applicant's abstract) The Candidate: Esther Langmack, M.D., is a Research Fellow in Pulmonary/Critical Care at the University of Colorado. Dr. Langmack's background includes research experience and publication in the areas of
Studies
51
enzyme biochemistry, immunology, and asthma. Her overall career goal is to study the role of lipid-derived mediators in the development and perpetuation of inflammation in asthma at a major academic medial center. Her Sponsor is Dr. Sally Wenzel, who has extensive experience studying the role of leukotrienes in asthma. The research Proposal: Cysteinyl leukotrienes (cLTs) are critical to the pathophysiology of asthma, in general, and aspirin-intolerant asthma in particular. However, the initial enzyme (phospholipase(s), 5-lipoxygenase (5-LO)) leading to cLT production in aspirinintolerant asthma and the mechanisms behind its activation are unknown. The specific hypothesis to be addressed in this proposal is that an increase in arachidonic acid substrate liberation by phospholipases, in the presence of cyclooxygenase inhibition, drives the rapid production of cLTs by 5-LO in aspirin-intolerant asthmatics. Increased arachidonic acid substrate also facilitates the overproduction of other inflammatory lipid mediators which are not 5-LO pathway products, such as HETEs, lipoxins, and platelet activating factor, leading to broad activation of inflammatory pathways. The relative contribution of the two main phospholipases involved in AA release, secretory phospholipase A2 (sPLA2) and cytosolic phospholipase A2 (cPLA2), to AA release and AA-derived mediator production in AIA, will be determined. The in vivo effect of 5-LO inhibition upon the spectrum of AA-derived mediators produced in AIA will be evaluated. This proposal will further understanding of the steps leading to the generation of lipid mediators in inflammatory conditions and the alteration of these mediators which may occur after 5-LO inhibition. These findings will not only improve the understanding of aspirin-intolerant asthma, but will clarify the regulation of lipid mediators in numerous other inflammatory conditions, as well. The Research Environment: National Jewish Medical and Research Center is an internationally recognized institution devoted to research in the areas of allergy, immunology, pulmonary medicine and infectious diseases. Dr. Langmack's collaborators for this project include Dr. Robert Murphy, Dr. Christina Leslie, and Dr. Jay Westcott, who will share their expertise in lipid mediator analysis. (End of Abstract) Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLATELET REACTION IN DEPRESSION--ASPIRIN/CLOPIDOGREL Principal Investigator & Institution: Musselman, Dominique L.; Assistant Professor; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 01-OCT-1974; Project End 30-NOV-2004 Summary: This study is an amendment to SPID 3250 to add aspirin and clopidogrel in order to understand further how paroxetine by itself helps to decrease the sticking of platelets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: POLYMORPHISMS IN PG/COX PATHWAY AND COLORECTAL POLYPS Principal Investigator & Institution: Ulrich, Cornelia M.; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2001; Project Start 05-JUN-2001; Project End 31-MAY-2004 Summary: Aspirin and other non-steroidal inflammatory drugs (NSAIDs) reduce the recurrence of colorectal polyps among patients with familial adenomatous polyposis (FAP) and are associated with a lower risk of both adenoma and colorectal cancer. Primary targets for these drugs are cyclooxygenases (COX1 and COX2) in the prostaglandin (PG) pathway. The goal of this study is to evaluate the association
52
Aspirin
between colorectal polyps and polymorphisms in enzymes, growth factors, and receptors linked to prostaglandin synthesis or COX activity. Currently, very few polymorphisms in this pathway have been reported, and, of those, the population allele frequency is not known. Thus, several steps in this proposal (Projects 1-3) aim to systematically identify new genetic polymorphisms in this pathway, and to establish allele frequency and potential impact on enzyme function. Methods include screening of enzymes in the COX/PG pathway for new polymorphisms both by searching genetic databases and by using other techniques (dHPLC, enzyme mismatch cleavage, DNA sequencing). Genotyping of a population of 75 Caucasians and 75 African Americans for candidate polymorphisms will be used to establish allele frequency. Subsequently (Project 4) we propose to investigate a selected 5 to 10 genetic polymorphisms in COX1,COX2, and other enzymes in the PG/COX pathway, or growth factors and receptors related to it, and their association with colorectal polyps. We propose to genotype 550 cases with adenomatous polyps, 200 cases with hyperplastic polyps only, and 700 polyp-free controls. Study participants were recruited as part of the Minnesota case-control study in 1991-4 and comprehensive questionnaire information on health status, family history, diet, physical activity, and use of aspirin and other NSAIDs has been obtained. We will 1) investigate the main effects of the genetic polymorphisms, and 2) investigate whether these polymorphisms modify the association between environmental factors (in particular aspirin and NSAID use) and colorectal polyps. Finally, we plan to develop a model for integrating information on genetic variability at multiple points in this metabolic pathway. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POSTMENOPAUSE CHD RISK: PLATELET GENES & HORMONE THERAPY Principal Investigator & Institution: Bray, Paul F.; Professor; Medicine; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 27-SEP-2003; Project End 31-AUG-2007 Summary: Coronary heart disease (CHD) is the number one killer of women in the United States. Hormone replacement therapy (HRT) with estrogen (E) and progesterone (P) should probably no longer be considered cardioprotective. In fact, data from the HERS and WHI studies indicate E+P may increase myocardial infarction (MI) and stroke despite its beneficial effects on cholesterol levels. Since blood platelets play a central role in the pathophysiology of MI and stroke, these findings raise questions about the effect of HRT on platelet thrombus formation in coronary vessels. Our published and preliminary data show that 1) female platelets are hyperreactive compared to male platelets, 2) sex hormones enhance platelet reactivity, 3) platelets express estrogen receptor (ER) beta and ER alpha, 4) functional platelet polymorphisms are risks for CHD, and 5) there are pharmacogenetic interactions between functional polymorphisms of platelet genes and specific cardiovascular therapies (aspirin, statins, and GPIIb-Illa blockers). Because women are at least as predisposed as men to genetic influences on CHD development, we hypothesize that inherited platelet variants dictate which postmenopausal women are susceptible to the prothrombotic effects of HRT. Our goal in this proposal is to identify genetic predictors of CHD events in women. We will perform a case-control study on the Observational Study of the Women's Health Initiative, analyzing DNA from 1,060 women who have experienced a CHD death or documented nonfatal MI (cases) and from 2,120 controls not having a CHD event. With this large number of CHD cases and controls we will test for associations between functional platelet polymorphisms and CHD events (Aim 1) and interactions between
Studies
53
these polymorphisms and HRT as a risk for CHD events (Aim 2). We have assembled an excellent group of investigators and have an extremely valuable resource, putting us in a unique position to achieve these goals and our long-term goal of optimizing the prevention and management of CHD in women. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROSPECTIVE STUDY OF DIET AND PROSTATE CANCER Principal Investigator & Institution: Giovannucci, Edward; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 23-AUG-1991; Project End 31-MAR-2006 Summary: (provided by Applicant) This project aims to identify dietary, hormonal, and genetic factors related to prostate cancer in the Health Professionals Follow-Up Study (HPFS). In spite of the slow progression rates of most prostate cancers, a subset of patients will experience a more aggressive and generally fatal course. The heterogeneity in biologic potential for progression among tumors is likely related to acquired molecular characteristics. Thus, we will try to link dietary and hormonal factors that are related to aggressive behavior in prostate cancer to specific molecular characteristics that determine biologic potential, including cell proliferation, differentiation, apoptosis, inflammation, and angiogenesis. We will also examine whether identified dietary and other modifiable risk factors can, in the post-diagnostic period, influence the risk for PSA relapse among men treated with apparently organ-confined prostate cancer. Because our ultimate goal is to provide feasible approaches for prevention, in addition to many aims geared towards understanding the disease (hormones, genetic factors, total energy intake), the focus of many of our aims is on modifiable factors (aspirin, calcium, omega-3 fatty acids, lycopene (tomatoes), and vitamin E). Among 47,000 HPFS men free of cancer at baseline in 1986, we anticipate 4,124 new cases of prostate cancer by 2004, including 573 metastatic cases. We also plan to acquire tumor blocks from 1,732 prostatectomy cases. The sources of the exposure data in the HPFS are (1) questionnaire, including diet, (2) plasma samples (insulin-like growth factors, sex hormones, vitamin D, carotenoids), and (3) blood and buccal cell DNA for MnSOD, vitamin D and androgen receptor CAG polymorphisms. The outcome data will be based on (1) medical record and pathology report review for initial diagnosis and relapse (PSA failure), and (2) tissue blocks for microvessel density, VEGF, COX-2, PTEN loss, proliferation, and apoptosis. Stratified analysis and multivariate analysis will be used to control for potential confounding factors. This project is likely to yield important new findings that may help our understanding of modifiable risk factors for prostate cancer incidence, progression, and relapse. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROSTAGLANDINS AND GASTROINTESTINAL INTEGRITY Principal Investigator & Institution: Miller, Thomas A.; Professor of Surgery; Surgery; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2002; Project Start 01-JUL-1979; Project End 31-JAN-2007 Summary: (Provided by Applicant): Gastrointestinal (GI) mucosal injury from insults such as ethanol, bile, and aspirin continues to be a major health care problem, oftennecessitating hospitalizations, and occasionally surgery. The underlying difficulty in managing this disorder relates to our current lack of understanding regarding the precise mechanism(s) responsible for its pathogenesis. A considerable body of knowledge indicates that prostaglandins (PGs) have the amazing capability to markedly
54
Aspirin
reduce the magnitude of GI damage histologically when induced under a wide variety of experimental circumstances. During the present funding period, we observed that damaging agents appear to mediate their injurious effects through a common mechanism, namely alterations in intracellular calcium accumulation that results in cytoskeletal disruption and ultimate cell death. We further observed that PG pretreatment can prevent these perturbations concomitant with its protective action through activation of protein kinase C that thereby restores calcium homeostasis via activation of calcium extrusion from cells. The protective action of growth factors (i.e. EGF and TGF alpha) against gut damaging agents appears to be mediated through a similar mechanism. Based on these observations, we believe that maintenance of cellular cytoskeletal integrity through intracellular calcium stabilization may be a fundamental mechanism by which PGs (and other protective agents) mediate their cellular protective action, and provides a unifying hypothesis to explain the underpinnings of GI injury and protection. To validate this hypothesis, our specific aims during this new grant period will be (1) to determine whether damaging substances induce apoptosis in gastric and intestinal cells and whether PGs and other protective agents initiate protection through prevention of this process, (2) to elucidate the role of protein kinase C in GI cellular injury and protection, and (3) to define more precisely the relationship between intracellular calcium homeostasis, cytoskeletal stability and GI cellular injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PSYCHOLOGICAL NONLINEARITIES IN MASKING Principal Investigator & Institution: Hicks, Michelle L.; Hearing and Speech Sciences; University of Maryland College Pk Campus College Park, Md 20742 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2003 Summary: The long-term objective of the proposed research is to further our understanding of the mechanisms underlying psychophysical masking. In particular, this project seeks to clarify the role of basilar membrane compressive nonlinearity on growth of masking by altering the nonlinearity through the ingestion of aspirin, an ototoxic drug known to adversely affect outer hair cell function, and hence basilar membrane compression. The goals of this research are to (1) gain insight into the role of basilar membane compressive nonlinearity on growth of masking in forward masking for on-frequency (masker and signal equal in frequency) and off-frequency (masker well below the signal in frequency) maskers, (2) gain a better understanding of the differences in the processing underlying growth of masking in simultaneous and forward masking for off-frequency maskers, and (3) evaluate the legitimacy of using temporary aspirin-induced hearing loss as a model for permanent sensorineural hearing loss. Results from the proposed study will resolve issues fundamental to our understanding of the role of cochlear nonlinearity in psychophysical masking. Moreover, the ability to use aspirin-induced hearing loss as a model for sensorineural hearing loss will be a valuable tool for future research on the processing abilities of hearing-impaired individuals. The proposed experiments will examine growth of masking in forward and simultaneous masking in normal-hearing individuals prior to, and during four days of moderate aspirin use. The aspirin will likely induce a temporary, mild-to-moderate cochlear hearing loss, and changes to the growth-ofmasking functions with aspirin will provide insight into the influence of basilar membrane nonlinearity on the functions. The results from individuals with temporary aspirin-induced hearing loss will be compared with those from individuals with permanent sensorineural hearing loss of similar degree and configuration. This comparison will test the hypothesis that sensorineural and aspirin-induced hearing
Studies
55
losses affect growth of masking similarly, supporting the aspirin-induced hearing loss as a model for sensorineural hearing loss. All testing will be completed using standard psychoacoustic forced-choice adaptive procedures. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RACIAL DIFFERENCES IN THE TREATMENT OF HEART DISEASE Principal Investigator & Institution: Heidenreich, Paul A.; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2004 Summary: Acute myocardial infarction and heart failure result are a common cause of morbidity and mortality for elderly patients in the United States. Numerous studies have documented that ethnic minority populations receive less intensive cardiac care than non-Hispanic whites in a variety of clinical settings. These studies have focused on major procedures such as coronary artery bypass grafting using both large administrative and small clinically detailed databases. Whether these differences are increasing, or decreasing is unclear. The reasons for racial and gender differences are also unclear. Several studies have documented that age, severity of illness, and insurance status can explain part, but not all of the observed differences in treatment. Whether physician, hospital and regional characteristics affect treatment differences remains unknown. In addition, little is known about differences between racial groups in less invasive interventions such as medication use or smoking cessation counseling. The degree to which these treatment differences explain differences in survival is also not known. The aim of this proposal is to further examine racial differences in treatment of acute myocardial infarction and heart failure among elderly patients in the United States. Using multiple national datasets from the Health Care Financing Administration (Medicare) already available to the investigators, we will examine trends in racial differences in treatment and outcome for elderly patients from 1985 through 1997. Detailed clinical data from Medicare and the National Registry of Myocardial Infarction will be used to examine racial differences in the appropriateness of care for acute myocardial infarction (aspirin, beta-blockers, reperfusion, angiotensin converting enzyme inhibitors, smoking cessation counseling and angiography) and heart failure (angiotensin converting enzyme inhibitors, measures of left ventricular function). Several potential causes of treatment differences will be examined by linking patient data to procedure refusal (Cooperative Cardiovascular Project) physician (American Medical Association Physician Master File), hospital (American Hospital Association data) and regional data (Census bureau statistics at the level of zip code). Examining the physician, hospital and regional variation in treatment differences are necessary if systematic strategies are to be implemented to reduce gender and racial disparities in the treatment of elderly patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RANDOMIZED THERAPEUTIC TRIALS IN PEDIATRIC HEART DISEASE Principal Investigator & Institution: Newburger, Jane W.; Associate Cardiologist-InChief; Children's Hospital (Boston) Boston, Ma 021155737 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant) This grant application proposes two randomized, double-blind, placebo-controlled trials to be performed in the Pediatric Heart Disease Clinical Research Network. Our shorter-term trial will study the efficacy and safety of
56
Aspirin
pulse steroid therapy, when added to conventional therapy with intravenous gamma globulin (IVIG) plus aspirin, in treatment of acute Kawasaki disease. Patients will be randomly assigned to receive either methylprednisolone (IVMP), 30 mg/kg, plus conventional therapy (i.e., "IVMP plus IVIG") versus placebo plus conventional therapy ("IVIG alone"). Our first aim is to test the hypothesis that treatment of acute Kawasaki disease with IVMP plus IVIG is more effective than treatment with IVIG alone. Our primary efficacy outcome variables will be BSA-adjusted coronary artery dimensions (zscores) for the proximal right, left main, and proximal left anterior descending coronary arteries; number of days of fever after completion of initial IVIG infusion; and C-reactive protein at 2 weeks after illness onset. Our second aim is to test the hypothesis that children treated with IMP plus IVIG will have fewer adverse effects than those treated with IVIG alone. Our primary safety outcome will be the prevalence of all adverse side effects. The structure of the study will allow us to explore and identify factors other than the two treatment strategies (e.g., immune gene polymorphisms) that relate to the occurrence of-coronary artery abnormalities. The KD trial will span less than two years from onset of enrollment to preliminary data. Our longer-term trial evaluates the efficacy of beta-blocker therapy in retarding progressive aortic root dilation and valvular aortic regurgitation in patients after the arterial switch operation (ASO). Patients will be randomly assigned to receive either propranolol (2-4 mg/kg/day) or placebo. Our first aim is to assess the effect of propranolol therapy on the rate of aortic root dilation after the ASO. The primary outcome variable is the change in aortic root size during two years of treatment, assessed as the aortic root diameter adjusted for body surface area (BSA). A second specific aim is to assess the incidence and magnitude of adverse effects of propranolol therapy. The primary end-point will be the change in the Physical Health Summary and Psychosocial Health Summary scores of the CHQ-50 at one and two years of therapy compared to pre-therapy. A third specific aim is to evaluate the role of collagen and fibrillin in the pathogenesis of aortic root dilation after the ASO by analyzing single nucleotide polymorphisms (SNPs) in candidate genes: fibrillin and Collagen types 3al, 5al, and 5a2 genes. The primary endpoint is the identification of SNPs that are significantly associated with severity of aortic root dilation. The ASO trial will involve an enrollment period of two years and a follow-up period of 2 years. Both trials are expected to yield information important to clinical practice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETINAL BLOOD FLOW AND MICROTHROMBI IN TYPE 1 DIABETES Principal Investigator & Institution: Lorenzi, Mara; Associate Professor; Schepens Eye Research Institute Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): The greatest likelihood of lessening the threat of diabetic retinopathy is through prevention. Preventative strategies must target pathogenic events that occur early in diabetes, and incorporate methods for monitoring outcomes longitudinally and noninvasively. Previous studies suggest that the formation of platelet-fibrin microthrombi could be an early pathogenic event in the closure and obliteration of diabetic retinal capillaries, and do show reduced retinal blood flow in patients with short diabetes duration and no or minimal retinopathy. The hypothesis to be tested in this project is that the reduced retinal blood flow reflects increased vascular resistance due to microthrombosis, and, operationally, that antiplatelet agents normalize the reduced retinal blood flow. The project aims to (1) confirm that, under basal
Studies
57
conditions, retinal blood flow measured with the laser Doppler method in a large group of type 1 diabetic patients with no or minimal retinopathy differs from the flow measured in age- and sex-matched nondiabetic control subjects; (2) determine whether the response of retinal blood flow to low-dose aspirin--expected to be mostly or solely antithrombotic--administered for two months versus placebo, differs between the diabetic and the control group; and (3) determine whether the response of retinal blood flow to low-dose aspirin in type 1 diabetic patients differs from the response to another antiplatelet agent, which is highly selective and acts downstream of the site of aspirin action. The study is designed as a two-arm (diabetic patients and controls), parallelgroup, double-masked, randomized, placebo-controlled trial, involving individuals 1840 years of age with diabetes duration of one to ten years and no or minimal retinopathy. The diabetic subjects will be recruited from the Diabetes Center of the Massachusetts General Hospital. The retinal blood flow measurements will be performed with the Canon Laser Blood Flowmeter, an instrument approved by the FDA and usable with ease in the clinical setting. A finding that early reduction of blood flow reflects the occurrence of microthrombosis in the retina of short-term diabetic patients will have identified a pathogenic process for diabetic retinopathy, a surrogate endpoint and a probe for its early detection, and a target for early intervention using benign and clinically available drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RICKETTSIA-INDUCED TRANSCRIPTIONAL ACTIVATION Principal Investigator & Institution: Sahni, Sanjeev K.; Res. Asst. Professor; Medicine; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 01-AUG-1997; Project End 31-AUG-2004 Summary: (provided by applicant): Rocky Mountain spotted fever, the most prevalent and important of the rickettsioses in the United States, is an acute tick-borne febrile illness caused by Rickettsia rickettsii. The organism infects and proliferates predominantly within vascular endothelial cells, which respond by activating a series of defense mechanisms, possibly via distinct signal transduction pathways. We have demonstrated that R. rickettsii infection of endothelial cells results in the activation of nuclear factor-kappaB (NF-kB a transcription factor which controls the expression of an array of genes involved in bacterial infections, immune response, and apoptosis. We have also shown that anti-apoptotic functions of NF-kB protect the host cell from apoptotic death during R. rickettsii infection. The objective of this application is to further our understanding of signaling mechanisms underlying Rickettsia-induced transcriptional activation and investigate their participation in the host cell response to infection. Since the seminal event in the activation of NF-kB is the degradation of IkB (inhibitors of NF-kB) proteins by IkB kinase (IKK) complex, Aim I will characterize the activation of IKK and phosphorylation/degradation of IkB proteins during infection. We will determine the kinetics of activation of catalytic subunits, IKK-a and IKK-b, by an immunoprecipitation (IP) kinase assay. The role of the regulatory subunit, IKK-g will be evaluated using a specific, cell permeable peptide that blocks its association with the IKK complex. Aim 2 will characterize the activation of mitogen activated protein (MAP) kinases and investigate their involvement in rickettsial invasion of endothelial cells and activation of NF-kB Modulation of MAP kinase cascades, ERK1/2 and p38, will be examined by immunoblotting using phosphorylation state specific antibodies and activity assays by IP western analysis. Aim 3 will define the regulation of chemokine induction in response to infection and explore its dependence on the MAP kinase and NF-kB pathways. Using molecular biology and microscopy techniques and strains of
58
Aspirin
Rickettsia with varying pathogenicity, we will investigate the correlation between infection, activation of IKK/NF-kB and MAP kinases, and induction of chemokine response. These studies will offer important perspectives in understanding rickettsial pathogenesis and provide valuable insight into the complex interplay of signaling events, which occur as part of the host-parasite relationship. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RISK FACTORS FOR PULMONARY HYPERTENSION OF THE NEWBORN Principal Investigator & Institution: Mitchell, Allen A.; Professor/Director; Slone Epidemiology Unit; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-MAR-2003 Summary: (Adapted from Investigator's Abstract) Persistent pulmonary hypertension of the newborn (PPHN), previously called persistent fetal circulation, is a birth defect affecting approximately 1 in 1250 liveborn term infants; even with complex and highrisk interventions, PPHN results in substantial mortality and morbidity. This defect results from the inappropriate muscularization of fetal pulmonary vessels, and experimental and human evidence consistently suggests that maternal cigarette smoking and antenatal exposure to non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin or ibuprofen, may play a role in the etiology of this condition. Because these exposures are quite prevalent (e.g., ibuprofen is currently taken in the first trimester or later in pregnancy by 15% and 3.2% of women, respectively), testing these hypotheses is of considerable public health importance. The investigators propose to conduct a multicenter case-control study of PPHN in relation to maternal exposure to smoking and NSAIDs. They will also assess other potential antenatal risk factors and collect and store buccal cell specimens for future analyses. There will be 560 case infants with PPHN and four controls per case (2240). All controls will be drawn from the birth hospitals of cases; half the controls will have malformations other than PPHN, and half will have normal formations. Cases and controls will be identified within 5 months of birth at 88 birth and tertiary hospitals in the areas surrounding Boston, Philadelphia, and Toronto. Mothers of subjects will be interviewed by telephone within six months of delivery; a standardized questionnaire will inquire in detail about demographic factors; reproductive, medical, and pregnancy illness histories; medication use (including a detailed focus on use of over-the-counter analgesic/antipyretic medications), smoking, and nutrition. Because of emerging genetic research suggesting an effect of NSAIDs on pathways possibly related to the etiology of PPHN, buccal swabs will also be collected and stored for future analyses. Exposure prevalences will be compared between mothers of cases and controls and relative risks will be estimated, controlling for potential confounding factors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SECONDARY PREVENTION IN SMALL SUBCORTICAL STROKES (SPS3) Principal Investigator & Institution: Benavente, Oscar R.; Associate Professor; Medicine; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2001; Project Start 05-SEP-1999; Project End 30-NOV-2002 Summary: Small subcortical strokes (S3), also known as lacunar infarcts, comprise nearly 25 percent of brain infarcts, are harbingers of vascular dementia, and are
Studies
59
particularly frequent in Mexican- Americans. Combination antiplatelet therapy using clopidogrel plus aspirin and intensive lowering of blood pressure could substantially reduce major vascular events and cognitive decline in S3 patients. However, a large randomized clinical trial is required to define the efficacy and safety of these interventions specifically in patients with S3 due to presumed small vessel disease. This proposal is for a pilot study to: 1. Determine the lowest tolerable, achievable target blood pressures among survivors of S3. 2. To assess whether the difference between the lowest tolerable blood pressures are sufficiently different from that achieved by standard targets to substantially impact the occurrence of subsequent stroke and cognitive decline. 3. To quantitatively assess white matter abnormalities in S3 patient by serial MRI, correlating these with patient features, cognitive status, blood pressure control and antiplatelet treatment. 4. To assess the relationship of Mexican-American ethnicity to blood pressure interventions, tolerance of antiplatelet therapy, extent and progression of white matter abnormalities, and cognitive status, as well as to modify and assess existing screening tests of cognitive status for those who primarily speak Spanish. Participants with S3 attributed to small vessel disease will be randomized to treatment with aspirin (650mg/d) or aspirin plus clopidogrel (75mg/d) (double-blind), while those with a history of hypertension will additionally be randomized to three different target levels of blood pressure lowering (not blinded). The tolerance and achieved blood pressures in each target level will be the primary outcome, with tolerance and side-effects of antiplatelet therapy also assessed. Quantitative MRI will be done at entry and after a mean of one year, correlated with cognitive status, interventions and ethnicity. No clinical trials have assessed secondary prevention in S3, the most common type of stroke in Mexican Americans and accounting for about 150,000 strokes yearly in the US. While this pilot study is a necessary first-step for a larger, definitive clinical trial, valuable and unique information about blood pressure control after stroke and about issues relevant to stroke prevention in MexicanAmericans will emerge. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SENSING PH AT THE GASTRIC SURFACE Principal Investigator & Institution: Montrose, Marshall H.; Professor; Physiology and Biophysics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2001; Project Start 15-AUG-1999; Project End 31-JUL-2004 Summary: The stomach must survive HCl secreted by the gastric epithelium. This challenge is heightened by the frequent presence of compounds (e.g. non-steroidal antiinflammatory drugs) or organisms (Helicobacter pylori) which compromise the gastric barrier to acid, leading to ulcers when the barrier is breached. An alkaline juxtamucosal gel layer is the first line of gastric defense: acting to protect the gastric epithelium from back-diffusion of acid from the lumen. We have developed a unique approach to noninvasively measure pH at the gastric surface in vivo. Using confocal microscopy, we have imaged a juxtamucosal alkaline layer, which converts to an acid layer when luminal pH is changed to values found in the fed stomach. Our results suggest a new model of gastric surface pH regulation, which includes a substantial change in the transporters that control surface pH. Our objective is to define the elements regulating luminal pH sensing and surface pH regulation in the stomach. Using primarily in vivo confocal microscopy of rat or mouse stomach, our first aim will define fundamental requirements for the stomach to sense and respond to luminal pH. We will a) define the timing and location of luminal pH change required for conversion from alkali to acid
60
Aspirin
secretion, and b) test the role of luminal nutrients and buffers in surface pH regulation. In the second aim, we will question which molecules are transducers of the luminal pH stimulus that mediate the integrated regulation of both gastric acid and alkali secretion. We will focus on the role of somatostatin, PGE2, and capsaicin-sensitive afferent nerves containing CGRP. The role of somatostatin will be analyzed using antagonists and agonists selective for the somatostatin type 2 receptor (SST2) with parallel studies of SST2-knockout mice. The role of prostaglandin synthesis will be approached using selective inhibitors of known cycloxygenase (COX) isoforms, with parallel studies of COX-1 and COX-2 knockout mice. Capsaicin-sensitive afferents will be analyzed using vanilloid receptor agonists, CGRP receptor agonists and antagonists, with parallel studies of chemically deafferented animals. The third aim will ask how gastric mucosal damage disrupts surface pH regulation. We will generate microscopic lesions in the gastric epithelium by two-photon microscopy. Using this new model of focal gastric damage, we will follow the disruptions in surface pH regulation and the tissue repair process in real time. We will ask if aspirin, a major cause of clinical mucosal damage, weakens the gastric barrier by disruption of luminal pH sensing and surface pH regulation in normal and COX-knockout mice. We will determine if aspirin affects the repair of focal lesions created by two-photon microscopy. Results will integrate understanding of gastric defense with regulation of acid and alkali secretion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SMOKING AND ATHEROSCLEROSIS: MECHANISMS AND MODULATION Principal Investigator & Institution: Burke, Anne; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2006 Summary: Objectives: This research is to investigate a mechanism of smoking induced atherosclerosis and to assess the impact of smoking reduction strategies on arterial injury. Improving our understanding of smoking induced atherosclerosis will increase our armamentarium against this and non-smoking induced atherosclerosis. Specific aims: 1) To address the hypothesis that nicotine substitution or buproprion reduces smoking induced thromboxane (TX) formation and consequent endothelial dysfunction. 2) To address the hypothesis that nicotine substitution or buproprion reduces the smoking induced increment in isoprostane generation and inflammatory cytokines. 3) To address the hypothesis that smoking reduction may improve endothelial function even in the absence of smoking cessation. Relationship to health: Smoking is the leading cause of preventable death in America. Smoking costs the United States approximately $1 billion per annum. Reducing the harm of smoking will have a considerable impact on the health and health care costs of the United States. Research design: Healthy endothelium displays a vasodilatory response to vasoactive stimuli, which is blunted or absent in arterial disease. Flow mediated vasodilatation (FMD) can be measured noninvasively by ultrasound and correlates closely with subsequent development of atherosclerosis. Urinary isoprostane measured by gas chromatography / mass spectrometry (GC/MS) provide a specific and sensitive means to measure oxidative stress (OS) in vivo in humans. GC/MS also allows for accurate non-invasive quantification of TX and prostacyclin (PGI2) metabolites in humans. This research will be carried out in healthy age and gender matched human volunteers. Subjects will be studied for 6 months. It will quantify FMD in non- smokers, light and heavy smokers, before and after administration of vitamin C - an antioxidant, and aspirin - an inhibitor of TX and PGI2 synthesis. It will correlate FMD and eicosanoid production, before
Studies
61
during and after smoking cessation on nicotine and non-nicotine smoking cessation medications. In addition, this research, in a separate experiment, will study the impact of nicotine and non nicotine assisted smoking reduction strategies on these parameters. Expected findings: We expect to find that smokers have impaired FMD and elevated OS, TX and PGI2 production. We expect that smoking reduction and cessation and the administration of antioxidants and aspirin will improve these parameters towards the levels of healthy volunteers and that the effects will be additive. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE/FUNCTION OF PROSTAGLANDIN H SYNTHASE 2 Principal Investigator & Institution: Kulmacz, Richard J.; Associate Professor; Internal Medicine; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, Tx 77225 Timing: Fiscal Year 2001; Project Start 01-DEC-1994; Project End 30-NOV-2002 Summary: The cyclooxygenase activity of prostaglandin H synthase (PGHS) catalyzes the first committed step in the biosynthesis of the prostaglandins, a group of potent, bioactive lipids believed important in many pathophysiological processes, including inflammation, vascular, gastric and renal function, reproduction, and tumorigenesis. Two PGHS isoforms are known: PGHS-1 is regarded as constitutive and is ascribed housekeeping function; PGHS 2 is strongly inducible by cytokines in many cells involved in inflammatory and proliferative processes. Besides the controls of PGHS- 1 and -2 gene expression, cellular prostaglandin synthesis is also tightly regulated at the cyclooxygenase catalytic level, with different catalytic controls for the two PGHS isoforms. PGHS-2 cyclooxygenase has a much lower hydroperoxide activator requirement than the PGHS-1 cyclooxygenase. This difference in feedback activation by the product provides a simple biochemical basis for differential cellular control of cyclooxygenase catalysis. Cellular cyclooxygenase catalysis also can be limited by fatty acid substrate availability. PGHS-1 cyclooxygenase activity exhibits cooperative behavior at low arachidonic acid levels, whereas the PGHS-2 enzyme follows simple saturable kinetics. The general goal of this project is to understand the regulation of catalysis by the PGHS isoforms at a molecular level. Kinetic, spectroscopic, and structural studies will be undertaken with the two PGHS isoforms and targeted mutant proteins to achieve the following specific aims: 1) Identify the mechanistic basis(es) for the different hydroperoxide activator requirements in PGHS-1 and -2, and investigate the mechanistic changes in aspirin-treated PGHS-2; 2) Identify the structural element(s) controlling the hydroperoxide activator requirements in PGHS-1 and -2, and investigate the mechanistic changes in aspirin-treated PGHS-2; 2) Identify the structural element(s) controlling the hydroperoxide activator requirements in the two isoforms; and 3) Evaluate the interdependence between fatty acid and peroxide in cyclooxygenase catalytic control for the two PGHS isoforms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STUDY OF DIABETIC RETINOPATHY Principal Investigator & Institution: Kern, Timothy S.; Professor; Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001; Project Start 01-DEC-1977; Project End 31-DEC-2004 Summary: (Applicant's Description): The goal of this research is to clarify the pathogenesis of diabetic retinopathy and to provide a rational basis for developing improved means to inhibit the retinopathy. The proposed studies are based on our recent findings that aminoguanidine and aspirin both inhibit the development of
62
Aspirin
retinopathy in diabetes. We will investigate the hypothesis that aminoguanidine and aspirin inhibit retinal pathology by inhibiting the same metabolic abnormalities in diabetes, especially excessive production of NO and of reactive dicarbonyls. The pathogenesis of diabetic retinopathy will be investigated by comparing effects of aminoguanidine and aspirin on retinal metabolism and histopathology to results observed using selective inhibitors of (1) dicarbonyl (and advanced glycation end product) production, (2) nitric oxide synthesis, and (3) poly (ADP-ribose) synthetase. Together, these selective inhibitors will investigate the roles of hyperglycemia-induced damage to DNA, caspase activation, and accelerated death of retinal capillary cells in the pathogenesis of diabetic retinopathy. Additional insight on how aminoguanidine inhibits retinopathy in diabetes will be gained by investigating why aminoguanidine fails to inhibit the morphologically similar retinopathy caused by galactose-feeding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TEMPORAL PROPERTIES OF AUDITORY MASKING Principal Investigator & Institution: Bacon, Sid P.; Professor; Speech and Hearing Science; Arizona State University P.O. Box 873503 Tempe, Az 852873503 Timing: Fiscal Year 2001; Project Start 01-JUL-1992; Project End 31-MAY-2006 Summary: The long-range goals of the proposed research are to further our understanding of the mechanisms underlying the auditory processing of time-varying stimuli, and to determine how those mechanisms are affected by sensorineural hearing loss. There are three separate but related lines of research, and all focus to some extent on the potential role of peripheral compression in temporal processing. The influence of compression is evaluated by studying the effects of temporary, aspirin- induced hearing loss, permanent hearing loss, and model simulations. The first line of research focuses on the detection of brief signals as a function of prior masker stimulation. The underlying mechanisms could play an important role in enhancing newly arriving or intermittent signals, especially those in an on-going background. The general goal of this line of research is to test the hypothesis that the mechanisms underlying the temporal effect with off frequency tonal maskers differ from those underlying the effect with broadband noise maskers. The second line of research concentrates on phase effects in simultaneous masking, particularly on how the resulting temporal fluctuations influence the amount of masking. The general goal of this research is to gain a better understanding of the within- and across-channel mechanisms underlying these phase effects. This research should enhance our understanding of how the auditory system processes the temporal fluctuations inherent in many complex sounds, including speech, and could ultimately provide insight into why individuals with a sensorineural hearing loss have particular difficulties understanding speech in temporally complex backgrounds. The third line of research focuses on a recently described change in response growth from compressive to linear at high levels. This change, inferred from growth-of-masking functions, is responsible for a measured decline in temporal processing at high stimulus levels. The primary goal of this line of research is to gain a better understanding of the processing underlying this change in response growth. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TRIAL OF ASPIRIN AND VITAMIN E IN WOMEN Principal Investigator & Institution: Buring, Julie E.; Professor of Ambulatory Care and Prevent; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-FEB-1991; Project End 31-AUG-2004
Studies
63
Summary: This application proposes to extend the Women's Health Study (WHS) for an additional 3 years of randomized treatment and follow-up. The WHS is an ongoing randomized, double-blind, placebo-controlled, 2x2 factorial trial evaluating the balance of benefits and risks of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer among 39,876 U.S. female health professionals aged 45 and older. Its goal is to provide either clear positive results or definitive null results on which sound clinical and public health recommendations for the use of low-dose aspirin and vitamin E can be made. Based on a review of the unblinded data, both the clinical and methodologic members of the trial's Data and Safety Monitoring Board unanimously recommended an extension of both randomized components beyond the trial's scheduled termination in August 2001. The primary rationale for the Board's recommendation was the likelihood of ambiguity at the scheduled end of the trial regarding the findings of both agents on both endpoints, ambiguity that could result in considerable clinical confusion. Three additional years will help clarify these ambiguities, more conclusively determine the balance of benefits and risks of these agents for the primary prevention of cardiovascular disease, and allow an adequate latent period to elapse for assessing the effects of both agents on cancer, thus providing clear clinical recommendations for health care providers and patients. The Women's Health Study is in a unique position to answer these important questions. Average duration of treatment is 6 years; morbidity and mortality follow-up rates are 98 percent and 100 percent, respectively. Compliance with both agents at 72 months is 75.6 percent. Pilot data indicate that 97 percent of compliers would definitely be willing to continue the trial for 3 additional years or would consider continuing. This trial is cost effective, at 75 dollars per randomized participant per year in direct costs. Given the gaps in knowledge this study is intended to address, as well as the certain intense interest in its findings by the medical, lay, and regulatory communities, the proposed extension of this trial in women is timely and important. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRIALS OF PREVENTION OF COGNITIVE DECLINE IN WOMEN AND M Principal Investigator & Institution: Grodstein, Francine; Assistant Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 31-JUL-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: VASCULAR INTERACTION WITH AGE IN MYOCARDIAL INFARCTION Principal Investigator & Institution: Schulman, Steven P.; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 10-SEP-2001; Project End 31-AUG-2005 Summary: (the applicant's description verbatim): Older age is associated with a marked increase in cardiac morbidity and mortality following a myocardial infarction regardless of the administration of thrombolytic therapy, an early invasive approach, and the use of aspirin, ACE-inhibitors and beta-blockers. A significant proportion of these adverse outcomes are related to the cardiac consequences of the infarct itself, namely left ventricular dysfunction, cardiogenic shock, and congestive heart failure; in spite of the fact that indices of infarct size tend to decrease with age. This proposal examines the
64
Aspirin
broad hypothesis that the age-associated physiologic changes in vascular and ventricular properties we previously studied and described, and most importantly increased stiffness, alter the substrate upon which a myocardial infarction is superimposed so as to increase the likelihood of left ventricular dysfunction, and clinical congestive heart failure in older patients. More specifically, we propose to use sophisticated techniques and models to characterize vascular load (Ea-arterial elastance) and its interaction with ventricular performance (Ees- left ventricular end-systolic elastance) in older post-infarction patients and to relate age-associated changes in ventricular-vascular coupling (Ea/Ees relationship) in these patients to six-month changes in left ventricular function and to clinical outcomes. Finally, we propose to test the hypothesis that decreasing arterial stiffness results in an improvement in 6-month outcomes in a prospective, randomized clinical trial employing L-arginine, an agent that decreases vascular load via mechanisms other than those influenced by routine postinfarction therapies. We anticipate that the study findings will suggest the use of new evaluation and therapeutic strategies, which will significantly decrease the age associated mortality and morbidity in post-infarction patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: WARFARIN VS ASPIRIN FOR INTRACRANIAL ARTERIAL STENOSIS Principal Investigator & Institution: Chimowitz, Marc I.; Neurology; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 25-SEP-1998; Project End 31-JUL-2003 Summary: Background and Relevance. Atherosclerotic stenosis of the major intracranial arteries causes 40,000 strokes per year in the USA, costing the country at least 600,000,000 dollars annually. There have been no prospective trials evaluating optimal medical therapy for this disease. The main objective of this clinical trial is to compare warfarin (INR 2-3) with aspirin (1300 mg/day) for preventing stroke (ischemic and hemorrhagic) and vascular death in patients with symptomatic stenosis of a major intracranial artery. Study Design. Prospective, randomized, double-blind, multi-center trial. The sample size required will be 403 patients per group (based on stroke and vascular death rates of 33 percent/3 years in the aspirin group vs 22 percent/3 years in the warfarin group, an alpha of 0.05, beta of 0.80, a 24 percent withdrawal of therapy rate, and a 1 percent drop out rate). Conduct of Trial. Patients with transient ischemic attack (TIA) or stroke caused by angiographically proven stenosis (greater than or equal to 50 percent) of a major intracranial artery will be randomized to warfarin or aspirin. The dose of warfarin will be adjusted to maintain the INR between 2-3 based on monthly blood tests. Patients will be contacted monthly by phone and examined every four months (mean follow-up of 3 years) to determine whether any endpoints have occurred. The primary analysis will compare the rates of stroke (ischemic and hemorrhagic) and vascular death in the two treatment groups. Secondary analyses will compare the two treatment groups with respect to rates of i) all vascular deaths and disabling stroke, ii) all stroke (ischemic and hemorrhagic), iii) fatal and nonfatal ischemic stroke, iv) all ischemic stroke, myocardial infarction and vascular death, v) all major systemic and any intracranial hemorrhage, vi) all ischemic stroke in the territory of the stenotic intracranial artery. Conclusion. This study will 1) define optimal medical therapy for patients with symptomatic intracranial arterial stenosis, and 2) identify patients whose rate of ischemic stroke in the territory of the stenotic intracranial artery on best medical therapy is sufficiently high (i.e., greater than or equal to 6 percent per
Studies
65
year) to justify a subsequent trial comparing intracranial angioplasty with best medical therapy in these patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: WARFARIN VS ASPIRIN FOR SYMPTOMATIC INTRACRANIAL DISEASE Principal Investigator & Institution: Hemphill, Jesse C.; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: WARFARIN VS ASPIRIN IN REDUCED EJECTION FRACTION STAT Principal Investigator & Institution: Thompson, John L.; Biostatistics; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2006 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: WARFARIN VS ASPIRIN IN REDUCED EJECTION FRACTION-CLIN Principal Investigator & Institution: Pullicino, Patrick M.; Professor and Chairman; Neurology and Neurosciences; Univ of Med/Dent Nj Newark Newark, Nj 07103 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2006 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “aspirin” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for aspirin in the PubMed Central database:
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
66
Aspirin
•
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. by Ouellet M, Riendeau D, Percival MD.; 2001 Dec 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=64725
•
Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. by Burtscher M, Likar R, Nachbauer W, Philadelphy M.; 1998 Apr 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28508
•
Aspirin Inhibits Interleukin 1-Induced Prostaglandin H Synthase Expression in Cultured Endothelial Cells. by Wu KK, Sanduja R, Tsai A, Ferhanoglu B, LooseMitchell DS.; 1991 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51236
•
Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. by Ruschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstadter F, Fishel R.; 1998 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21637
•
Aspirin Triggers Previously Undescribed Bioactive Eicosanoids by Human Endothelial Cell-Leukocyte Interactions. by Claria J, Serhan CN.; 1995 Oct 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40824
•
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. by Napoli C, Ackah E, de Nigris F, Del Soldato P, D'Armiento FP, Crimi E, Condorelli M, Sessa WC.; 2002 Sep 17; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129468
•
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. by Meade TW, Brennan PJ.; 2000 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27417
•
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. by Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, Pinto A, Ignarro LJ.; 2001 Feb 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=30230
•
Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. by Napoli C, Aldini G, Wallace JL, de Nigris F, Maffei R, Abete P, Bonaduce D, Condorelli G, Rengo F, Sica V, D'Armiento FP, Mignogna C, de Rosa G, Condorelli M, Lerman LO, Ignarro LJ.; 2002 Feb 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122252
•
Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority. by Khunti K, Sorrie R, Jennings S, Farooqi A.; 1999 Jul 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28184
•
Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. by Ray JG, Deniz S, Olivieri A, Pollex E, Vermeulen MJ, Alexander KS, Cain DJ, Cybulsky I, Hamielec CM.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=162165
Studies
67
•
Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. by Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R.; 1995 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162820
•
Inhibition of Wound-Induced Accumulation of Allene Oxide Synthase Transcripts in Flax Leaves by Aspirin and Salicylic Acid. by Harms K, Ramirez I, Pena-Cortes H.; 1998 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34779
•
Is clopidogrel superior to aspirin in secondary prevention of vascular disease? by Algra A, Gijn JV.; 2000; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59615
•
ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. by Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R.; 1998 May 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28530
•
Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin. by Oo C, Barrett J, Dorr A, Liu B, Ward P.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127254
•
Leukocyte Lipid Body Formation and Eicosanoid Generation: CyclooxygenaseIndependent Inhibition by Aspirin. by Bozza PT, Payne JL, Morham SG, Langenbach R, Smithies O, Weller PF.; 1996 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38289
•
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-[kappa]B and AP-1 activation, and IL-8 gene expression in human leukocytes. by Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG.; 2002 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130622
•
Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. by Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN.; 1999 Jul 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22220
•
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. by Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI.; 2002 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150979
•
Modes of action of aspirin-like drugs: Salicylates inhibit Erk activation and integrindependent neutrophil adhesion. by Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, Weissmann G.; 1998 Nov 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24409
•
Platelet responsiveness to aspirin in patients with hyperlipidaemia. by Friend M, Vucenik I, Miller M.; 2003 Jan 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=139938
•
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin
68
Aspirin
with aspirin. by Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, van Ree JW, Knottnerus JA.; 1999 Oct 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28250 •
Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. by Mant JW, Richards SH, Hobbs FD, Fitzmaurice D, Lip GY, Murray E, Banting M, Fletcher K, Rahman J, Allan T, Raftery J, Bryan S.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=201020
•
Regular aspirin use and lung cancer risk. by Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM, Bepler G.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=138809
•
Regular use of aspirin and pancreatic cancer risk. by Menezes RJ, Huber KR, Mahoney MC, Moysich KB.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126211
•
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. by Derry S, Loke YK.; 2000 Nov 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27521
•
Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. by Thrift AG, McNeil JJ, Forbes A, Donnan GA.; 1999 Mar 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27788
•
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. by de Abajo FJ, Garcia Rodriguez LA.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=32172
•
Sunflower (Helianthus annuus L.) Pathogenesis-Related Proteins (Induction by Aspirin (Acetylsalicylic Acid) and Characterization). by Jung JL, Fritig B, Hahne G.; 1993 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=158702
•
Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. by Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK.; 1999 Apr 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21857
•
The Mode of Action of Aspirin-Like Drugs: Effect on Inducible Nitric Oxide Synthase. by Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissman G, Abramson SB.; 1995 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41259
•
Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. by Reuter BK, Zhang XJ, Miller MJ.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122065
•
Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. by Short D, Frischer M, Bashford J, Ashcroft D.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=183829
Studies
69
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with aspirin, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “aspirin” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for aspirin (hyperlinks lead to article summaries): •
A magic bullet for mucosal protection.and aspirin is the trigger! Author(s): Wallace JL, Fiorucci S. Source: Trends in Pharmacological Sciences. 2003 July; 24(7): 323-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12871661&dopt=Abstract
•
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. Author(s): Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, Robinson TI, Moher D; Investigators of the Multicenter Aspirin Study in Infective Endocarditis. Source: Journal of the American College of Cardiology. 2003 September 3; 42(5): 775-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12957419&dopt=Abstract
•
A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Author(s): Stern C, Chamley L, Norris H, Hale L, Baker HW. Source: Fertility and Sterility. 2003 August; 80(2): 376-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12909502&dopt=Abstract
•
Acetyl salicylic acid (aspirin), micronutrients and chloroquine in the management of the acquired immunodeficiency syndrome (AIDS). Author(s): Stanczuk GA, Thomsen M, Soerensen AM, Sibanda EN. Source: Cent Afr J Med. 2002 March-April; 48(3-4): 42-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12971157&dopt=Abstract
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
70
Aspirin
•
After 100 years of aspirin, the anticytokine drugs offer a new approach to antiinflammatory therapy. Author(s): Higgs G. Source: Curr Opin Investig Drugs. 2003 May; 4(5): 517-8. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12833642&dopt=Abstract
•
An aspirin a day keeps the MI away (for some). Author(s): Miser WF. Source: American Family Physician. 2002 May 15; 65(10): 2000, 2003. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12046769&dopt=Abstract
•
Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs. Author(s): Martini AC, Molina RI, Tissera AD, Ruiz RD, Fiol de Cuneo M. Source: Fertility and Sterility. 2003 July; 80(1): 221-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12849830&dopt=Abstract
•
Anti-inflammatory effects of aspirin and sodium salicylate. Author(s): Amann R, Peskar BA. Source: European Journal of Pharmacology. 2002 June 28; 447(1): 1-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12106797&dopt=Abstract
•
Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three? Author(s): Harding SA, Boon NA, Flapan AD. Source: Heart (British Cardiac Society). 2002 July; 88(1): 11-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12067932&dopt=Abstract
•
Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 1). Author(s): Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, Uzan S, Marquis P, Parmentier D, Churlet A; Essai Regional Aspirine Mere-Enfant (ERASME) Collaborative Group. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2003 May; 110(5): 475-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12742332&dopt=Abstract
Studies
71
•
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Author(s): van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE; Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Source: Lancet. 2002 July 13; 360(9327): 109-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126819&dopt=Abstract
•
Aspirin and cyclooxygenase-2 inhibitors. Author(s): Armstrong TA. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2003 July 15; 60(14): 1481. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12892035&dopt=Abstract
•
Aspirin and heart failure: square evidence meets a round patient. Author(s): Konstam MA. Source: Congestive Heart Failure (Greenwich, Conn.). 2003 July-August; 9(4): 203-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12937356&dopt=Abstract
•
Aspirin and indomethacin exhibit antiproliferative effects and induce apoptosis in T98G human glioblastoma cells. Author(s): Amin R, Kamitani H, Sultana H, Taniura S, Islam A, Sho A, Ishibashi M, Eling TE, Watanabe T. Source: Neurological Research. 2003 June; 25(4): 370-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12870263&dopt=Abstract
•
Aspirin and lung cancer in women. Author(s): Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE. Source: British Journal of Cancer. 2002 July 1; 87(1): 49-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12085255&dopt=Abstract
•
Aspirin and microvascular surgery: an update. Author(s): Peter FW, Steinau HU, Homann HH, Barker JH. Source: Plastic and Reconstructive Surgery. 2003 October; 112(5): 1368-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14504522&dopt=Abstract
•
Aspirin and Reye's syndrome: is the response appropriate? Author(s): Langford NJ. Source: Journal of Clinical Pharmacy and Therapeutics. 2002 June; 27(3): 157-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081628&dopt=Abstract
72
Aspirin
•
Aspirin and the prevention of colorectal cancer. Author(s): Berman KS. Source: The New England Journal of Medicine. 2003 June 12; 348(24): 2466-7; Author Reply 2466-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12803217&dopt=Abstract
•
Aspirin and the prevention of colorectal cancer. Author(s): Hassan Y. Source: The New England Journal of Medicine. 2003 June 12; 348(24): 2466-7; Author Reply 2466-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802036&dopt=Abstract
•
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. Author(s): Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S; African American Antiplatelet Stroke Prevention Study Investigators. Source: Jama : the Journal of the American Medical Association. 2003 June 11; 289(22): 2947-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799402&dopt=Abstract
•
Aspirin and trauma--uncommon and preventable causes of intracranial haemorrhage in the newborn. Author(s): Adhikari M, Pillay T, Nathoo N. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2002 May; 92(5): 345-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12108160&dopt=Abstract
•
Aspirin beyond platelet inhibition. Author(s): Verheugt FW, Gersh BJ. Source: The American Journal of Cardiology. 2002 July 1; 90(1): 39-41. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12088777&dopt=Abstract
•
Aspirin curbs colon polyps. But for many, bleeding risks may offset benefits. Author(s): Terdiman JP. Source: Health News. 2003 May; 9(5): 1-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12739451&dopt=Abstract
•
Aspirin cuts return of precursor to colorectal cancer. Author(s): Levenson D. Source: Rep Med Guidel Outcomes Res. 2003 March 21; 14(6): 7-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12838968&dopt=Abstract
Studies
73
•
Aspirin dosage and thromboxane synthesis in patients with vascular disease. Author(s): Hart RG, Leonard AD, Talbert RL, Pearce LA, Cornell E, Bovill E, Feinberg WM. Source: Pharmacotherapy. 2003 May; 23(5): 579-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12741431&dopt=Abstract
•
Aspirin for cardiovascular disease prevention. Author(s): Hung J; Medical Issues Committee of the National Heart Foundation of Australia. Source: The Medical Journal of Australia. 2003 August 4; 179(3): 147-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12885284&dopt=Abstract
•
Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Author(s): Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Source: Obstetrics and Gynecology. 2003 June; 101(6): 1319-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12798543&dopt=Abstract
•
Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Author(s): U.S. Preventive Services Task Force. Source: American Family Physician. 2002 May 15; 65(10): 2107-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12046780&dopt=Abstract
•
Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells. Author(s): Tiran A, Gruber HJ, Graier WF, Wagner AH, Van Leeuwen EB, Tiran B. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2002 July 1; 22(7): 1075-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12117719&dopt=Abstract
•
Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Author(s): O'Kane PD, Queen LR, Ji Y, Reebye V, Stratton P, Jackson G, Ferro A. Source: Cardiovascular Research. 2003 July 1; 59(1): 152-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12829186&dopt=Abstract
•
Aspirin overdose. Author(s): Kamanyire R. Source: Emergency Nurse : the Journal of the Rcn Accident and Emergency Nursing Association. 2002 July-August; 10(4): 17-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12138590&dopt=Abstract
74
Aspirin
•
Aspirin protects Caco-2 cells from apoptosis after serum deprivation through the activation of a phosphatidylinositol 3-kinase/AKT/p21Cip/WAF1pathway. Author(s): Ricchi P, Palma AD, Matola TD, Apicella A, Fortunato R, Zarrilli R, Acquaviva AM. Source: Molecular Pharmacology. 2003 August; 64(2): 407-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869645&dopt=Abstract
•
Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity. Author(s): Hillarp A, Lethagen S, Mattiasson I. Source: Journal of Thrombosis and Haemostasis : Jth. 2003 January; 1(1): 196-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12871563&dopt=Abstract
•
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Author(s): Berger AK, Duval S, Krumholz HM. Source: Journal of the American College of Cardiology. 2003 July 16; 42(2): 201-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875751&dopt=Abstract
•
Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Author(s): Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Source: Archives of Internal Medicine. 2003 July 14; 163(13): 1574-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12860580&dopt=Abstract
•
Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. Author(s): Szczeklik A, Stevenson DD. Source: The Journal of Allergy and Clinical Immunology. 2003 May; 111(5): 913-21; Quiz 922. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743549&dopt=Abstract
•
Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Author(s): Picado C. Source: Allergy. 2002; 57 Suppl 72: 58-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12144557&dopt=Abstract
•
Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. Author(s): Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Source: Journal of Immunology (Baltimore, Md. : 1950). 2003 June 15; 170(12): 6266-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12794159&dopt=Abstract
Studies
75
•
Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Author(s): Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Source: International Journal of Cancer. Journal International Du Cancer. 2003 September 20; 106(5): 784-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12866040&dopt=Abstract
•
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. Author(s): Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I, Wedel H; HOT Study Group. Source: Journal of Hypertension. 2002 November; 20(11): 2301-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12409970&dopt=Abstract
•
Benefit or risk of aspirin treatment of giant cell arteritis: comment on the article by Weyand et al. Author(s): Rothschild BM. Source: Arthritis and Rheumatism. 2002 November; 46(11): 3113; Author Reply 3113-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12428270&dopt=Abstract
•
Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Author(s): McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Source: American Heart Journal. 2002 August; 144(2): 226-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12177638&dopt=Abstract
•
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. Author(s): Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlen SE, Szczeklik A, Murray JJ, Dahlen B. Source: The Journal of Allergy and Clinical Immunology. 2003 May; 111(5): 1116-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743579&dopt=Abstract
•
Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Author(s): Charman WN, Charman SA, Monkhouse DC, Frisbee SE, Lockhart EA, Weisman S, Fitzgerald GA. Source: British Journal of Clinical Pharmacology. 1993 November; 36(5): 470-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12959298&dopt=Abstract
76
Aspirin
•
Blocking colon cancer. An aspirin a day helps. Author(s): Fischman J. Source: U.S. News & World Report. 2003 March 17; 134(8): 45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12645309&dopt=Abstract
•
Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Author(s): Menzel T, Schauber J, Kreth F, Kudlich T, Melcher R, Gostner A, Scheppach W, Luhrs H. Source: European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). 2002 June; 11(3): 271-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131661&dopt=Abstract
•
Can aspirin ever be surpassed for stroke prevention? Author(s): Tong DC. Source: Stroke; a Journal of Cerebral Circulation. 2003 April; 34(4): 847-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12680382&dopt=Abstract
•
Cardioprotective effects of aspirin compromised by other NSAIDs. Author(s): Gottlieb S. Source: Bmj (Clinical Research Ed.). 2003 September 6; 327(7414): 520. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12958094&dopt=Abstract
•
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. Author(s): Wilner KD, Rushing M, Walden C, Adler R, Eskra J, Noveck R, Vargas R. Source: Journal of Clinical Pharmacology. 2002 September; 42(9): 1027-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12211219&dopt=Abstract
•
Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. Author(s): Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T. Source: J Investig Allergol Clin Immunol. 2003; 13(1): 20-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12861847&dopt=Abstract
•
Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a population-based perspective. Author(s): Jackson EA, Sivasubramian R, Spencer FA, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. Source: American Heart Journal. 2002 August; 144(2): 259-68. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12177643&dopt=Abstract
Studies
77
•
Clinical evidence of dose-dependent interaction between aspirin and angiotensinconverting enzyme inhibitors. Author(s): Fisman EZ, Grossman E, Motro M, Tenenbaum A. Source: Journal of Human Hypertension. 2002 June; 16(6): 379-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12037691&dopt=Abstract
•
Clopidogrel but not aspirin reduces P-selectin expression and formation of plateletleukocyte aggregates in patients with atherosclerotic vascular disease. Author(s): Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Source: Clinical Pharmacology and Therapeutics. 2003 March; 73(3): 232-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12621388&dopt=Abstract
•
Clopidogrel does not suppress blood markers of coagulation activation in aspirintreated patients with non-ST-elevation acute coronary syndromes. Author(s): Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, Johnston M, Yusuf S. Source: European Heart Journal. 2002 November; 23(22): 1771-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12419297&dopt=Abstract
•
Clopidogrel plus aspirin for stroke prevention. Author(s): Alberts MJ, Easton JD. Source: Stroke; a Journal of Cerebral Circulation. 2002 November; 33(11): 2546-7; Author Reply 2546-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12411639&dopt=Abstract
•
Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. Author(s): Payne DA, Hayes PD, Jones CI, Belham P, Naylor AR, Goodall AH. Source: Journal of Vascular Surgery : Official Publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 2002 June; 35(6): 1204-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12042732&dopt=Abstract
•
Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Author(s): Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y. Source: Clinical Nephrology. 2003 June; 59(6): 458-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12834179&dopt=Abstract
78
Aspirin
•
Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Author(s): Saulsbury FT. Source: Clinical Pediatrics. 2002 October; 41(8): 597-601. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403377&dopt=Abstract
•
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Author(s): Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T; TACIP Investigators. Source: Stroke; a Journal of Cerebral Circulation. 2003 April; 34(4): 840-8. Epub 2003 March 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12649515&dopt=Abstract
•
Coronary artery bypass graft surgery in patients with recent exposure to clopidogrel and aspirin therapy. Author(s): Akowuah E, Shrivastava V, Cooper G. Source: Journal of the American College of Cardiology. 2003 April 16; 41(8): 1421-2; Author Reply 1422-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12706946&dopt=Abstract
•
Coronary intervention with a heparin-coated stent and aspirin only. Author(s): Ruygrok PN, Sim KH, Chan C, Rachman OJ, Adipranoto JD, Trisnohadi HB, Stewart JT, Ahmad N, Mak KH, Yusak M, Boestan I, Santoso T, Suryapranata H. Source: J Invasive Cardiol. 2003 August; 15(8): 439-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12890872&dopt=Abstract
•
Correlation between erosive oesophageal and gastro-duodenal diseases. the influence of aspirin, simple analgesics, and Helicobacter pylori. Author(s): Taha AS, Angerson WJ, Morran CG. Source: European Journal of Gastroenterology & Hepatology. 2002 December; 14(12): 1313-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468951&dopt=Abstract
•
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. Author(s): Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Source: The New England Journal of Medicine. 2002 June 6; 346(23): 1800-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12050341&dopt=Abstract
Studies
79
•
COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirinexacerbated respiratory disease. Author(s): Crofford LJ. Source: Arthritis Research & Therapy. 2003; 5(1): 25-7. Epub 2002 December 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716444&dopt=Abstract
•
Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Author(s): Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Source: Clinical Reviews in Allergy & Immunology. 2003 April; 24(2): 125-36. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668893&dopt=Abstract
•
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. Author(s): McQuillan A, Eikelboom JW. Source: The New England Journal of Medicine. 2002 May 16; 346(20): 1589-90; Author Reply 1589-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12017164&dopt=Abstract
•
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. Author(s): Burnakis TG. Source: The New England Journal of Medicine. 2002 May 16; 346(20): 1589-90; Author Reply 1589-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12015403&dopt=Abstract
•
Cyclooxygenase-2 inhibitors in aspirin-induced asthma. Author(s): Inoue K, Takano H, Kawahito Y, Sano H, Yoshikawa T. Source: Chest. 2003 April; 123(4): 1317-8; Author Reply 1318. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684334&dopt=Abstract
•
Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma. Author(s): Passero M, Chowdhry S. Source: Chest. 2003 June; 123(6): 2155-6; Author Reply 2156. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796206&dopt=Abstract
•
Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Author(s): Habel LA, Zhao W, Stanford JL. Source: Cancer Causes & Control : Ccc. 2002 June; 13(5): 427-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12146847&dopt=Abstract
80
Aspirin
•
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Author(s): Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Source: Gastroenterology. 2003 August; 125(2): 328-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12891533&dopt=Abstract
•
Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. Author(s): Kowalski ML, Grzegorczyk J, Pawliczak R, Kornatowski T, WagrowskaDanilewicz M, Danilewicz M. Source: Allergy. 2002 June; 57(6): 493-500. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12028114&dopt=Abstract
•
Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. Author(s): Pierzchalska M, Szabo Z, Sanak M, Soja J, Szczeklik A. Source: The Journal of Allergy and Clinical Immunology. 2003 May; 111(5): 1041-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743569&dopt=Abstract
•
Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Author(s): Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Source: Neuroepidemiology. 2003 March-April; 22(2): 106-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12656117&dopt=Abstract
•
Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Author(s): Steinhubl SR, Varinasi JS, Goldberg L. Source: Journal of the American College of Cardiology. 2003 October 1; 42(7): 1336; Author Reply 1336-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14522508&dopt=Abstract
•
Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis. Author(s): Bochenek G, Banska K, Szabo Z, Nizankowska E, Szczeklik A. Source: Curr Drug Targets Inflamm Allergy. 2002 March; 1(1): 1-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14561202&dopt=Abstract
Studies
81
•
Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial. Author(s): Schubert A, Przybelski RJ, Eidt JF, Lasky LC, Marks KE, Karafa M, Novick AC, O'Hara JF Jr, Saunders ME, Blue JW, Tetzlaff JE, Mascha E; Perioperative Avoidance or Reduction of Transfusion Trial (PARTT) Study Group. Source: Anesthesia and Analgesia. 2003 August; 97(2): 323-32, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12873912&dopt=Abstract
•
Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteers. Author(s): De La Cruz JP, Gonzalez-Correa JA, Guerrero A, Marquez E, Martos F, Sanchez De La Cuesta F. Source: Fundamental & Clinical Pharmacology. 2003 June; 17(3): 363-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12803576&dopt=Abstract
•
Differential effect of aspirin on platelet aggregation in patients with coronary artery disease in relation with associated risk factors. Author(s): Ersoz G, Tikiz H, Yakaryilmaz A, Tezcan K, Genc Y, Korkmaz S. Source: Japanese Heart Journal. 2003 January; 44(1): 21-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622434&dopt=Abstract
•
Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. Author(s): Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L. Source: The Journal of Allergy and Clinical Immunology. 2003 September; 112(3): 50512. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13679808&dopt=Abstract
•
Disappearance of aspirin intolerance with antiasthma treatment. Author(s): Choi IS. Source: The Journal of Allergy and Clinical Immunology. 2002 October; 110(4): 665-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373279&dopt=Abstract
•
Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? Author(s): Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ. Source: Gastroenterology. 2002 November; 123(5): 1451-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12404219&dopt=Abstract
82
Aspirin
•
Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis. Author(s): Devine ME, Rands G. Source: International Journal of Geriatric Psychiatry. 2003 May; 18(5): 425-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12766920&dopt=Abstract
•
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? Author(s): Lapane KL, Hume AL, Barbour MM, Lipsitz LA. Source: Journal of the American Geriatrics Society. 2002 July; 50(7): 1198-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133013&dopt=Abstract
•
Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Author(s): Jonker C, Comijs HC, Smit JH. Source: Neurobiology of Aging. 2003 July-August; 24(4): 583-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12714115&dopt=Abstract
•
Early and late effects of low-dose aspirin on renal function in elderly patients. Author(s): Segal R, Lubart E, Leibovitz A, Berkovitch M, Habot B, Yaron M, Caspi D. Source: The American Journal of Medicine. 2003 October 15; 115(6): 462-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14563503&dopt=Abstract
•
Early effects of aspirin desensitization treatment in asthmatic patients with aspirinexacerbated respiratory disease. Author(s): Berges-Gimeno MP, Simon RA, Stevenson DD. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2003 March; 90(3): 338-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12669898&dopt=Abstract
•
Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Author(s): Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Source: European Journal of Pharmacology. 2003 February 21; 462(1-3): 139-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591106&dopt=Abstract
•
Effect of diaspirin crosslinked hemoglobin (DCLHb HemAssist) during high blood loss surgery on selected indices of organ function. Author(s): Schubert A, O'Hara JF Jr, Przybelski RJ, Tetzlaff JE, Marks KE, Mascha E, Novick AC. Source: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 2002 July; 30(4): 259-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12227646&dopt=Abstract
Studies
83
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): Cross PL. Source: Lancet. 2003 May 3; 361(9368): 1560-1; Author Reply 1561. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737891&dopt=Abstract
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): Curtis JP, Krumholz HM. Source: Lancet. 2003 May 3; 361(9368): 1560; Author Reply 1561. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737890&dopt=Abstract
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): Weiss HJ. Source: Lancet. 2003 May 3; 361(9368): 1560; Author Reply 1561. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737889&dopt=Abstract
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): Jerie P. Source: Lancet. 2003 May 3; 361(9368): 1559; Author Reply 1559. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737887&dopt=Abstract
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): Smout J, Cleanthis M, Stansby G. Source: Lancet. 2003 May 3; 361(9368): 1559-60; Author Reply 1561. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737886&dopt=Abstract
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): Etminan M, Samii A. Source: Lancet. 2003 May 3; 361(9368): 1558-9; Author Reply 1559. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12737885&dopt=Abstract
•
Effect of ibuprofen on cardioprotective effect of aspirin. Author(s): MacDonald TM, Wei L. Source: Lancet. 2003 February 15; 361(9357): 573-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12598144&dopt=Abstract
•
Effect of increasing doses of aspirin on platelet aggregation among stroke patients. Author(s): Gan R, Teleg RA, Florento L, Bitanga ES. Source: Cerebrovascular Diseases (Basel, Switzerland). 2002; 14(3-4): 252-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403959&dopt=Abstract
84
Aspirin
•
Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Author(s): Srinivasan AK, Grayson AD, Pullan DM, Fabri BM, Dihmis WC. Source: The Annals of Thoracic Surgery. 2003 July; 76(1): 41-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12842510&dopt=Abstract
•
Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. Author(s): Clarke R, Harrison G, Richards S; Vital Trial Collaborative Group. Source: Journal of Internal Medicine. 2003 July; 254(1): 67-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823643&dopt=Abstract
•
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Author(s): Cannon CP; CAPRIE Investigators. Source: The American Journal of Cardiology. 2002 October 1; 90(7): 760-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356393&dopt=Abstract
•
Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Author(s): Azar RR, Klayme S, Germanos M, Kassab R, Tawm S, Aboujaoude S, Naman R. Source: The American Journal of Cardiology. 2003 July 15; 92(2): 236-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12860235&dopt=Abstract
•
Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB). Author(s): Muller I, Massberg S, Zierhut W, Binz C, Schuster A, Rudiger-von Hoch S, Braun S, Gawaz M. Source: Pathophysiology of Haemostasis and Thrombosis. 2002 January-February; 32(1): 16-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12214159&dopt=Abstract
•
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Author(s): Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Source: Circulation. 2003 October 7; 108(14): 1682-7. Epub 2003 September 22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14504182&dopt=Abstract
Studies
85
•
Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Author(s): Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'connor CM. Source: American Heart Journal. 2003 October; 146(4): 713-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14564328&dopt=Abstract
•
Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Author(s): Kindsvater S, Leclerc K, Ward J. Source: The American Journal of Cardiology. 2003 June 1; 91(11): 1350-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767432&dopt=Abstract
•
Effects of combined octreotide and aspirin on the growth of gastric cancer. Author(s): Tang C, Wang C, Tang L. Source: Chinese Medical Journal. 2003 March; 116(3): 373-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12781040&dopt=Abstract
•
Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Author(s): Nakamura T, Uchiyama S, Yamazaki M, Iwata M. Source: Cerebrovascular Diseases (Basel, Switzerland). 2002; 14(3-4): 234-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403957&dopt=Abstract
•
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Author(s): Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R; ACE Inhibitors Collaborative Group. Source: Lancet. 2002 October 5; 360(9339): 1037-43. Review. Erratum In: Lancet 2003 January 4; 361(9351): 90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12383982&dopt=Abstract
•
Effects of low-dose warfarin and aspirin versus no treatment on stroke in a mediumrisk patient population with atrial fibrillation. Author(s): Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K. Source: Journal of Internal Medicine. 2003 July; 254(1): 95-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823646&dopt=Abstract
86
Aspirin
•
Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Author(s): Gray PA, Warner TD, Vojnovic I, Del Soldato P, Parikh A, Scadding GK, Mitchell JA. Source: British Journal of Pharmacology. 2002 December; 137(7): 1031-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12429575&dopt=Abstract
•
Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. Author(s): Esslinger HU, Kohne S, Radziwon P, Walenga JM, Breddin HK. Source: Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2003 January; 9(1): 79-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12643328&dopt=Abstract
•
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Author(s): Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, Solito E, Serhan CN. Source: Nature Medicine. 2002 November; 8(11): 1296-302. Epub 2002 October 07. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12368905&dopt=Abstract
•
Endogenous salicylates, aspirin, and inflammation. Author(s): Paterson JR, Lawrence JR. Source: Archives of Internal Medicine. 2002 July 8; 162(13): 1531-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12090898&dopt=Abstract
•
Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. Author(s): Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL. Source: Journal of Cellular Physiology. 2003 June; 195(3): 402-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12704649&dopt=Abstract
•
Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and lowdose aspirin. Author(s): Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davi G, Basili S. Source: Circulation. 2003 October 7; 108(14): 1673-5. Epub 2003 September 22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14504184&dopt=Abstract
Studies
87
•
Enhanced serum neutrophil chemotactic activity was noted in both early and late asthmatic responses during lysine-aspirin bronchoprovocation test in ASA-sensitive asthmatic patients. Author(s): Kim SS, Park HS, Yoon HJ, Lee YM, Lee SK, Nahm DH. Source: Journal of Korean Medical Science. 2003 February; 18(1): 42-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12589085&dopt=Abstract
•
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Author(s): Weisman SM, Graham DY. Source: Archives of Internal Medicine. 2002 October 28; 162(19): 2197-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390062&dopt=Abstract
•
Excessive prolongation of the Ivy bleeding time after aspirin in essential thrombocythemia is also demonstrable in vitro in the high shear stress system PFA100. Author(s): Troost MM, van Genderen PJ. Source: Annals of Hematology. 2002 June; 81(6): 353-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12141271&dopt=Abstract
•
Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin. Author(s): Germann A, Dihlmann S, Hergenhahn M, Doeberitz MK, Koesters R. Source: International Journal of Cancer. Journal International Du Cancer. 2003 August 20; 106(2): 187-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12800193&dopt=Abstract
•
Failure of montelukast to prevent aspirin-induced asthma. Author(s): Broadfoot A, Gillis D, Heddle R, Smith W, Kette F. Source: Internal Medicine Journal. 2002 May-June; 32(5-6): 271-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12036228&dopt=Abstract
•
Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Author(s): Sane DC, McKee SA, Malinin AI, Serebruany VL. Source: The American Journal of Cardiology. 2002 October 15; 90(8): 893-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12372584&dopt=Abstract
•
Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Author(s): Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer MJ. Source: Pharmacoepidemiology and Drug Safety. 2002 December; 11(8): 687-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512245&dopt=Abstract
88
Aspirin
•
Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Author(s): Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schror K, Hohlfeld T. Source: Circulation. 2003 August 5; 108(5): 542-7. Epub 2003 July 21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12874188&dopt=Abstract
•
Gastrointestinal safety of low-dose aspirin. Author(s): Cryer B. Source: Am J Manag Care. 2002 December; 8(22 Suppl): S701-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512737&dopt=Abstract
•
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Author(s): Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Source: Gastroenterology. 2003 March; 124(3): 600-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12612897&dopt=Abstract
•
Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses. Author(s): Rampal P, Moore N, Van Ganse E, Le Parc JM, Wall R, Schneid H, Verriere F. Source: J Int Med Res. 2002 May-June; 30(3): 301-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12166347&dopt=Abstract
•
General adverse reaction to aspirin administered by transdermal iontophoresis. Author(s): Macchia L, Caiaffa MF, Vacca A, Tursi A. Source: European Journal of Clinical Pharmacology. 2002 December; 58(9): 641-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12602340&dopt=Abstract
•
Genetic variation in cyclooxygenase 1: effects on response to aspirin. Author(s): Halushka MK, Walker LP, Halushka PV. Source: Clinical Pharmacology and Therapeutics. 2003 January; 73(1): 122-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12545150&dopt=Abstract
•
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Author(s): Jonsson B, Hansson L, Stalhammar NO. Source: Journal of Internal Medicine. 2003 April; 253(4): 472-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12653877&dopt=Abstract
Studies
89
•
Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Author(s): Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schroder H. Source: Biochemical and Biophysical Research Communications. 2003 September 5; 308(4): 956-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12927812&dopt=Abstract
•
High levels of nitric oxide synthase activity are associated with nasal polyp tissue from aspirin-sensitive asthmatics. Author(s): Parikh A, Scadding GK, Gray P, Belvisi MG, Mitchell JA. Source: Acta Oto-Laryngologica. 2002 April; 122(3): 302-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030579&dopt=Abstract
•
High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Author(s): ten Berg JM, Gerritsen WB, Haas FJ, Kelder HC, Verheugt FW, Plokker HW. Source: Thrombosis Research. 2002 March 1; 105(5): 385-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12062539&dopt=Abstract
•
How much daily aspirin should I take to prevent a heart attack or stroke? Author(s): Lilly LS. Source: Health News. 2002 July; 8(7): 12. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12132497&dopt=Abstract
•
How prevalent is aspirin induced asthma? Author(s): Knox AJ. Source: Thorax. 2002 July; 57(7): 565-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12096195&dopt=Abstract
•
I'm a 65-year-old man with high blood pressure and a family history of stroke. Which stroke-prevention medication would be better for me--aspirin or clopidogrel (Plavix)? Author(s): Ornato JP. Source: Health News. 2003 February; 9(2): 12. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12632550&dopt=Abstract
•
Impact of aspirin on the gastrointestinal-sparing effects of cyclooxygenase-2 inhibitors. Author(s): Nathan JP, Castellanos JT, Rosenberg JM, Cicero LA. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2003 February 15; 60(4): 392-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12625225&dopt=Abstract
90
Aspirin
•
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Author(s): Steg PG, Iung B, Feldman LJ, Cokkinos D, Deckers J, Fox KA, Keil U, Maggioni AP. Source: Heart (British Cardiac Society). 2002 July; 88(1): 20-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12067934&dopt=Abstract
•
Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. Author(s): Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Source: Journal of the American College of Cardiology. 2003 April 2; 41(7): 1198-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12679222&dopt=Abstract
•
Improving aspirin prophylaxis in a primary care diabetic population. Author(s): Faragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburgh JA, Migden H. Source: Pharmacotherapy. 2003 January; 23(1): 73-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12523462&dopt=Abstract
•
In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition. Author(s): Harris JR. Source: Micron (Oxford, England : 1993). 2002; 33(7-8): 609-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12475558&dopt=Abstract
•
Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Author(s): Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Source: American Journal of Respiratory and Critical Care Medicine. 2002 August 1; 166(3): 301-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12153961&dopt=Abstract
•
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Author(s): Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I. Source: The American Journal of Cardiology. 2003 October 1; 92(7): 843-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14516890&dopt=Abstract
•
Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. Author(s): Zijlstra F, Ernst N, de Boer MJ, Nibbering E, Suryapranata H, Hoorntje JC, Dambrink JH, van't Hof AW, Verheugt FW. Source: Journal of the American College of Cardiology. 2002 June 5; 39(11): 1733-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12039484&dopt=Abstract
Studies
91
•
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Author(s): Storey RF, Judge HM, Wilcox RG, Heptinstall S. Source: Thrombosis and Haemostasis. 2002 September; 88(3): 488-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12353080&dopt=Abstract
•
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Author(s): Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM. Source: Circulation. 2003 September 9; 108(10): 1191-5. Epub 2003 August 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12939216&dopt=Abstract
•
Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Author(s): Nannizzi-Alaimo L, Alves VL, Phillips DR. Source: Circulation. 2003 March 4; 107(8): 1123-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12615789&dopt=Abstract
•
Insulin resistance, oxidative stress and aspirin: therapeutic implications? Author(s): Quilley J. Source: Journal of Hypertension. 2002 July; 20(7): 1279-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131520&dopt=Abstract
•
Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Author(s): Takkouche B, Etminan M, Caamano F, Rochon PA. Source: Drug Safety : an International Journal of Medical Toxicology and Drug Experience. 2002; 25(5): 373-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12020174&dopt=Abstract
•
Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure? Author(s): Ahmed A. Source: Journal of the American Geriatrics Society. 2002 July; 50(7): 1293-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133028&dopt=Abstract
92
Aspirin
•
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Author(s): Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, del Soldato P, Morelli A. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 September 16; 100(19): 10937-41. Epub 2003 Sep 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12960371&dopt=Abstract
•
Is aspirin “the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Author(s): Cleland JG. Source: Progress in Cardiovascular Diseases. 2002 January-February; 44(4): 275-92. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12007083&dopt=Abstract
•
Is aspirin part of your chest pain protocol? Author(s): Bledsoe BE. Source: Emerg Med Serv. 2003 February; 32(2): 52-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12619249&dopt=Abstract
•
Is aspirin still the antiplatelet drug of choice for patients with peripheral arterial disease? Author(s): Matsagas MI, Jagroop IA, Mikhailidis DP, Geroulakos G. Source: European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery. 2003 March; 25(3): 281-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12624855&dopt=Abstract
•
Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate. Author(s): Gilmer JF, Moriarty LM, Lally MN, Clancy JM. Source: European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 2002 September; 16(4-5): 297-304. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12208460&dopt=Abstract
•
Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Author(s): Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Source: Clinical Pharmacology and Therapeutics. 2003 March; 73(3): 264-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12621391&dopt=Abstract
•
IVIG, aspirin, and Kawasaki disease. Author(s): Morgan GJ, MacLeod C, Jenkins J, Stewart C, Craig B. Source: The Journal of Pediatrics. 2003 August; 143(2): 280-1; Author Reply 281. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12970651&dopt=Abstract
Studies
93
•
Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule. Author(s): Food and Drug Administration, HHS. Source: Federal Register. 2003 April 17; 68(74): 18861-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12701599&dopt=Abstract
•
Lack of effects of low-dose aspirin on high-sensitivity C-reactive protein, hemostatic factors, and troponin T in CAPD patients. Author(s): Kim SB, Lee SK, Min WK, Chi HS, Park JS. Source: Perit Dial Int. 2002 November-December; 22(6): 721-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12556076&dopt=Abstract
•
Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Author(s): Oo C, Barrett J, Dorr A, Liu B, Ward P. Source: Antimicrobial Agents and Chemotherapy. 2002 June; 46(6): 1993-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12019123&dopt=Abstract
•
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. Author(s): CMAJ. 2002 Sep 17;167(6):671 Source: The New England Journal of Medicine. 2002 June 27; 346(26): 2033-8. /entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12358205
•
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin. Author(s): Maiden LP, Harris AW. Source: The New England Journal of Medicine. 2002 November 14; 347(20): 1623-4; Author Reply 1623-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432054&dopt=Abstract
•
Late preconditioning against myocardial stunning. Does aspirin close the “second window” of endogenous cardioprotection? Author(s): Przyklenk K, Heusch G. Source: Journal of the American College of Cardiology. 2003 April 2; 41(7): 1195-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12679221&dopt=Abstract
•
Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirininduced asthma. Author(s): Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, Higashi N, Kashii T, Kobayashi M, Akiyama K. Source: The Journal of Allergy and Clinical Immunology. 2002 June; 109(6): 936-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12063521&dopt=Abstract
94
Aspirin
•
Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Author(s): Volkman JA, Pontikes PJ. Source: The Annals of Pharmacotherapy. 2002 September; 36(9): 1457-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196067&dopt=Abstract
•
Leukotriene receptors and aspirin sensitivity. Author(s): Arm JP, Austen KF. Source: The New England Journal of Medicine. 2002 November 7; 347(19): 1524-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12421897&dopt=Abstract
•
Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirinsensitive rhinosinusitis. Author(s): Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Source: The New England Journal of Medicine. 2002 November 7; 347(19): 1493-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12421891&dopt=Abstract
•
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. Author(s): Fierro IM, Colgan SP, Bernasconi G, Petasis NA, Clish CB, Arita M, Serhan CN. Source: Journal of Immunology (Baltimore, Md. : 1950). 2003 March 1; 170(5): 2688-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12594298&dopt=Abstract
•
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Author(s): Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 October 1; 99(20): 13266-71. Epub 2002 September 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12235371&dopt=Abstract
•
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 modulate adhesion molecule expression on human leukocytes in whole blood and inhibit neutrophil-endothelial cell adhesion. Author(s): Filep JG, Zouki C, Petasis NA, Hachicha M, Serhan CN. Source: Advances in Experimental Medicine and Biology. 2002; 507: 223-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12664589&dopt=Abstract
Studies
95
•
Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in antiinflammation and pro-resolution. Author(s): Serhan CN. Source: Prostaglandins & Other Lipid Mediators. 2002 August; 68-69: 433-55. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432935&dopt=Abstract
•
Lipoxins and aspirin-triggered lipoxins in airway responses. Author(s): Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt B, Szczeklik W, Drazen JM, Serhan CN. Source: Advances in Experimental Medicine and Biology. 2003; 525: 19-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12751730&dopt=Abstract
•
Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. Author(s): Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, Brady HR, Godson C. Source: Journal of the American Society of Nephrology : Jasn. 2002 October; 13(10): 2497507. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12239238&dopt=Abstract
•
Long-term treatment with aspirin desensitization in asthmatic patients with aspirinexacerbated respiratory disease. Author(s): Berges-Gimeno MP, Simon RA, Stevenson DD. Source: The Journal of Allergy and Clinical Immunology. 2003 January; 111(1): 180-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12532116&dopt=Abstract
•
Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. Author(s): Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H. Source: Journal of Hypertension. 2002 May; 20(5): 1015-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12011664&dopt=Abstract
•
Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Author(s): Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW. Source: Pediatrics. 2003 January; 111(1): E77-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12509599&dopt=Abstract
96
Aspirin
•
Low-dose aspirin: protection from the panacea. Author(s): Guda N, Vakil N. Source: The American Journal of Gastroenterology. 2002 December; 97(12): 3202-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12492214&dopt=Abstract
•
Management of patients taking anticoagulant, aspirin, non-steroidal antiinflammatory and other anti-platelet drugs undergoing dermatological surgery. Author(s): Stables G, Lawrence CM. Source: Clinical and Experimental Dermatology. 2002 September; 27(6): 432-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12372076&dopt=Abstract
•
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Author(s): Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Source: The Journal of Clinical Investigation. 2002 May; 109(10): 1321-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12021247&dopt=Abstract
•
Might proton pump inhibitors prevent the antiplatelet effects of low- or very lowdose aspirin? Author(s): Fernandez-Fernandez FJ. Source: Archives of Internal Medicine. 2002 October 28; 162(19): 2248. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390073&dopt=Abstract
•
Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina. Author(s): Cipollone F, Ganci A, Greco A, Panara MR, Pasquale M, Di Gregorio D, Porreca E, Mezzetti A, Cuccurullo F, Patrignani P. Source: Circulation. 2003 January 7; 107(1): 55-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12515743&dopt=Abstract
•
Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Author(s): Mueller T, Haltmayer M, Poelz W, Haidinger D. Source: Vascular and Endovascular Surgery. 2003 March-April; 37(2): 117-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12669143&dopt=Abstract
•
Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. Author(s): Maan Z, Cutting CW, Patel U, Kerry S, Pietrzak P, Perry MJ, Kirby RS. Source: Bju International. 2003 June; 91(9): 798-800. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12780835&dopt=Abstract
Studies
97
•
Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Author(s): MacGregor EA, Dowson A, Davies PT. Source: Headache. 2002 April; 42(4): 249-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010380&dopt=Abstract
•
Naproxen's interaction with aspirin may affect its cardioprotective effect. Author(s): Schechter S. Source: Archives of Internal Medicine. 2003 June 9; 163(11): 1374. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796081&dopt=Abstract
•
Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Author(s): Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, RobledoEcharren T, Cimarra-Alvarez M, Mesa del Castillo M. Source: Allergy. 2002 July; 57(7): 632-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100305&dopt=Abstract
•
Natural history and clinical features of aspirin-exacerbated respiratory disease. Author(s): Fahrenholz JM. Source: Clinical Reviews in Allergy & Immunology. 2003 April; 24(2): 113-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668892&dopt=Abstract
•
NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Author(s): Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W. Source: International Journal of Oncology. 2003 June; 22(6): 1297-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12738997&dopt=Abstract
•
NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. Author(s): Fiorucci S, Mencarelli A, Mannucci R, Distrutti E, Morelli A, del Soldato P, Moncada S. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2002 October; 16(12): 1645-7. Epub 2002 August 07. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12207011&dopt=Abstract
•
Neuroprotective effects of aspirin in patients with acute cerebral infarction. Author(s): Castillo J, Leira R, Moro MA, Lizasoain I, Serena J, Davalos A. Source: Neuroscience Letters. 2003 March 27; 339(3): 248-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12633899&dopt=Abstract
98
Aspirin
•
Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. Author(s): Shukla N, Angelini GD, Ascione R, Talpahewa S, Capoun R, Jeremy JY. Source: The Annals of Thoracic Surgery. 2003 May; 75(5): 1437-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12735559&dopt=Abstract
•
Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Author(s): Yu J, Rudic RD, Sessa WC. Source: Laboratory Investigation; a Journal of Technical Methods and Pathology. 2002 July; 82(7): 825-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12118084&dopt=Abstract
•
Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Author(s): Johnsen SP, Pedersen L, Friis S, Blot WJ, McLaughlin JK, Olsen JH, Sorensen HT. Source: Stroke; a Journal of Cerebral Circulation. 2003 February; 34(2): 387-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12574547&dopt=Abstract
•
Non-aspirin nonsteroidal anti-inflammatory drugs. Author(s): Townsend RR. Source: Journal of Clinical Hypertension (Greenwich, Conn.). 2002 NovemberDecember; 4(6): 436, 440. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12461311&dopt=Abstract
•
Nonplatelet-mediated effects of aspirin. Author(s): Aude YW, Mehta JL. Source: Drugs Today (Barc). 2002 July; 38(7): 501-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12582467&dopt=Abstract
•
Non-prostaglandin effects of aspirin III and salicylate: inhibition of integrindependent human neutrophil aggregation and inflammation in COX 2- and NF kappa B (P105)-knockout mice. Author(s): Weissmann G, Montesinos MC, Pillinger M, Cronstein BN. Source: Advances in Experimental Medicine and Biology. 2002; 507: 571-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12664642&dopt=Abstract
•
Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a casecontrol study. Author(s): Gleeson MH, Davis AJ. Source: Alimentary Pharmacology & Therapeutics. 2003 March 15; 17(6): 817-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12641504&dopt=Abstract
Studies
99
•
Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirinsensitive asthmatics. Author(s): Picado C, Bioque G, Roca-Ferrer J, Pujols L, Mullol J, Benitez P, Bulbena O. Source: Allergy. 2003 February; 58(2): 122-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622742&dopt=Abstract
•
On call. I've read that aspirin may help prevent colon cancer as well as heart attacks. I take an aspirin every day, and I wonder if it may also help with prostate cancer. Author(s): Simon HB. Source: Harvard Men's Health Watch. 2002 November; 7(4): 8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12453742&dopt=Abstract
•
Optimizing the diabetic formulary: beyond aspirin and insulin. Author(s): Marso SP. Source: Journal of the American College of Cardiology. 2002 August 21; 40(4): 652-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12204494&dopt=Abstract
•
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. Author(s): van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Source: Jama : the Journal of the American Medical Association. 2002 November 20; 288(19): 2441-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12435257&dopt=Abstract
•
Oral single high-dose aspirin results in a long-lived inhibition of anodal currentinduced vasodilatation. Author(s): Durand S, Fromy B, Koitka A, Tartas M, Saumet JL, Abraham P. Source: British Journal of Pharmacology. 2002 October; 137(3): 384-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237259&dopt=Abstract
•
Out of hospital antithrombotic prophylaxis after total hip replacement: lowmolecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Author(s): Sarasin FP, Bounameaux H. Source: Thrombosis and Haemostasis. 2002 April; 87(4): 586-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12008939&dopt=Abstract
•
Outcome of aspirin use during excision of cutaneous lesions. Author(s): Shalom A, Wong L. Source: Annals of Plastic Surgery. 2003 March; 50(3): 296-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12800908&dopt=Abstract
100 Aspirin
•
Outcome of myocardial infarction in patients treated with aspirin is enhanced by prehospital administration. Author(s): Barbash IM, Freimark D, Gottlieb S, Hod H, Hasin Y, Battler A, Crystal E, Matetzky S, Boyko V, Mandelzweig L, Behar S, Leor J; Israeli working group on intensive cardiac care, Israel heart society. Source: Cardiology. 2002; 98(3): 141-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12417813&dopt=Abstract
•
Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Author(s): Csiszar A, Stef G, Pacher P, Ungvari Z. Source: Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2002 May-June; 66(5-6): 557-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12144879&dopt=Abstract
•
Paracetamol pack size restriction: the impact on paracetamol poisoning and the overthe-counter supply of paracetamol, aspirin and ibuprofen. Author(s): Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM. Source: Pharmacoepidemiology and Drug Safety. 2002 June; 11(4): 329-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12138601&dopt=Abstract
•
Parsing an enigma: the pharmacodynamics of aspirin resistance. Author(s): FitzGerald GA. Source: Lancet. 2003 February 15; 361(9357): 542-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12598136&dopt=Abstract
•
Pathogenesis of aspirin-exacerbated respiratory disease. Author(s): Stevenson DD, Zuraw BL. Source: Clinical Reviews in Allergy & Immunology. 2003 April; 24(2): 169-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668897&dopt=Abstract
•
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a casecrossover study. Author(s): Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Source: Stroke; a Journal of Cerebral Circulation. 2003 April; 34(4): 849-54. Epub 2003 March 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12637702&dopt=Abstract
Studies
101
•
Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Author(s): Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, Broekman MJ, Marcus AJ. Source: Blood. 2002 June 1; 99(11): 3978-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12010797&dopt=Abstract
•
Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Author(s): Michiels JJ. Source: Pathologie-Biologie. 2003 April; 51(3): 167-75. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12781799&dopt=Abstract
•
Platelets: is aspirin sufficient or must we know how to pronounce abciximab? Author(s): Brinkman WT, Terramani TT, Najibi S, Chaikof EL. Source: Semin Vasc Surg. 2002 December; 15(4): 245-55. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478499&dopt=Abstract
•
Post hoc mortality analysis on the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock. Author(s): Ward CG, Sloan EP. Source: The Journal of Trauma. 2002 November; 53(5): 1031; Author Reply 1031-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12435966&dopt=Abstract
•
Potential cardioprotective actions of no-releasing aspirin. Author(s): Wallace JL, Ignarro LJ, Fiorucci S. Source: Nature Reviews. Drug Discovery. 2002 May; 1(5): 375-82. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12120413&dopt=Abstract
•
Pravastatin and Aspirin. Author(s): Armstrong PW, Lorell BH, Nissen S, Borer J. Source: Circulation. 2002 August 6; 106(6): E9011-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187915&dopt=Abstract
•
Prevention of inflammation-induced endothelial dysfunction: a novel vasculoprotective action of aspirin. Author(s): Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, Vallance P. Source: Circulation. 2002 June 4; 105(22): 2600-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12045164&dopt=Abstract
102 Aspirin
•
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. Author(s): Mateos-Careres PJ, Garcia-Mendez A, Farre J, Sanchez de Miguel L, Gomez J, de Andres R, Rico L, Romero J, Lopez-Farre A. Source: European Journal of Clinical Investigation. 2002 December; 32(12): 895-900. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534448&dopt=Abstract
•
Prolonged aspirin inhibition of anodal vasodilation is not due to the trafficking delay of neural mediators. Author(s): Durand S, Fromy B, Tartas M, Jardel A, Saumet JL, Abraham P. Source: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2003 July; 285(1): R155-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12793996&dopt=Abstract
•
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Author(s): Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, Gerner EW. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 June 24; 100(13): 7859-64. Epub 2003 Jun 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12810952&dopt=Abstract
•
Protection against exercise-induced bronchoconstriction by montelukast in aspirinsensitive and aspirin-tolerant patients with asthma. Author(s): Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, Cmiel A, Szczeklik A. Source: Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology. 2002 September; 32(9): 1360-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12220476&dopt=Abstract
•
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Author(s): Corley DA, Kerlikowske K, Verma R, Buffler P. Source: Gastroenterology. 2003 January; 124(1): 47-56. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512029&dopt=Abstract
•
Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 2). Author(s): Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, Uzan S, Quandalle F, Delcourt YM, Malek YM; Essai Regional Aspirine Mere-Enfant (ERASME) Collaborative Group. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2003 May; 110(5): 485-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12742333&dopt=Abstract
Studies
103
•
Randomized controlled trial using low-dose aspirin in the prevention of preeclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Author(s): Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Source: Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2003 September; 22(3): 233-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12942493&dopt=Abstract
•
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Author(s): Cohen M, Theroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F; ACUTE II Investigators. Source: American Heart Journal. 2002 September; 144(3): 470-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12228784&dopt=Abstract
•
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Author(s): Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Licata G. Source: Arthritis and Rheumatism. 2003 March; 48(3): 728-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12632426&dopt=Abstract
•
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage? Author(s): Serebruany VL, Malinin AI, Sane DC. Source: American Journal of Hematology. 2003 April; 72(4): 280-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12666142&dopt=Abstract
•
Reasons for resistance to aspirin in cardiovascular disease. Author(s): Szczeklik A, Musial J, Undas A. Source: Circulation. 2002 November 26; 106(22): E181-2; Author Reply E181-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12451018&dopt=Abstract
•
Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins. Author(s): Aronow WS, Ahn C. Source: Heart Disease. 2002 May-June; 4(3): 159-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12028600&dopt=Abstract
104 Aspirin
•
Regular aspirin use and lung cancer risk. Author(s): Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM, Bepler G. Source: Bmc Cancer [electronic Resource]. 2002 November 26; 2(1): 31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12453317&dopt=Abstract
•
Regular use of aspirin and pancreatic cancer risk. Author(s): Menezes RJ, Huber KR, Mahoney MC, Moysich KB. Source: Bmc Public Health [electronic Resource]. 2002 September 4; 2(1): 18. Epub 2002 Sep 04. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12213184&dopt=Abstract
•
Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. Author(s): Friend M, Vucenik I, Miller M. Source: Bmj (Clinical Research Ed.). 2003 January 11; 326(7380): 82-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521973&dopt=Abstract
•
Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. Author(s): Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. Source: Journal of the American College of Cardiology. 2003 September 17; 42(6): 1115-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13678940&dopt=Abstract
•
Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Author(s): Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Source: Thrombosis Research. 2002 July 15; 107(1-2): 45-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12413588&dopt=Abstract
•
Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. Author(s): Boissonnault WG, Meek PD. Source: The Journal of Orthopaedic and Sports Physical Therapy. 2002 October; 32(10): 510-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403202&dopt=Abstract
Studies
105
•
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Author(s): Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Source: European Journal of Gastroenterology & Hepatology. 2003 February; 15(2): 1738. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12560762&dopt=Abstract
•
Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Author(s): Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Source: Alimentary Pharmacology & Therapeutics. 2002 November; 16(11): 1945-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390104&dopt=Abstract
•
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensinconverting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in antiinflammatory and immunomodulatory treatment of cardiovascular diseases. Author(s): Schieffer B, Drexler H. Source: The American Journal of Cardiology. 2003 June 19; 91(12A): 12H-18H. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12818730&dopt=Abstract
•
Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Author(s): Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T, Iscar A. Source: Chest. 2002 June; 121(6): 1812-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12065343&dopt=Abstract
•
Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Author(s): Mehran R, Aymong ED, Ashby DT, Fischell T, Whitworth H Jr, Siegel R, Thomas W, Wong SC, Narasimaiah R, Lansky AJ, Leon MB. Source: Circulation. 2003 September 2; 108(9): 1078-83. Epub 2003 August 18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12925457&dopt=Abstract
•
Seeking the optimal aspirin dose in acute coronary syndromes. Author(s): Kong DF, Hasselblad V, Kandzari DE, Newby LK, Califf RM. Source: The American Journal of Cardiology. 2002 September 15; 90(6): 622-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12231088&dopt=Abstract
•
Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction. Author(s): Dalen JE. Source: Archives of Internal Medicine. 2002 May 27; 162(10): 1091-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12020175&dopt=Abstract
106 Aspirin
•
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Author(s): Ann Intern Med. 2003 Jan 21;138(2):I10 Source: Arthritis and Rheumatism. 2003 January; 48(1): 12-20. Review. /entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12529114
•
Should aspirin be used with angiotensin-converting enzyme inhibitors in patients with chronic heart failure? Author(s): Park MH. Source: Congestive Heart Failure (Greenwich, Conn.). 2003 July-August; 9(4): 206-11; Quiz 212-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12937357&dopt=Abstract
•
Should aspirin therapy be withheld before insertion and/or removal of a permanent peritoneal dialysis catheter? Author(s): Shpitz B, Plotkin E, Spindel Z, Buklan G, Klein E, Bernheim J, Korzets Z. Source: The American Surgeon. 2002 September; 68(9): 762-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356145&dopt=Abstract
•
Signal transduction: aspirin, ubiquitin and cancer. Author(s): Wilkinson KD. Source: Nature. 2003 August 14; 424(6950): 738-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12917671&dopt=Abstract
•
Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Author(s): Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Source: Anesthesia and Analgesia. 2003 April; 96(4): 923-8, Table of Contents. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12651635&dopt=Abstract
•
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. Author(s): Gille J, Bernotat J, Bohm S, Behrens P, Lohr JF. Source: Zeitschrift Fur Rheumatologie. 2003 February; 62(1): 80-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12624808&dopt=Abstract
•
Spontaneous suprachoroidal haemorrhage associated with high myopia and aspirin. Author(s): Chak M, Williamson TH. Source: Eye (London, England). 2003 May; 17(4): 525-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802356&dopt=Abstract
Studies
107
•
Statins: the new aspirin? Author(s): Veillard NR, Mach F. Source: Cellular and Molecular Life Sciences : Cmls. 2002 November; 59(11): 1771-86. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12530513&dopt=Abstract
•
Structural characterization of arachidonyl radicals formed by aspirin-treated prostaglandin H synthase-2. Author(s): Tsai AL, Palmer G, Wu G, Peng S, Okeley NM, van der Donk WA, Kulmacz RJ. Source: The Journal of Biological Chemistry. 2002 October 11; 277(41): 38311-21. Epub 2002 August 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12167656&dopt=Abstract
•
Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Author(s): Ng HJ, Koh LP, Lee LH. Source: Annals of Hematology. 2003 April; 82(4): 257-8. Epub 2003 March 08. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12707733&dopt=Abstract
•
Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Author(s): Jilma B. Source: Stroke; a Journal of Cerebral Circulation. 2003 April; 34(4): 849-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12680383&dopt=Abstract
•
Testing for aspirin hypersensitivity. Author(s): Bochenek G, Niz Ankowska E, Szczeklik A. Source: Allergy. 2002 July; 57(7): 562-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100294&dopt=Abstract
•
The antiplatelet aggregation effects of aspirin suppositories. Author(s): Nakayasu H, Maeda M, Soda T, Iijima K, Ishimoto M, Ieiri I, Tabuchi F, Otsubo K, Nakashima K. Source: Cerebrovascular Diseases (Basel, Switzerland). 2003; 16(1): 31-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12766359&dopt=Abstract
•
The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents. Author(s): Sloan EP. Source: Intensive Care Medicine. 2003 March; 29(3): 347-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12710459&dopt=Abstract
108 Aspirin
•
The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Author(s): Kim KY, Seol JY, Jeon GA, Nam MJ. Source: Cancer Letters. 2003 January 28; 189(2): 157-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12490308&dopt=Abstract
•
The effect of anticoagulation on the restoration of range of motion after total knee arthroplasty: enoxaparin versus aspirin. Author(s): Keays AC, Mason M, Keays SL, Newcombe PA. Source: The Journal of Arthroplasty. 2003 February; 18(2): 180-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629608&dopt=Abstract
•
The effect of aspirin on the periodontal parameter bleeding on probing. Author(s): Schrodi J, Recio L, Fiorellini J, Howell H, Goodson M, Karimbux N. Source: J Periodontol. 2002 August; 73(8): 871-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12211496&dopt=Abstract
•
The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. Author(s): Hongo RH, Ley J, Dick SE, Yee RR. Source: Journal of the American College of Cardiology. 2002 July 17; 40(2): 231-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12106925&dopt=Abstract
•
The effect of dosing interval on the efficacy of misoprostol in the prevention of aspirin-induced gastric injury. Author(s): Ward DM, Leib MS, Johnston SA, Marini M. Source: J Vet Intern Med. 2003 May-June; 17(3): 282-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12774967&dopt=Abstract
•
The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Author(s): Berges-Gimeno MP, Simon RA, Stevenson DD. Source: Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology. 2002 October; 32(10): 1491-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12372130&dopt=Abstract
•
The effectiveness of child-resistant packaging for aspirin. Author(s): Rodgers GB. Source: Archives of Pediatrics & Adolescent Medicine. 2002 September; 156(9): 929-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12197802&dopt=Abstract
Studies
109
•
The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Author(s): Narendran N, Williamson TH. Source: Acta Ophthalmologica Scandinavica. 2003 February; 81(1): 38-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12631017&dopt=Abstract
•
The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Author(s): Pearson DA, Paglieroni TG, Rein D, Wun T, Schramm DD, Wang JF, Holt RR, Gosselin R, Schmitz HH, Keen CL. Source: Thrombosis Research. 2002 May 15; 106(4-5): 191-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297125&dopt=Abstract
•
The influence of aspirin on exercise-induced changes in adrenocorticotrophic hormone (ACTH), cortisol and aldosterone (ALD) concentrations. Author(s): Przybylowski J, Obodynski K, Lewicki C, Kuzniar J, Zaborniak S, Drozd S, Czarny W, Garmulewicz M. Source: European Journal of Applied Physiology. 2003 April; 89(2): 177-83. Epub 2003 February 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12665982&dopt=Abstract
•
The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Author(s): Berges-Gimeno MP, Simon RA, Stevenson DD. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2002 November; 89(5): 474-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452205&dopt=Abstract
•
The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Author(s): Vally H, Taylor ML, Thompson PJ. Source: Thorax. 2002 July; 57(7): 569-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12096197&dopt=Abstract
•
The public health potential of aspirin. Author(s): Vainio H, Morgan G, Elwood P. Source: Pharmacology & Toxicology. 2002 August; 91(2): 49-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12420791&dopt=Abstract
•
The role of aspirin in carcinogenesis. Author(s): Caine GJ, Kehoe ST, Lip GY. Source: British Journal of Cancer. 2002 November 18; 87(11): 1337-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12439726&dopt=Abstract
110 Aspirin
•
The role of aspirin in vernal keratoconjunctivitis. Author(s): Anwar MS. Source: J Coll Physicians Surg Pak. 2003 March; 13(3): 178-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12689545&dopt=Abstract
•
The safety of celecoxib in patients with aspirin-sensitive asthma. Author(s): Woessner KM, Simon RA, Stevenson DD. Source: Arthritis and Rheumatism. 2002 August; 46(8): 2201-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209526&dopt=Abstract
•
Thromboembolism after total knee arthroplasty: intermittent pneumatic compression and aspirin prophylaxis. Author(s): Larson CM, MacMillan DP, Lachiewicz PF. Source: J South Orthop Assoc. 2001 Fall; 10(3): 155-63; Discussion 163. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12132827&dopt=Abstract
•
Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. Author(s): Kovich O, Otley CC. Source: Journal of the American Academy of Dermatology. 2003 February; 48(2): 233-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12582394&dopt=Abstract
•
Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. Author(s): Moore N, Le Parc JM, van Ganse E, Wall R, Schneid H, Cairns R. Source: Int J Clin Pract. 2002 December; 56(10): 732-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12510944&dopt=Abstract
•
Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and SLS-inflamed skin, but does not decrease itch. A randomized, doubleblind and placebo-controlled human study. Author(s): Thomsen JS, Benfeldt E, Jensen SB, Serup J, Menne T. Source: Acta Dermato-Venereologica. 2002; 82(1): 30-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12013195&dopt=Abstract
•
Transcriptional regulation of COX-2: a key mechanism in the pathogenesis of nasal polyposis in aspirin-sensitive asthmatics? Author(s): Vignola AM, Bellia V. Source: Allergy. 2003 February; 58(2): 95-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12622739&dopt=Abstract
Studies
111
•
Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Author(s): Lanas A, Ferrandez A. Source: Expert Opinion on Drug Safety. 2002 September; 1(3): 245-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12904140&dopt=Abstract
•
Uncoupled regulation of leukotriene C4 synthase in platelets from aspirin-intolerant asthmatics and healthy volunteers after aspirin treatment. Author(s): Tornhamre S, Ehnhage A, Kolbeck KG, Edenius C, Lindgren JA. Source: Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology. 2002 November; 32(11): 1566-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12569976&dopt=Abstract
•
Underutilization of aspirin for secondary prophylaxis of cardiovascular disease in a long-term-care facility. Author(s): Sleeper RB, Rojas-Fernandez C. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2002 July 1; 59(13): 1294-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12116896&dopt=Abstract
•
Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. Author(s): Ghosh S, Ziesmer V, Aronow WS. Source: The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2002 June; 57(6): M398-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12023270&dopt=Abstract
•
Unstable angina and non-Q-wave myocardial infarction. Treatment beyond aspirin and heparin. Author(s): Theroux P. Source: Cardiologia. 1999 December; 44 Suppl 1(Pt 2): 799. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12497824&dopt=Abstract
•
Update on aspirin in the treatment and prevention of cardiovascular disease. Author(s): Hennekens CH. Source: Am J Manag Care. 2002 December; 8(22 Suppl): S691-700. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512736&dopt=Abstract
112 Aspirin
•
Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Author(s): Cook NR, Cole SR, Hennekens CH. Source: American Journal of Epidemiology. 2002 June 1; 155(11): 1045-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12034583&dopt=Abstract
•
Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. Author(s): Harjai KJ, Solis S, Prasad A, Loupe J. Source: International Journal of Cardiology. 2003 April; 88(2-3): 207-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12714200&dopt=Abstract
•
Use of statins and aspirin to reduce risks of cardiovascular disease. Author(s): Hebert PR, Pfeffer MA, Hennekens CH. Source: Journal of Cardiovascular Pharmacology and Therapeutics. 2002 April; 7(2): 7780. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075395&dopt=Abstract
•
Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Author(s): Lauten WB, Khan QA, Rajagopalan S, Lerakis S, Rahman ST, Parthasarathy S, Khan BV. Source: The American Journal of Cardiology. 2003 May 1; 91(9): 1116-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12714159&dopt=Abstract
•
VHA heart attack initiative increases aspirin and beta blocker usage. Author(s): Rollins G. Source: Rep Med Guidel Outcomes Res. 2001 May 17; 12(10): 7-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12134872&dopt=Abstract
•
Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. Author(s): Doggrell SA. Source: Expert Opinion on Pharmacotherapy. 2003 April; 4(4): 587-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12667121&dopt=Abstract
•
Warfarin versus aspirin in the secondary prevention of stroke: the WARSS study. Author(s): Redman AR, Allen LC. Source: Current Atherosclerosis Reports. 2002 July; 4(4): 319-25. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12052284&dopt=Abstract
Studies
113
•
Warfarin, aspirin, or both after myocardial infarction. Author(s): Amit G, Ilia R, Zahger D. Source: The New England Journal of Medicine. 2003 January 16; 348(3): 256-7; Author Reply 256-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12530435&dopt=Abstract
•
Warfarin, aspirin, or both after myocardial infarction. Author(s): Aronow WS. Source: The New England Journal of Medicine. 2003 January 16; 348(3): 256-7; Author Reply 256-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12530434&dopt=Abstract
•
Warfarin, aspirin, or both after myocardial infarction. Author(s): Pullicino P, Thompson JL. Source: The New England Journal of Medicine. 2003 January 16; 348(3): 256-7; Author Reply 256-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12529470&dopt=Abstract
•
Warfarin, aspirin, or both after myocardial infarction. Author(s): Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Source: The New England Journal of Medicine. 2002 September 26; 347(13): 969-74. Summary for Patients In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12324552&dopt=Abstract
•
Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Author(s): Hankey GJ. Source: Stroke; a Journal of Cerebral Circulation. 2002 June; 33(6): 1723-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12053018&dopt=Abstract
•
What are all the things that aspirin does? Author(s): Flower R. Source: Bmj (Clinical Research Ed.). 2003 September 13; 327(7415): 572-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12969898&dopt=Abstract
•
Will an aspirin a day keep the endoscope away? Author(s): Dubois RN. Source: Gastroenterology. 2003 August; 125(2): 612-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12891566&dopt=Abstract
115
CHAPTER 2. NUTRITION AND ASPIRIN Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and aspirin.
Finding Nutrition Studies on Aspirin The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “aspirin” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
116 Aspirin
The following is a typical result when searching for recently indexed consumer information on aspirin: •
A vanadium/aspirin complex controlled release using a poly(beta-propiolactone) film. Effects on osteosarcoma cells. Author(s): INIFTA, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Argentina.
[email protected] Source: Cortizo, M S Alessandrini, J L Etcheverr, S B Cortizo, A M J-Biomater-Sci-PolymEd. 2001; 12(9): 945-59 0920-5063
•
Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. Author(s): DNA Unit, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Spain. Source: Planaguma, A Titos, E Lopez Parra, M Gaya, J Pueyo, G Arroyo, V Claria, J FASEB-J. 2002 December; 16(14): 1937-9 1530-6860
•
Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. Author(s): Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA.
[email protected] Source: Bruno, Askiel McConnell, Joseph P Mansbach, Harry H 3rd Cohen, Stanley N Tietjen, Gretchen E Bang, Nils U Stroke. 2002 January; 33(1): 57-60 1524-4628
•
Aspirin intolerance and nasal polyposis. Author(s): Servei de Pneumologia, Hospital Clinic, Barcelona, Spain.
[email protected] Source: Picado, C Curr-Allergy-Asthma-Repage 2002 November; 2(6): 488-93 1529-7322
•
Aspirin-sensitive asthma due to diffuse neuroendocrine system pathology. Author(s): Department of Hospital Therapy, The I.P. Pavlov Medical University, Raevsky st. 7, appt. 7, 194064 St. Petersburg, Russia.
[email protected] Source: Evsyukova, H V Neuroendocrinol-Lett. 2002 August; 23(4): 281-5 0172-780X
•
Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. Author(s): Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. Source: Qiu, F H Devchand, P R Wada, K Serhan, C N FASEB-J. 2001 December; 15(14): 2736-8 1530-6860
•
Attenuation of Zn2+ neurotoxicity by aspirin: role of N-type Ca2+ channel and the carboxyl acid group. Author(s): Department of Pharmacology and Center for the Interventional Therapy of Stroke and Alzheimer's Disease, Ajou University School of Medicine, Suwon, Kyunggido, 442-749, Korea. Source: Kim, E Y Chang, S Y Chung, J M Ryu, B R Joo, C K Moon, H S Kang, K Yoon, S H Han, P L Gwag, B J Neurobiol-Dis. 2001 October; 8(5): 774-83 0969-9961
•
Circulation and hemostatic function of autologous fresh, liquid-preserved, and cryopreserved baboon platelets transfused to correct an aspirin-induced thrombocytopathy. Author(s): Naval Blood Research Laboratory, Boston University School of Medicine, Massachusetts 02118, USA.
[email protected]
Nutrition
117
Source: Valeri, C R MacGregor, H Giorgio, A Ragno, G Transfusion. 2002 September; 42(9): 1206-16 0041-1132 •
Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). Author(s): Department of Clinical Neurosciences, Brown Medical School, Providence, RI, USA.
[email protected] Source: Wilterdink, J L Bendixen, B Adams, H P Jr Woolson, R F Clarke, W R Hansen, M D Stroke. 2001 December 1; 32(12): 2836-40 1524-4628
•
Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Author(s): Department of Neurology, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan.
[email protected] Source: Nakamura, T Uchiyama, S Yamazaki, M Iwata, M Cerebrovasc-Dis. 2002; 14(34): 234-8 1015-9770
•
Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Author(s): Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, Spain.
[email protected] Source: de la Cruz, J P Guerrero, A Gonzalez Correa, J A Marquez, E Nacle, I Sanchez de la Cuesta, F Eur-J-Clin-Pharmacol. 2002 January; 57(11): 775-80 0031-6970
•
Experience of 10 years with Churg-Strauss syndrome: An accompaniment to or a transition from aspirin-induced asthma? Author(s): Hacettepe University Hospital, Department of Chest Diseases, Adult Allergy Unit, Ankara, Turkey.
[email protected] Source: Kalyoncu, A Karakaya, G Sahin, A Artvinli, M Allergol-Immunopathol-(Madr). 2001 Sep-October; 29(5): 185-90 0301-0546
•
Immediate treatment of frostbite using rapid rewarming in tea decoction followed by combined therapy of pentoxifylline, aspirin & vitamin C. Author(s): Cold Physiology Department, Defence Institute of Physiology & Allied Sciences, Defence Research & Development Organization, Lucknow Road, Timarpur, Delhi 110054, India. Source: Purkayastha, S S Bhaumik, G Chauhan, S K Banerjee, P K Selvamurthy, W Indian-J-Med-Res. 2002 July; 116: 29-34 0971-5916
•
Impregnation and release of aspirin from chitosan/poly(acrylic acid) graft copolymer microspheres. Author(s): Departamento de Quimica, Universidade Estadual de Ponta Grossa, Brazil. Source: Nascimento, A Laranjeira, M C Favere, V T Josue, A J-Microencapsul. 2001 SepOctober; 18(5): 679-84 0265-2048
•
In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition. Author(s): Institute of Zoology, University of Mainz, D-55099 Mainz, Germany.
[email protected] Source: Harris, J R Micron. 2002; 33(7-8): 609-26 0968-4328
•
Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Author(s): Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital,
118 Aspirin
Harvard Medical School, Boston, Massachusetts 02115, USA.
[email protected] Source: Serhan, C N Arch-Immunol-Ther-Exp-(Warsz). 2001; 49(3): 177-88 0004-069X •
NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. Author(s): Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed Epatologia, Universita degli Studi di Perugia, 06122 Perugia, Italy.
[email protected] Source: Fiorucci, S Mencarelli, A Mannucci, R Distrutti, E Morelli, A del Soldato, P Moncada, S FASEB-J. 2002 October; 16(12): 1645-7 1530-6860
•
On call. I'm a 62-year-old man in good health. I take Zocor for my cholesterol as well as a baby aspirin and several vitamins every day. My problem may seem silly, but it's really a nuisance: uncontrollable yawning. Do you have any idea why I yawn so much or what I can do about it? Source: Simon, Harvey B Harv-Mens-Health-Watch. 2002 April; 6(9): 8 1089-1102
•
Oral buprenorphine and aspirin analgesia in rats undergoing liver transplantation. Author(s): Monash University, Department of Surgery, Monash Medical Centre, Clayton, Australia. Source: Jablonski, P Howden, B O Lab-Anim. 2002 April; 36(2): 134-43 0023-6772
•
Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Author(s): Community Health Center of Area 4, Madrid, Spain. Source: Juarranz, M Calle Puron, M E Gonzalez Navarro, A Regidor Poyatos, E Soriano, T Martinez Hernandez, D Rojas, V D Guinee, V F Eur-J-Cancer-Prevolume 2002 October; 11(5): 465-72 0959-8278
•
Platelets: is aspirin sufficient or must we know how to pronounce abciximab? Author(s): Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA. Source: Brinkman, W T Terramani, T T Najibi, S Chaikof, E L Semin-Vasc-Surg. 2002 December; 15(4): 245-55 0895-7967
•
Possible mechanisms of aspirin resistance. Author(s): Massachusetts College of Pharmacy and Health Sciences-Worcester, Department of Pharmacy Practice, Worcester, MA 01608, USA. Source: Cambria Kiely, J A Gandhi, P J J-Thromb-Thrombolysis. 2002 February; 13(1): 49-56 0929-5305
•
Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin. Author(s): Department of Neurology, The Albert Einstein College of Medicine, F-121N, 1300 Morris Park Ave, Bronx, NY 10461, USA. Source: Carrasco, E Werner, P Parkinsonism-Relat-Disord. 2002 September; 8(6): 407-11 1353-8020
•
Structural requirements for the neuroprotective effects of aspirin analogues against N-methyl-D-aspartate and zinc ion neurotoxicity. Author(s): Department of Molecular Science and Technology, Ajou University, Suwon, South Korea. Source: Moon, H S Nam, S I Kim, S D Kim, D Gwag, B J Lee, Y Yoon, S H J-PharmPharmacol. 2002 July; 54(7): 935-44 0022-3573
Nutrition
119
•
The effect of aspirin and prostaglandin E(1) on the patency of microvascular anastomosis in the rats. Author(s): Department of Orthopaedic Surgery, Korea University Hospital, Seoul, Korea.
[email protected] Source: Lee, K S Suh, J D Han, S B Yoo, J C Lee, S J Cho, S J Hand-Surg. 2001 December; 6(2): 177-85 0218-8104
•
The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis. Author(s): Division of Neurosurgery, University of Vermont, Burlington 05405, USA. Source: Bednar, M M Gross, C E Howard, D B Russell, S R Ellenberger, C Neurol-Res. 2001 October; 23(7): 745-50 0161-6412
•
Warfarin, aspirin, or both after myocardial infarction. Author(s): Department of Cardiology, Ulleval University Hospital, Oslo, Norway. Source: Hurlen, M Abdelnoor, M Smith, P Erikssen, J Arnesen, H N-Engl-J-Med. 2002 September 26; 347(13): 969-74 1533-4406
•
Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Author(s): Department of Neurology, Royal Perth Hospital, Perth, Western Australia.
[email protected] Source: Hankey, Graeme J Stroke. 2002 June; 33(6): 1723-6 1524-4628
The following information is typical of that found when using the “Full IBIDS Database” to search for “aspirin” (or a synonym): •
A vanadium/aspirin complex controlled release using a poly(beta-propiolactone) film. Effects on osteosarcoma cells. Author(s): INIFTA, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Argentina.
[email protected] Source: Cortizo, M S Alessandrini, J L Etcheverr, S B Cortizo, A M J-Biomater-Sci-PolymEd. 2001; 12(9): 945-59 0920-5063
•
Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. Author(s): DNA Unit, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Spain. Source: Planaguma, A Titos, E Lopez Parra, M Gaya, J Pueyo, G Arroyo, V Claria, J FASEB-J. 2002 December; 16(14): 1937-9 1530-6860
•
Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. Author(s): Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA.
[email protected] Source: Bruno, Askiel McConnell, Joseph P Mansbach, Harry H 3rd Cohen, Stanley N Tietjen, Gretchen E Bang, Nils U Stroke. 2002 January; 33(1): 57-60 1524-4628
•
Aspirin intolerance and nasal polyposis. Author(s): Servei de Pneumologia, Hospital Clinic, Barcelona, Spain.
[email protected] Source: Picado, C Curr-Allergy-Asthma-Repage 2002 November; 2(6): 488-93 1529-7322
120 Aspirin
•
Aspirin-sensitive asthma due to diffuse neuroendocrine system pathology. Author(s): Department of Hospital Therapy, The I.P. Pavlov Medical University, Raevsky st. 7, appt. 7, 194064 St. Petersburg, Russia.
[email protected] Source: Evsyukova, H V Neuroendocrinol-Lett. 2002 August; 23(4): 281-5 0172-780X
•
Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. Author(s): Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. Source: Qiu, F H Devchand, P R Wada, K Serhan, C N FASEB-J. 2001 December; 15(14): 2736-8 1530-6860
•
Attenuation of Zn2+ neurotoxicity by aspirin: role of N-type Ca2+ channel and the carboxyl acid group. Author(s): Department of Pharmacology and Center for the Interventional Therapy of Stroke and Alzheimer's Disease, Ajou University School of Medicine, Suwon, Kyunggido, 442-749, Korea. Source: Kim, E Y Chang, S Y Chung, J M Ryu, B R Joo, C K Moon, H S Kang, K Yoon, S H Han, P L Gwag, B J Neurobiol-Dis. 2001 October; 8(5): 774-83 0969-9961
•
Circulation and hemostatic function of autologous fresh, liquid-preserved, and cryopreserved baboon platelets transfused to correct an aspirin-induced thrombocytopathy. Author(s): Naval Blood Research Laboratory, Boston University School of Medicine, Massachusetts 02118, USA.
[email protected] Source: Valeri, C R MacGregor, H Giorgio, A Ragno, G Transfusion. 2002 September; 42(9): 1206-16 0041-1132
•
Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). Author(s): Department of Clinical Neurosciences, Brown Medical School, Providence, RI, USA.
[email protected] Source: Wilterdink, J L Bendixen, B Adams, H P Jr Woolson, R F Clarke, W R Hansen, M D Stroke. 2001 December 1; 32(12): 2836-40 1524-4628
•
Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Author(s): Department of Neurology, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan.
[email protected] Source: Nakamura, T Uchiyama, S Yamazaki, M Iwata, M Cerebrovasc-Dis. 2002; 14(34): 234-8 1015-9770
•
Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Author(s): Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, Spain.
[email protected] Source: de la Cruz, J P Guerrero, A Gonzalez Correa, J A Marquez, E Nacle, I Sanchez de la Cuesta, F Eur-J-Clin-Pharmacol. 2002 January; 57(11): 775-80 0031-6970
•
Experience of 10 years with Churg-Strauss syndrome: An accompaniment to or a transition from aspirin-induced asthma? Author(s): Hacettepe University Hospital, Department of Chest Diseases, Adult Allergy Unit, Ankara, Turkey.
[email protected] Source: Kalyoncu, A Karakaya, G Sahin, A Artvinli, M Allergol-Immunopathol-(Madr). 2001 Sep-October; 29(5): 185-90 0301-0546
Nutrition
121
•
Immediate treatment of frostbite using rapid rewarming in tea decoction followed by combined therapy of pentoxifylline, aspirin & vitamin C. Author(s): Cold Physiology Department, Defence Institute of Physiology & Allied Sciences, Defence Research & Development Organization, Lucknow Road, Timarpur, Delhi 110054, India. Source: Purkayastha, S S Bhaumik, G Chauhan, S K Banerjee, P K Selvamurthy, W Indian-J-Med-Res. 2002 July; 116: 29-34 0971-5916
•
Impregnation and release of aspirin from chitosan/poly(acrylic acid) graft copolymer microspheres. Author(s): Departamento de Quimica, Universidade Estadual de Ponta Grossa, Brazil. Source: Nascimento, A Laranjeira, M C Favere, V T Josue, A J-Microencapsul. 2001 SepOctober; 18(5): 679-84 0265-2048
•
In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition. Author(s): Institute of Zoology, University of Mainz, D-55099 Mainz, Germany.
[email protected] Source: Harris, J R Micron. 2002; 33(7-8): 609-26 0968-4328
•
Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Author(s): Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
[email protected] Source: Serhan, C N Arch-Immunol-Ther-Exp-(Warsz). 2001; 49(3): 177-88 0004-069X
•
NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. Author(s): Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed Epatologia, Universita degli Studi di Perugia, 06122 Perugia, Italy.
[email protected] Source: Fiorucci, S Mencarelli, A Mannucci, R Distrutti, E Morelli, A del Soldato, P Moncada, S FASEB-J. 2002 October; 16(12): 1645-7 1530-6860
•
On call. I'm a 62-year-old man in good health. I take Zocor for my cholesterol as well as a baby aspirin and several vitamins every day. My problem may seem silly, but it's really a nuisance: uncontrollable yawning. Do you have any idea why I yawn so much or what I can do about it? Source: Simon, Harvey B Harv-Mens-Health-Watch. 2002 April; 6(9): 8 1089-1102
•
Oral buprenorphine and aspirin analgesia in rats undergoing liver transplantation. Author(s): Monash University, Department of Surgery, Monash Medical Centre, Clayton, Australia. Source: Jablonski, P Howden, B O Lab-Anim. 2002 April; 36(2): 134-43 0023-6772
•
Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Author(s): Community Health Center of Area 4, Madrid, Spain. Source: Juarranz, M Calle Puron, M E Gonzalez Navarro, A Regidor Poyatos, E Soriano, T Martinez Hernandez, D Rojas, V D Guinee, V F Eur-J-Cancer-Prevolume 2002 October; 11(5): 465-72 0959-8278
•
Platelets: is aspirin sufficient or must we know how to pronounce abciximab? Author(s): Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
122 Aspirin
Source: Brinkman, W T Terramani, T T Najibi, S Chaikof, E L Semin-Vasc-Surg. 2002 December; 15(4): 245-55 0895-7967 •
Possible mechanisms of aspirin resistance. Author(s): Massachusetts College of Pharmacy and Health Sciences-Worcester, Department of Pharmacy Practice, Worcester, MA 01608, USA. Source: Cambria Kiely, J A Gandhi, P J J-Thromb-Thrombolysis. 2002 February; 13(1): 49-56 0929-5305
•
Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin. Author(s): Department of Neurology, The Albert Einstein College of Medicine, F-121N, 1300 Morris Park Ave, Bronx, NY 10461, USA. Source: Carrasco, E Werner, P Parkinsonism-Relat-Disord. 2002 September; 8(6): 407-11 1353-8020
•
Structural requirements for the neuroprotective effects of aspirin analogues against N-methyl-D-aspartate and zinc ion neurotoxicity. Author(s): Department of Molecular Science and Technology, Ajou University, Suwon, South Korea. Source: Moon, H S Nam, S I Kim, S D Kim, D Gwag, B J Lee, Y Yoon, S H J-PharmPharmacol. 2002 July; 54(7): 935-44 0022-3573
•
The effect of aspirin and prostaglandin E(1) on the patency of microvascular anastomosis in the rats. Author(s): Department of Orthopaedic Surgery, Korea University Hospital, Seoul, Korea.
[email protected] Source: Lee, K S Suh, J D Han, S B Yoo, J C Lee, S J Cho, S J Hand-Surg. 2001 December; 6(2): 177-85 0218-8104
•
The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis. Author(s): Division of Neurosurgery, University of Vermont, Burlington 05405, USA. Source: Bednar, M M Gross, C E Howard, D B Russell, S R Ellenberger, C Neurol-Res. 2001 October; 23(7): 745-50 0161-6412
•
Warfarin, aspirin, or both after myocardial infarction. Author(s): Department of Cardiology, Ulleval University Hospital, Oslo, Norway. Source: Hurlen, M Abdelnoor, M Smith, P Erikssen, J Arnesen, H N-Engl-J-Med. 2002 September 26; 347(13): 969-74 1533-4406
•
Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Author(s): Department of Neurology, Royal Perth Hospital, Perth, Western Australia.
[email protected] Source: Hankey, Graeme J Stroke. 2002 June; 33(6): 1723-6 1524-4628
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
Nutrition
123
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to aspirin; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Ascorbic Acid Alternative names: Vitamin C (Ascorbic Acid) Source: Integrative Medicine Communications; www.drkoop.com Folic Acid Source: Healthnotes, Inc.; www.healthnotes.com
124 Aspirin
Folic Acid Alternative names: Vitamin B9 (Folic Acid) Source: Integrative Medicine Communications; www.drkoop.com Niacin Alternative names: Vitamin B3 (Niacin) Source: Integrative Medicine Communications; www.drkoop.com Riboflavin Source: Integrative Medicine Communications; www.drkoop.com Vitamin B2 (riboflavin) Source: Integrative Medicine Communications; www.drkoop.com Vitamin B3 Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin B3 (niacin) Alternative names: Niacin Source: Integrative Medicine Communications; www.drkoop.com Vitamin B9 (folic Acid) Alternative names: Folate Source: Integrative Medicine Communications; www.drkoop.com Vitamin C Source: Healthnotes, Inc.; www.healthnotes.com Vitamin C Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin C (ascorbic Acid) Alternative names: Ascorbic Acid Source: Integrative Medicine Communications; www.drkoop.com Vitamin E Source: Healthnotes, Inc.; www.healthnotes.com Vitamin E Alternative names: Alpha-Tocopherol Source: Integrative Medicine Communications; www.drkoop.com Vitamin E Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin E Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,906,00.html
Nutrition
125
Vitamin K Alternative names: Menadione, Menaphthone, Menaquinone, Phylloquinone Source: Integrative Medicine Communications; www.drkoop.com Vitamin K Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10068,00.html •
Minerals Alpha-tocopherol Alternative names: Vitamin E Source: Integrative Medicine Communications; www.drkoop.com Beta-tocopherol Alternative names: Vitamin E Source: Integrative Medicine Communications; www.drkoop.com Chondroitin Source: Integrative Medicine Communications; www.drkoop.com Chondroitin Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10017,00.html Copper Source: Integrative Medicine Communications; www.drkoop.com D-alpha-tocopherol Alternative names: Vitamin E Source: Integrative Medicine Communications; www.drkoop.com Delta-tocopherol Alternative names: Vitamin E Source: Integrative Medicine Communications; www.drkoop.com Folate Alternative names: Vitamin B9 (Folic Acid) Source: Integrative Medicine Communications; www.drkoop.com Gamma-tocopherol Alternative names: Vitamin E Source: Integrative Medicine Communications; www.drkoop.com Glucosamine/chondroitin Source: Healthnotes, Inc.; www.healthnotes.com Iron Source: Healthnotes, Inc.; www.healthnotes.com
126 Aspirin
Naproxen/naproxen Sodium Source: Healthnotes, Inc.; www.healthnotes.com Potassium-sparing Diuretics Source: Prima Communications, Inc.www.personalhealthzone.com Vinpocetine Source: Prima Communications, Inc.www.personalhealthzone.com Zinc Source: Healthnotes, Inc.; www.healthnotes.com •
Food and Diet Apricots Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,45,00.html Blackberries Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,142,00.html Bruising Source: Healthnotes, Inc.; www.healthnotes.com Feingold Diet Source: Healthnotes, Inc.; www.healthnotes.com Garlic Alternative names: Allium sativum Source: Integrative Medicine Communications; www.drkoop.com Garlic Source: Prima Communications, Inc.www.personalhealthzone.com Garlic Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,786,00.html Gluten-free Diet Source: Healthnotes, Inc.; www.healthnotes.com Mushrooms Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10046,00.html Omega-3 Fatty Acids Source: Integrative Medicine Communications; www.drkoop.com
Nutrition
Pain Source: Healthnotes, Inc.; www.healthnotes.com
127
129
CHAPTER 3. ALTERNATIVE MEDICINE AND ASPIRIN Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to aspirin. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to aspirin and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “aspirin” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to aspirin: •
A characteristic of aspirin-induced hearing loss in auditory brainstem response of conscious rats. Author(s): Kurata K, Yamamoto M, Tsukuda R, Suzuki T, Sato S. Source: The Journal of Veterinary Medical Science / the Japanese Society of Veterinary Science. 1997 January; 59(1): 9-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9035071&dopt=Abstract
•
A natural flavonoid present in unripe plantain banana pulp (Musa sapientum L. var. paradisiaca) protects the gastric mucosa from aspirin-induced erosions. Author(s): Lewis DA, Fields WN, Shaw GP. Source: Journal of Ethnopharmacology. 1999 June; 65(3): 283-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10404428&dopt=Abstract
•
A prospective randomized trial of aspirin-clopidogrel combination therapy and doseadjusted warfarin on indices of thrombogenesis and platelet activation in atrial
130 Aspirin
fibrillation. Author(s): Kamath S, Blann AD, Chin BS, Lip GY. Source: Journal of the American College of Cardiology. 2002 August 7; 40(3): 484-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12142115&dopt=Abstract •
Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone). Author(s): Dorr VJ, Cook J. Source: Southern Medical Journal. 1996 June; 89(6): 612-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8638202&dopt=Abstract
•
An aspirin-triggered lipoxin A4 stable analog displays a unique topical antiinflammatory profile. Author(s): Schottelius AJ, Giesen C, Asadullah K, Fierro IM, Colgan SP, Bauman J, Guilford W, Perez HD, Parkinson JF. Source: Journal of Immunology (Baltimore, Md. : 1950). 2002 December 15; 169(12): 706370. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12471142&dopt=Abstract
•
An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole. Author(s): Sukavaneshvar S, Solen KA, Mohammad SF. Source: Thrombosis and Haemostasis. 2000 February; 83(2): 322-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10739393&dopt=Abstract
•
Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin. Author(s): Tsai SK, Huang CH, Huang SS, Hung LM, Hong CY. Source: Pharmacology. 1999 November; 59(5): 227-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10529654&dopt=Abstract
•
Anti-ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants of Pakistan in aspirin-ulcerated rats. Author(s): Akhtar AH, Ahmad KU. Source: Journal of Ethnopharmacology. 1995 April; 46(1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7475118&dopt=Abstract
•
Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal antiinflammatory drugs. Author(s): Thomas T, Nadackal GT, Thomas K.
Alternative Medicine 131
Source: Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association. 2003 February; 111(1): 811. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12605343&dopt=Abstract •
Aspirin chemoprevention of colorectal and oesophageal cancers. An overview of the literature and homeopathic explanation. Author(s): Morgan G. Source: European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). 1996 December; 5(6): 439-43. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9061274&dopt=Abstract
•
Aspirin in pregnancy. Author(s): Crawford MA. Source: Lancet. 1993 March 20; 341(8847): 753-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8095644&dopt=Abstract
•
Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Author(s): Subbegowda R, Frommel TO. Source: Cancer Research. 1998 July 1; 58(13): 2772-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9661890&dopt=Abstract
•
Aspirin: past, present and future. Author(s): Elwood PC. Source: Clinical Medicine (London, England). 2001 March-April; 1(2): 132-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11333459&dopt=Abstract
•
Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Analysis of the effects of a combination of aspirin and n-3 fatty acids on the eicosanoid profile. Author(s): Force T, Milani R, Hibberd P, Lorenz R, Uedelhoven W, Leaf A, Weber P. Source: Circulation. 1991 December; 84(6): 2286-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1959184&dopt=Abstract
•
Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates. Author(s): Boerboom LE, Olinger GN, Almassi GH, Skrinska VA. Source: Circulation. 1997 August 5; 96(3): 968-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9264508&dopt=Abstract
132 Aspirin
•
Caffeine-induced hypercalciuria and renal prostaglandins: effect of aspirin and n-3 polyunsaturated fatty acids. Author(s): Morgan LJ, Liebman M, Broughton KS. Source: The American Journal of Clinical Nutrition. 1994 September; 60(3): 362-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8074066&dopt=Abstract
•
Calcium and low-dose aspirin prophylaxis in women at high risk of pregnancyinduced hypertension. Author(s): Rogers MS, Fung HY, Hung CY. Source: Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy. 1999; 18(2): 165-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10476618&dopt=Abstract
•
Chemopreventive effects of calcium but not aspirin supplementation in cholic acidpromoted colon carcinogenesis: correlation with intermediate endpoints. Author(s): Pence BC, Dunn DM, Zhao C, Landers M, Wargovich MJ. Source: Carcinogenesis. 1995 April; 16(4): 757-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7728952&dopt=Abstract
•
Chili protects against aspirin-induced gastroduodenal mucosal injury in humans. Author(s): Yeoh KG, Kang JY, Yap I, Guan R, Tan CC, Wee A, Teng CH. Source: Digestive Diseases and Sciences. 1995 March; 40(3): 580-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7895549&dopt=Abstract
•
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Author(s): Napoli C, Ackah E, De Nigris F, Del Soldato P, D'Armiento FP, Crimi E, Condorelli M, Sessa WC. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 September 17; 99(19): 12467-70. Epub 2002 Sep 03. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209007&dopt=Abstract
•
Comparative effects of garlic and aspirin on diabetic cardiovascular complications. Author(s): Patumraj S, Tewit S, Amatyakul S, Jariyapongskul A, Maneesri S, Kasantikul V, Shepro D. Source: Drug Delivery. 2000 April-June; 7(2): 91-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10892409&dopt=Abstract
•
Differential effect of aspirin on platelet aggregation in IDDM. Author(s): Mori TA, Vandongen R, Douglas AJ, McCulloch RK, Burke V.
Alternative Medicine 133
Source: Diabetes. 1992 March; 41(3): 261-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1551486&dopt=Abstract •
Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids. Author(s): Engstrom K, Wallin R, Saldeen T. Source: Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2001 June; 64(6): 291-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11427037&dopt=Abstract
•
Effect of maternal low dose aspirin on neonatal platelet function. Author(s): Dasari R, Narang A, Vasishta K, Garewal G. Source: Indian Pediatrics. 1998 June; 35(6): 507-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10216644&dopt=Abstract
•
Effect of portal vein ligation and silymarin treatment on aspirin metabolism and disposition in rats. Author(s): Favari L, Soto C, Mourelle M. Source: Biopharmaceutics & Drug Disposition. 1997 January; 18(1): 53-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9008269&dopt=Abstract
•
Effect of sairei-to combined with aspirin and prednisolone on four recurrent reproductive failure women who are positive for anti-phospholipid antibodies. Author(s): Takakuwa K, Ishii K, Takaki Y, Natsume N, Adachi H, Kurata H, Tamura M, Kurabayasi T, Tanaka K. Source: The American Journal of Chinese Medicine. 2003; 31(4): 659-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14587888&dopt=Abstract
•
Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. Author(s): Mustapha A, Yakasai IA, Aguye IA. Source: Eur J Drug Metab Pharmacokinet. 1996 July-September; 21(3): 223-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8980919&dopt=Abstract
•
Effect of various doses of palm vitamin E and tocopherol on aspirin-induced gastric lesions in rats. Author(s): Jaarin K, Gapor MT, Nafeeza MI, Fauzee AM. Source: International Journal of Experimental Pathology. 2002 December; 83(6): 295-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12657138&dopt=Abstract
•
Effect of vitamin E supplementation on prostaglandin concentrations in aspirininduced acute gastric injury in aged rats. Author(s): Stickel F, Meydani M, Wu D, Bronson R, Martin A, Smith D, Meydani SN, Russell RM.
134 Aspirin
Source: The American Journal of Clinical Nutrition. 1997 November; 66(5): 1218-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9356541&dopt=Abstract •
Effects of aspirin and garlic on cyclooxygenase-induced chemiluminescence in human term placenta. Author(s): Das I, Patel S, Sooranna SR. Source: Biochemical Society Transactions. 1997 February; 25(1): 99S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9056997&dopt=Abstract
•
Effects of aspirin on human auditory filters. Author(s): Carlyon RP, Butt M. Source: Hearing Research. 1993 April; 66(2): 233-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8509313&dopt=Abstract
•
Effects of aspirin on human psychophysical tuning curves in forward and simultaneous masking. Author(s): Beveridge HA, Carlyon RP. Source: Hearing Research. 1996 September 15; 99(1-2): 110-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8970819&dopt=Abstract
•
Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination. Author(s): Akopov SE, Gabrielian ES. Source: European Journal of Clinical Pharmacology. 1992; 42(3): 257-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1577042&dopt=Abstract
•
Effects of continuous supplementations of ascorbic acid, aspirin, vitamin E and selenium on some haematological parameters and serum superoxide dismutase level in broiler chickens. Author(s): Tras B, Inal F, Bas AL, Altunok V, Elmas M, Yazar E. Source: British Poultry Science. 2000 December; 41(5): 664-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11201449&dopt=Abstract
•
Effects of feeding aspirin and supplemental vitamin E on plasma concentrations of 3methylindole, 3-methyleneindolenine-adduct concentrations in blood and pulmonary tissues, lung lesions, and growth performance in feedlot cattle. Author(s): Loneragan GH, Morley PS, Wagner JJ, Mason GL, Yost GS, Thoren MA, Wittum TE, Bray TM. Source: Am J Vet Res. 2002 December; 63(12): 1641-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12492277&dopt=Abstract
•
Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein
Alternative Medicine 135
assay. Author(s): Feldman M, Jialal I, Devaraj S, Cryer B. Source: Journal of the American College of Cardiology. 2001 June 15; 37(8): 2036-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11419884&dopt=Abstract •
Experimental thrombosis model induced by laser beam. Application of aspirin and an extract of Ginkgo biloba: EGb 761. Author(s): Belougne E, Aguejouf O, Imbault P, Azougagh Oualane F, Doutremepuich F, Droy-Lefaix MT, Doutremepuich C. Source: Thrombosis Research. 1996 June 1; 82(5): 453-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8771706&dopt=Abstract
•
Formation of endogenous “antiinflammatory” lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability. Author(s): Serhan CN, Takano T, Chiang N, Gronert K, Clish CB. Source: American Journal of Respiratory and Critical Care Medicine. 2000 February; 161(2 Pt 2): S95-S101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10673235&dopt=Abstract
•
Frequency selectivity on aspirin-induced hearing loss in rats with auditory stimulusinduced conditioned suppression. Author(s): Kurata K, Nishida N, Tsukuda R, Suzuki T, Sato S, Tokuriki M. Source: The Journal of Veterinary Medical Science / the Japanese Society of Veterinary Science. 1997 October; 59(10): 879-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9362035&dopt=Abstract
•
Gastrointestinal decontamination for enteric-coated aspirin overdose: what to do depends on who you ask. Author(s): Juurlink DN, McGuigan MA. Source: Journal of Toxicology. Clinical Toxicology. 2000; 38(5): 465-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10981955&dopt=Abstract
•
In vitro effects of aspirin on malondialdehyde formation and on activity of antioxidant and some metal-containing enzymes. Author(s): Kirkova M, Ivancheva E, Russanov E. Source: Comp Biochem Physiol Pharmacol Toxicol Endocrinol. 1994 July; 108(2): 145-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7981976&dopt=Abstract
•
Influence of garlic compared to aspirin on induced photothrombosis in mouse pial microvessels, in vivo. Author(s): el-Sabban F, Radwan GM.
136 Aspirin
Source: Thrombosis Research. 1997 October 15; 88(2): 193-203. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9361372&dopt=Abstract •
Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Author(s): Putter M, Grotemeyer KH, Wurthwein G, Araghi-Niknam M, Watson RR, Hosseini S, Rohdewald P. Source: Thrombosis Research. 1999 August 15; 95(4): 155-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10498385&dopt=Abstract
•
Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin? Author(s): Rota S, Flynn PD, Wareham NJ, Baglin TP, Byrne CD. Source: Thrombosis Research. 1996 August 15; 83(4): 329-38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8870177&dopt=Abstract
•
Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids. Author(s): Iacoviello L, Amore C, De Curtis A, Tacconi MT, de Gaetano G, Cerletti C, Donati MB. Source: Arterioscler Thromb. 1992 October; 12(10): 1191-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1390591&dopt=Abstract
•
Nitric oxide-releasing aspirin protects gastric mucosa against ethanol damage in rats with functional ablation of sensory nerves. Author(s): Konturek PC, Brzozowski T, Kania J, Konturek SJ, Hahn EG. Source: Inflammation Research : Official Journal of the European Histamine Research Society. [et Al.]. 2003 September; 52(9): 359-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14504662&dopt=Abstract
•
No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The “Petites Cellules” Group. Author(s): Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C. Source: Cancer. 1993 March 1; 71(5): 1741-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8383578&dopt=Abstract
•
Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. Author(s): Reimann JD, Modi NB, Novotny W. Source: Journal of Clinical Pharmacology. 2000 May; 40(5): 488-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10806602&dopt=Abstract
Alternative Medicine 137
•
Pharmacy through the ages. Aspirin: past, present, and future. Author(s): Belicastro PF. Source: Journal of the American Pharmaceutical Association (Washington,D.C. : 1996). 2002 May-June; 42(3): 522. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030643&dopt=Abstract
•
Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Author(s): Juarranz M, Calle-Puron ME, Gonzalez-Navarro A, Regidor-Poyatos E, Soriano T, Martinez-Hernandez D, Rojas VD, Guinee VF. Source: European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). 2002 October; 11(5): 465-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12394244&dopt=Abstract
•
Red wine, aspirin and platelet function. Author(s): Rotondo S, Rotilio D, Cerletti C, de Gaetano G. Source: Thrombosis and Haemostasis. 1996 November; 76(5): 818-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8950800&dopt=Abstract
•
Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Author(s): Seideman P, Muller-Suur R. Source: Annals of the Rheumatic Diseases. 1993 August; 52(8): 613-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8215627&dopt=Abstract
•
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. Author(s): Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Source: The Journal of Experimental Medicine. 2002 October 21; 196(8): 1025-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12391014&dopt=Abstract
•
Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. Author(s): Blacklock CJ, Lawrence JR, Wiles D, Malcolm EA, Gibson IH, Kelly CJ, Paterson JR. Source: Journal of Clinical Pathology. 2001 July; 54(7): 553-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11429429&dopt=Abstract
•
Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Author(s): Braden GA, Knapp HR, FitzGerald GA.
138 Aspirin
Source: Circulation. 1991 August; 84(2): 679-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1860212&dopt=Abstract •
The effect of aspirin on cochlear mechanical tuning. Author(s): Brown AM, Williams DM, Gaskill SA. Source: The Journal of the Acoustical Society of America. 1993 June; 93(6): 3298-307. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8326058&dopt=Abstract
•
The in vitro effect of aspirin on increased whole blood platelet aggregation in oral contraceptive users. Author(s): Norris LA, Bonnar J. Source: Thrombosis Research. 1994 May 1; 74(3): 309-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8042198&dopt=Abstract
•
The protective effect of liquorice components and their derivatives against gastric ulcer induced by aspirin in rats. Author(s): Dehpour AR, Zolfaghari ME, Samadian T, Vahedi Y. Source: The Journal of Pharmacy and Pharmacology. 1994 February; 46(2): 148-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8021806&dopt=Abstract
•
TNFalpha processing enzyme inhibitors prevent aspirin-induced TNFalpha release and protect against gastric mucosal injury in rats. Author(s): Fiorucci S, Antonelli E, Migliorati G, Santucci L, Morelli O, Federici B, Morelli A. Source: Alimentary Pharmacology & Therapeutics. 1998 November; 12(11): 1139-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9845404&dopt=Abstract
•
Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. Author(s): Lawrence JR, Peter R, Baxter GJ, Robson J, Graham AB, Paterson JR. Source: Journal of Clinical Pathology. 2003 September; 56(9): 651-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12944546&dopt=Abstract
•
Why is aspirin a contraindication for trigger-point injections? Author(s): Weiss BD. Source: American Family Physician. 2003 January 1; 67(1): 32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12537164&dopt=Abstract
Alternative Medicine 139
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to aspirin; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Allergies and Sensitivities Source: Healthnotes, Inc.; www.healthnotes.com Alzheimer's Disease Source: Healthnotes, Inc.; www.healthnotes.com Alzheimer's Disease Source: Integrative Medicine Communications; www.drkoop.com Anaphylaxis Source: Integrative Medicine Communications; www.drkoop.com Angina Source: Integrative Medicine Communications; www.drkoop.com Angioedema Source: Integrative Medicine Communications; www.drkoop.com
140 Aspirin
Asthma Source: Healthnotes, Inc.; www.healthnotes.com Asthma Source: Prima Communications, Inc.www.personalhealthzone.com Atherosclerosis and Heart Disease Prevention Source: Prima Communications, Inc.www.personalhealthzone.com Attention Deficit hyperactivity Disorder Source: Healthnotes, Inc.; www.healthnotes.com Bone Marrow Disorders Source: Integrative Medicine Communications; www.drkoop.com Breast Cancer Source: Healthnotes, Inc.; www.healthnotes.com Bursitis Source: Healthnotes, Inc.; www.healthnotes.com Bursitis Source: Integrative Medicine Communications; www.drkoop.com Cancer Prevention (reducing the Risk) Source: Prima Communications, Inc.www.personalhealthzone.com Capillary Fragility Source: Healthnotes, Inc.; www.healthnotes.com Cardiovascular Disease Overview Source: Healthnotes, Inc.; www.healthnotes.com Carpal Tunnel Syndrome Source: Healthnotes, Inc.; www.healthnotes.com Cataracts Source: Healthnotes, Inc.; www.healthnotes.com Cataracts (prevention) Source: Prima Communications, Inc.www.personalhealthzone.com Chronic Fatigue Syndrome Source: Integrative Medicine Communications; www.drkoop.com Chronic Myelogenous Leukemia Source: Integrative Medicine Communications; www.drkoop.com Cold Sores Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 141
Colorectal Cancer Source: Integrative Medicine Communications; www.drkoop.com Common Cold Source: Integrative Medicine Communications; www.drkoop.com Common Cold/sore Throat Source: Healthnotes, Inc.; www.healthnotes.com Congestive Heart Failure Source: Healthnotes, Inc.; www.healthnotes.com Cutaneous Drug Reactions Source: Integrative Medicine Communications; www.drkoop.com Cyclic Mastalgia Alternative names: Cyclic Mastitis, Fibrocystic Breast Disease Source: Prima Communications, Inc.www.personalhealthzone.com Depression (mild to Moderate) Source: Prima Communications, Inc.www.personalhealthzone.com Diabetes Source: Prima Communications, Inc.www.personalhealthzone.com Eczema Source: Prima Communications, Inc.www.personalhealthzone.com Epstein-barr Virus Source: Integrative Medicine Communications; www.drkoop.com Fever of Unknown Origin Source: Integrative Medicine Communications; www.drkoop.com Fibrocystic Breast Disease Source: Healthnotes, Inc.; www.healthnotes.com Fibromyalgia Source: Healthnotes, Inc.; www.healthnotes.com Flu Source: Integrative Medicine Communications; www.drkoop.com Gastritis Source: Healthnotes, Inc.; www.healthnotes.com Gastritis Source: Integrative Medicine Communications; www.drkoop.com Genital Herpes Source: Healthnotes, Inc.; www.healthnotes.com
142 Aspirin
Gout Source: Integrative Medicine Communications; www.drkoop.com Heart Attack Source: Healthnotes, Inc.; www.healthnotes.com Heart Attack Source: Integrative Medicine Communications; www.drkoop.com Hemophilia Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Prima Communications, Inc.www.personalhealthzone.com Hives Source: Healthnotes, Inc.; www.healthnotes.com Hypercholesterolemia Source: Integrative Medicine Communications; www.drkoop.com Hypochondriasis Source: Integrative Medicine Communications; www.drkoop.com Influenza Source: Healthnotes, Inc.; www.healthnotes.com Influenza Source: Integrative Medicine Communications; www.drkoop.com Insect Bites and Stings Source: Integrative Medicine Communications; www.drkoop.com Iron-deficiency Anemia Source: Healthnotes, Inc.; www.healthnotes.com Low Back Pain Source: Integrative Medicine Communications; www.drkoop.com Migraine Headache Source: Integrative Medicine Communications; www.drkoop.com Miscarriage Source: Integrative Medicine Communications; www.drkoop.com Mitral Valve Prolapse Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 143
Mononucleosis Source: Integrative Medicine Communications; www.drkoop.com Myelofibrosis Source: Integrative Medicine Communications; www.drkoop.com Myeloproliferative Disorders Source: Integrative Medicine Communications; www.drkoop.com Myocardial Infarction Source: Integrative Medicine Communications; www.drkoop.com Nausea Source: Prima Communications, Inc.www.personalhealthzone.com Osteoarthritis Source: Healthnotes, Inc.; www.healthnotes.com Osteoarthritis Source: Integrative Medicine Communications; www.drkoop.com Osteoarthritis Source: Prima Communications, Inc.www.personalhealthzone.com Peptic Ulcer Source: Healthnotes, Inc.; www.healthnotes.com Pericarditis Source: Integrative Medicine Communications; www.drkoop.com Pharyngitis Source: Integrative Medicine Communications; www.drkoop.com Polycythemia Vera Source: Integrative Medicine Communications; www.drkoop.com Recurrent Ear Infections Source: Healthnotes, Inc.; www.healthnotes.com Rheumatoid Arthritis Source: Healthnotes, Inc.; www.healthnotes.com Rheumatoid Arthritis Source: Integrative Medicine Communications; www.drkoop.com Roseola Source: Integrative Medicine Communications; www.drkoop.com Rubella Source: Integrative Medicine Communications; www.drkoop.com
144 Aspirin
Scleroderma Source: Integrative Medicine Communications; www.drkoop.com Serum Sickness Source: Integrative Medicine Communications; www.drkoop.com Sore Throat Source: Integrative Medicine Communications; www.drkoop.com Spontaneous Abortion Source: Integrative Medicine Communications; www.drkoop.com Sprains and Strains Source: Healthnotes, Inc.; www.healthnotes.com Sprains and Strains Source: Integrative Medicine Communications; www.drkoop.com Stomach Inflammation Source: Integrative Medicine Communications; www.drkoop.com Stroke Source: Healthnotes, Inc.; www.healthnotes.com Stroke Source: Integrative Medicine Communications; www.drkoop.com Temporomandibular Joint Dysfunction Source: Integrative Medicine Communications; www.drkoop.com Tendinitis Source: Integrative Medicine Communications; www.drkoop.com Tension Headache Source: Integrative Medicine Communications; www.drkoop.com Thrombocytosis Source: Integrative Medicine Communications; www.drkoop.com Thyroid Inflammation Source: Integrative Medicine Communications; www.drkoop.com Thyroiditis Source: Integrative Medicine Communications; www.drkoop.com Tias Source: Integrative Medicine Communications; www.drkoop.com Tmj Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 145
Transient Ischemic Attacks Source: Integrative Medicine Communications; www.drkoop.com Ulcers Source: Prima Communications, Inc.www.personalhealthzone.com •
Alternative Therapy Naturopathy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,722,00.html Testing for Stomach Acidity Source: Healthnotes, Inc.; www.healthnotes.com
•
Herbs and Supplements 5-aminosalicylic Acid Derivatives Source: Integrative Medicine Communications; www.drkoop.com Acetaminophen Alternative names: Acephen, Aceta, Amaphen, Anoquan, Apacet, Arthritis Foundation Aspirin Free, Arthritis Foundation Nighttime, Aspirin Free Anacin, Aspirin Free Excedrin, Bayer Select, Dapacin, Dynafed, Endolor, Esgic, Excedrin P.M., Fem-Etts, Femcet, Feverall, Fioricet, Fiorpap, Genapap, Genebs, Halenol, Isocet, Liquiprin, Mapap, Maranox, Meda, Medigesic, Midol, Multi-Symptom Pamprin, Neopap, Nighttime Pamprin, Oraphen-PD, Panadol, Phrenilin, Repan, Ridenol, Sedapap, Silapap, Sominex Pain Relief, Tapanol, Tempra, Tylenol, Uni-Ace, Unisom with Pain Relief Source: Prima Communications, Inc.www.personalhealthzone.com Alka-seltzer Source: Healthnotes, Inc.; www.healthnotes.com Allium Sativum Alternative names: Garlic Source: Integrative Medicine Communications; www.drkoop.com Aloe Alternative names: Aloe vera L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Anacin Source: Healthnotes, Inc.; www.healthnotes.com Aortic Glycosaminoglycans Source: Prima Communications, Inc.www.personalhealthzone.com Aspirin Source: Healthnotes, Inc.; www.healthnotes.com
146 Aspirin
Astragalus Mem Alternative names: Huang-Qi; Astragalus membranaceus Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Berberis Alternative names: Barberry; Berberis sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Bismuth Subsalicylate Source: Healthnotes, Inc.; www.healthnotes.com Boswellia Alternative names: Frankincense; Boswellia serrata Roxb. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Bovine Colostrum Source: Healthnotes, Inc.; www.healthnotes.com Bromelain Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,760,00.html Capsaicin Alternative names: Cayenne Source: Integrative Medicine Communications; www.drkoop.com Capsicum Frutescens Alternative names: Cayenne Source: Integrative Medicine Communications; www.drkoop.com Cayenne Alternative names: Capsaicin Source: Integrative Medicine Communications; www.drkoop.com Cayenne Source: Prima Communications, Inc.www.personalhealthzone.com Celecoxib Source: Healthnotes, Inc.; www.healthnotes.com Cherry Fruit Extract Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10015,00.html Chili Pepper Alternative names: Cayenne Source: Integrative Medicine Communications; www.drkoop.com Cysteine Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 147
Darvon Compound Source: Healthnotes, Inc.; www.healthnotes.com Dha Alternative names: Docosahexaenoic Acid (DHA) Source: Integrative Medicine Communications; www.drkoop.com Diclofenac Source: Healthnotes, Inc.; www.healthnotes.com Dipyridamole Source: Healthnotes, Inc.; www.healthnotes.com Docosahexaenoic Acid (dha) Alternative names: DHA Source: Integrative Medicine Communications; www.drkoop.com Eicosapentaenoic Acid (epa) Alternative names: EPA Source: Integrative Medicine Communications; www.drkoop.com Empirin with Codeine Source: Healthnotes, Inc.; www.healthnotes.com Epa Alternative names: Eicosapentaenoic Acid (EPA) Source: Integrative Medicine Communications; www.drkoop.com Ephedra Alternative names: Ephedra sinensis, Ma huang Source: Integrative Medicine Communications; www.drkoop.com Ephedra Sinensis Source: Integrative Medicine Communications; www.drkoop.com Etodolac Source: Healthnotes, Inc.; www.healthnotes.com Eugenia Clove Alternative names: Cloves; Eugenia sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Feverfew Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,780,00.html Fiorinal Source: Healthnotes, Inc.; www.healthnotes.com
148 Aspirin
Flurbiprofen Source: Healthnotes, Inc.; www.healthnotes.com Ginger Source: Prima Communications, Inc.www.personalhealthzone.com Ginkgo Alternative names: Ginkgo biloba Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Ginkgo Source: Prima Communications, Inc.www.personalhealthzone.com Ginkgo Biloba Source: Healthnotes, Inc.; www.healthnotes.com Ginkgo Biloba Alternative names: Maidenhair Tree Source: Integrative Medicine Communications; www.drkoop.com Ginkgo Biloba Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,788,00.html Glucosamine Source: Prima Communications, Inc.www.personalhealthzone.com Glucosamine Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,790,00.html Glutamine Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10030,00.html Glycyrrhiza Glabra Alternative names: Licorice Source: Integrative Medicine Communications; www.drkoop.com Glycyrrhiza1 Alternative names: Licorice; Glycyrrhiza glabra L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Grape Seed Extract Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,793,00.html
Alternative Medicine 149
Green-lipped Mussel Source: Healthnotes, Inc.; www.healthnotes.com Heparin Alternative names: Hep-Lock Source: Prima Communications, Inc.www.personalhealthzone.com Horse Chestnut Source: Prima Communications, Inc.www.personalhealthzone.com Ibuprofen Source: Healthnotes, Inc.; www.healthnotes.com Indomethacin Source: Healthnotes, Inc.; www.healthnotes.com Ketoprofen Source: Healthnotes, Inc.; www.healthnotes.com Ketorolac Source: Healthnotes, Inc.; www.healthnotes.com Licorice Alternative names: Glycyrrhiza glabra Source: Integrative Medicine Communications; www.drkoop.com Licorice Source: Prima Communications, Inc.www.personalhealthzone.com Ma Huang Source: Integrative Medicine Communications; www.drkoop.com Maidenhair Tree Alternative names: Ginkgo Biloba Source: Integrative Medicine Communications; www.drkoop.com Meadowsweet Alternative names: Filipendula ulmaria Source: Healthnotes, Inc.; www.healthnotes.com Meadowsweet Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Melatonin Source: Healthnotes, Inc.; www.healthnotes.com Menadione Source: Integrative Medicine Communications; www.drkoop.com Menaphthone Source: Integrative Medicine Communications; www.drkoop.com
150 Aspirin
Menaquinone Source: Integrative Medicine Communications; www.drkoop.com Methotrexate Alternative names: Rheumatrex Source: Prima Communications, Inc.www.personalhealthzone.com Metoclopramide Source: Healthnotes, Inc.; www.healthnotes.com Milk Thistle Alternative names: Silybum marianum, St. Mary's Thistle Source: Integrative Medicine Communications; www.drkoop.com Msm Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,807,00.html Musa Banana Alternative names: Plantain, Banana; Musa sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Nabumetone Source: Healthnotes, Inc.; www.healthnotes.com Non-steroidal Anti-inflammatory Drugs Source: Healthnotes, Inc.; www.healthnotes.com Nonsteroidal Anti-inflammatory Drugs Source: Prima Communications, Inc.www.personalhealthzone.com Ocimum Alternative names: Basil, Albahaca; Ocimum basilicum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Opcs (oligomeric Proanthocyanidins) Source: Prima Communications, Inc.www.personalhealthzone.com Oxaprozin Source: Healthnotes, Inc.; www.healthnotes.com Panax Alternative names: Ginseng; Panax ginseng Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Pentoxifylline Alternative names: Trental Source: Prima Communications, Inc.www.personalhealthzone.com
Alternative Medicine 151
Percodan Source: Healthnotes, Inc.; www.healthnotes.com Phylloquinone Source: Integrative Medicine Communications; www.drkoop.com Piroxicam Source: Healthnotes, Inc.; www.healthnotes.com Proanthocyanidins Source: Healthnotes, Inc.; www.healthnotes.com Red Clover Source: Integrative Medicine Communications; www.drkoop.com Red Clover Source: Prima Communications, Inc.www.personalhealthzone.com Red Pepper Alternative names: Cayenne Source: Integrative Medicine Communications; www.drkoop.com Repaglinide Source: Healthnotes, Inc.; www.healthnotes.com Rofecoxib Source: Healthnotes, Inc.; www.healthnotes.com Roxiprin Source: Healthnotes, Inc.; www.healthnotes.com S-adenosylmethionine (same) Source: Integrative Medicine Communications; www.drkoop.com Salicylates Source: Integrative Medicine Communications; www.drkoop.com Salsalate Source: Healthnotes, Inc.; www.healthnotes.com Same Source: Integrative Medicine Communications; www.drkoop.com Same (s-adenosylmethionine) Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,818,00.html Silybum Marianum Source: Integrative Medicine Communications; www.drkoop.com Soma Compound Source: Healthnotes, Inc.; www.healthnotes.com
152 Aspirin
Soma Compound with Codeine Source: Healthnotes, Inc.; www.healthnotes.com Spanish Licorice Alternative names: Licorice Source: Integrative Medicine Communications; www.drkoop.com St. Mary's Thistle Source: Integrative Medicine Communications; www.drkoop.com Sulindac Source: Healthnotes, Inc.; www.healthnotes.com Ticlopidine Source: Healthnotes, Inc.; www.healthnotes.com Trimethoprim/sulfamethoxazole Alternative names: Bactrim, Cotrim, Septra, Sulfatrim Source: Prima Communications, Inc.www.personalhealthzone.com Turmeric Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,312,00.html Valproic Acid Source: Prima Communications, Inc.www.personalhealthzone.com Warfarin Alternative names: Coumadin Source: Prima Communications, Inc.www.personalhealthzone.com White Willow Source: Prima Communications, Inc.www.personalhealthzone.com White Willow Bark Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10069,00.html Willow Alternative names: Salix alba Source: Healthnotes, Inc.; www.healthnotes.com Willow Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Willow Bark Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 153
Zafirlukast Source: Healthnotes, Inc.; www.healthnotes.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
155
CHAPTER 4. DISSERTATIONS ON ASPIRIN Overview In this chapter, we will give you a bibliography on recent dissertations relating to aspirin. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “aspirin” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on aspirin, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Aspirin ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to aspirin. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
Aspirin for Primary and Secondary Prevention of an Acute Myocardial Infarction in Worksite Program by Humbles, Patricia Lee; Phd from University of Illinois at Chicago, Health Sciences Center, 2002, 118 pages http://wwwlib.umi.com/dissertations/fullcit/3058236
•
The Mechanism of Aspirin Absorption in the Caco-2 Model of Intestinal Mucosa by Dunnington, Katherine Michelle; Phd from University of Missouri - Kansas City, 2002, 113 pages http://wwwlib.umi.com/dissertations/fullcit/3059712
156 Aspirin
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
157
CHAPTER 5. CLINICAL TRIALS AND ASPIRIN Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning aspirin.
Recent Trials on Aspirin The following is a list of recent trials dedicated to aspirin.8 Further information on a trial is available at the Web site indicated. •
Aspirin Or Warfarin To Prevent Stroke Condition(s): Stroke; Cerebral Infarction; Atherosclerosis; Constriction, Pathologic Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: The purpose of this study is to determine whether aspirin or warfarin is more effective in preventing stroke in patients with intracranial stenosis. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00004728
•
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer Condition(s): Colorectal Cancer; stage I colon cancer; stage II colon cancer; stage III colon cancer; stage IV colon cancer Study Status: This study is currently recruiting patients. Sponsor(s): M.D. Anderson Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether
8
These are listed at www.ClinicalTrials.gov.
158 Aspirin
sulindac, aspirin, or ursodiol is more effective in preventing colorectal cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of sulindac, aspirin, and ursodiol in preventing colorectal cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00062023 •
Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial Condition(s): Heart Disease; Stroke; Ischemic Heart Disease; Myocardial Infarction; Atrial Fibrillation Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00041938
•
Are Aspirin, Warfarin, and Clopidogrel Equally Effective in the Treatment of Patients With Symptomatic CHF and Reduced Ejection Fraction? Condition(s): NYHA Class II, III or IV CHF; Left ventricular ejection fraction less than or equal to 35% Study Status: This study is no longer recruiting patients. Sponsor(s): Department of Veterans Affairs; Department of Veterans Affairs Cooperative Studies Program; Canadian Regional Coordinating Center; UK Regional Coordinating Center; Economic Analysis Lab; Echo Core Lab; Sanofi-Synthelabo; Bristol-Myers Squibb; Dupont Pharmaceuticals Purpose - Excerpt: Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events). Phase(s): Phase III; MEDLINEplus consumer health information Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00007683
Clinical Trials 159
•
Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps Condition(s): prevention of colorectal cancer; Colon Cancer; Rectal Cancer Study Status: This study is no longer recruiting patients. Sponsor(s): Queen's Medical Centre Purpose - Excerpt: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin and/or folic acid may be effective in preventing recurrent polyps in patients who have had polyps removed previously. PURPOSE: Randomized clinical trial to determine the effectiveness of aspirin and/or folic acid in preventing the recurrence of colorectal polyps. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00033319
•
Aspirin-Myocardial Infarction Study (AMIS) Condition(s): Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia Study Status: This study is completed. Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) Purpose - Excerpt: To determine whether the daily administration of 1 gm of aspirin to individuals with a documented myocardial infarction would result in a significant reduction in mortality over a three year period. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000491
•
Observational Aspirin Use and CVD in the Physicians' Health Study Condition(s): Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Cerebrovascular Accident Study Status: This study is completed. Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) Purpose - Excerpt: To analyze existing data from the Physicians Health Study (PHS), a randomized primary prevention trial of low-dose aspirin and beta carotene conducted among 22,071 U.S. male physicians, to address questions concerning aspirin and cardiovascular (CV) disease that could not adequately be addressed during the randomized aspirin period. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00005493
160 Aspirin
•
Randomized Trial of Aspirin and Cataracts in U.S. Physicians Condition(s): Cataract Study Status: This study is completed. Sponsor(s): National Eye Institute (NEI) Purpose - Excerpt: To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000157
•
Trial of Aspirin and Vitamin E in Women (Women's Health Study - WHS) Condition(s): Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia; Vascular Diseases Study Status: This study is completed. Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) Purpose - Excerpt: To evaluate the effects of vitamin E and low-dose aspirin in primary prevention of cardiovascular disease and cancer in apparently healthy women. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00000479
•
Warfarin Versus Aspirin Recurrent Stroke Study Condition(s): Stroke Study Status: This study is completed. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: The goal of this study is to compare aspirin to warfarin for the prevention of recurrent stroke. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00027066
Clinical Trials 161
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “aspirin” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
162 Aspirin
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
163
CHAPTER 6. PATENTS ON ASPIRIN Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “aspirin” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on aspirin, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Aspirin By performing a patent search focusing on aspirin, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We
9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
164 Aspirin
will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on aspirin: •
Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease Inventor(s): Christakis; George (Sunrise, FL), Riley; Patricia A. (Sunrise, FL) Assignee(s): Medical Doctor's Research Institute, Inc. (Sunrise, FL) Patent Number: 5,948,443 Date filed: February 21, 1997 Abstract: The present invention pertains generally to the field of Public Health, including the prevention and treatment of coronary heart disease which is currently the first cause of death in the American population. More specifically, the present invention concerns a total modular system of multivitamin and mineral supplementation composed of 7 distinct modules for improving public health by insuring adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to, for example, lifestyle factors and common inadequate dietary patterns. A module, as used herein throughout, is defined as a separate and distinct combination of vitamin-mineral and other health promoting compounds which are directed to specific target populations. The formulations of the present invention which, when combined in one capsule or tablet or as separate modules, exert a joint and enhancing effect on the major pathogenetic factors involved in the atherosclerotic process. Moreover, certain modular formulations of the present invention incorporate both antioxidants and acetylsalicylic acid (aspirin) as a single preventive modality. Such a combination of antioxidants and aspirin is believed to act to prevent oxidation of low density lipoproteins within coronary arterial walls and to cause platelet deagluttination thereby inhibiting thrombus formation. The benefit of preventing these two major processes is believed to reduce the risk of coronary heart disease. Excerpt(s): The present invention concerns a total modular system of multivitamin and mineral supplementation composed of 7 distinct modules for improving public health by insuring adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to, for example, lifestyle factors and common inadequate dietary patterns. A module, as used herein throughout, is a separate and distinct combination of vitamin-mineral and other health promoting compounds which are directed to specific target populations. Micronutrients are elements or compounds which are present in foods in small or trace amounts and includes vitamins, minerals or other elements; and compounds found in foods for which a Recommended Dietary Allowance (RDA) has not yet been determined (pantothenic acid, biotin, choline, etc.). The macronutrients consist of carbohydrates, fats and proteins which supply nutrients and calories. Some elements such as calcium, sodium, potassium, chloride and phosphorus are elements consumed in relatively large amounts, while many such as iron, iodine, and zinc are consumed in small amounts (milligrams). Vitamins such as vitamin B12, and folic acid and the minerals copper, selenium and chromium are consumed in very small, or trace amounts (micrograms). Inasmuch as the human body, does not synthesize many "essential compounds", these specific vitamins and minerals can be obtained from only two sources: foods and supplements. The primary source of all nutrients is food. Over the past four decades, ample evidence documents that major portions of various subgroups of Americans stratified by age, gender, socioeconomic status and other variables, cannot meet the "Recommended Dietary Allowances" of the foods containing these essential compounds
Patents 165
and elements. Thus vitamin and mineral supplementation has become a recognized method of meeting accepted medical and public health nutrition standards. The enrichment of bread with iron and B vitamins in 1940 is considered a major factor in assuring favorable nutritional status for the general population of that time, and has been retained as a major advance for public health. In 1993, the Interagency Board of Nutrition Monitoring and Related Research reported that women did not meet the RDA's of 6 out of 15 micronutrients: B6, E, calcium, iron, magnesium and zinc. Men also failed to met the RDA's for 4 of 15 micronutrients: B6, E, magnesium and zinc. Their findings reveal significant prevalence and incidence of various population subgroups deficient in specific vitamins and minerals. The importance of these findings relate to the prevention of micronutrient deficiency diseases such as scurvy (vitamin C deficiency), pellagra (niacin deficiency), beri-beri (vitamin B1 deficiency), iron deficiency anemia and other vitamin and mineral deficiency states. The effect of marginal deficiency states is only now being considered as a cause of suboptimal health status. Moreover, research conducted and published in the past three decades indicates that antioxidant micronutrients are involved in preventing molecular biological processes affecting health and disease at the subcellular and submolecular level. It is current thought that free-radical effects on cells and tissues can be modified by antioxidant micronutrients reducing cellular damage. Specific micronutrients maintain immune system integrity, moderate the aging process, and play a role in the prevention of atherogenesis and cancer. Furthermore, substantial segments of the population do not manifest desirable eating patterns, that is, an adequate intake in both the quantity and variety of food to fulfill the Recommended Dietary Allowances, as indicated by recent government survey. Only 22% of the subjects of a National Cancer Institute Study, consumed the recommended number of dietary servings of fruits and vegetables. Web site: http://www.delphion.com/details?pn=US05948443__ •
Acoustic emission monitor, method and memory media for solid material processing machinery Inventor(s): Foucher; Etienne (Paris, FR), Rothea; Remi (Millery, FR) Assignee(s): Rhodia, Inc. (Cranbury, NJ) Patent Number: 6,418,384 Date filed: May 11, 1999 Abstract: Apparatus and method for monitoring acoustic emission signals in machinery that processes solid material such as aspirin to detect rubbing conditions. The apparatus includes an acoustic signal processing system having a computer, an acoustic signal processing program capable of configuring the computer as a filter, and a rubbing signal identifier that configures the computer to set filter conditions for the filter and to detect a rubbing signal. The filter conditions remove some operating noise having a hit rate higher than the operating rate of the rotating part of the machinery by excluding amplitudes less than a front end filter threshold amplitude and durations less than a front end filter duration. The rubbing signals are detected according to the criteria: intensity greater than a predetermined intensity, acoustic emission activity greater than the operating rate of the rotating part and signal length greater than a predetermined signal length. Excerpt(s): This invention relates to machinery for processing solid material and, in particular, to a monitor for monitoring acoustic emission signals in the machinery to detect rubbing of rotating or vibrating parts contained in the machinery. Machinery is
166 Aspirin
generally known for processing solid material that is in the form of a powder, crystals, granules, chips, flakes, pellets and the like. For example, machinery used to process aspirin includes a granulator, a sifter and a large and a small screw conveyor. This machinery involves the relative motion of two metallic parts with a narrow clearance in between. One part is usually stationary (for example, a screen, a trough or a casing) and the other has a rotating or vibrating motion (such as a rotor or a screw). Rubbing occurs between the rotating and stationary parts when there are changes in the parts due to use and/or wear. The granulator breaks compacted aspirin chunks into small granules using oscillating steel blades to force the chunks through a wire screen. The blades are located close enough to the screen to make rubbing or wear contact that produces metallic particles that contaminate the aspirin material. Web site: http://www.delphion.com/details?pn=US06418384__ •
Associations of active principles containing clopidogrel and an antithrombotic agent Inventor(s): Bernat; Andre (Cugnaux, FR), Herbert; Jean Marc (Tournefeuille, FR), Savi; Pierre (Muret, FR) Assignee(s): Sanofi (Paris, FR) Patent Number: 5,989,578 Date filed: August 12, 1998 Abstract: The invention relates to a pharmaceutical composition containing an association of active principles, wherein the active principles are clopidogrel and aspirin, each constituent being present in a free form or in the form of a pharmaceutically acceptable salt. Excerpt(s): The subject of the present invention is a new combination of active ingredients with anti-platelet aggregation activity consisting of clopidogrel and aspirin, and pharmaceutical compositions containing them. The active ingredients constituting the combination are present in the free state or in the form of one of their pharmacologically acceptable salts. During the last decade, there has been a lot of interest in the study of the role played by the platelets in the development of diseases associated with atherosclerosis (myocardial infarction, angor, cerebral attack, peripheral arterial diseases and the like). The well-established role of the platelets in arterial thrombosis has allowed the development of numerous medicaments which inhibit the functions of the platelets and the discovery of the essential role of ADP in the thrombotic process has led to the development of ticlopidin, a potent antithrombotic agent. This thieno[3,2-c]pyridine derivative is described in Patent FR 73 03503. Ticlopidin selectively inhibits the platelet aggregation induced by ADP as well as that of other agonists, mediated by ADP [Feliste et al., Thromb. Res., 1987, 48, 403-415). Web site: http://www.delphion.com/details?pn=US05989578__
•
Beta-carotene vitamin E therapy for inhibition of major vascular events Inventor(s): Hennekens; Charles H. (Wellesley, MA) Assignee(s): Brigham and Women's Hospital (Boston, MA) Patent Number: 5,871,766 Date filed: December 21, 1994
Patents 167
Abstract: This invention is directed to a method for inhibiting the occurrence of a major vascular event in a subject whereby a subject is administered beta-carotene and/or vitamin E, either alone or in combination. Beta-carotene and/or vitamin E is administered such that the subject's risk of experiencing a major vascular event is thereby reduced. In another preferred embodiment, beta-carotene in combination with aspirin is particularly effective.The invention further includes pharmaceutical compositions comprising beta-carotene in combination with vitamin E. Excerpt(s): The invention generally relates to the field of medicinal chemistry. More specifically, the invention relates to the administration of beta-carotene and/or vitamin E to inhibit the occurrence of a major vascular event. The invention is further directed to pharmaceutical compositions comprising beta-carotene in combination with vitamin E. In one embodiment, beta-carotene is administered in combination with aspirin. Despite a recent decline in cardiovascular disease-related mortality, cardiovascular disease remains the leading cause of morbidity and mortality in men and women in the United States, accounting for 47% of all deaths in 1986 (Dept. of Health and Human Services, Mortality Part B 88-1114:170-95 (1988). Recent evidence suggests that antioxidant therapy may prevent or impede atherogenesis. Free radical oxidation has been postulated to play a role in the pathogenesis of atherosclerotic disease (Steinberg et al., N. Engl. J. Med. 320(14):915-24 (1989)). Serum lipoproteins can become oxidized in vivo (Warso et al., J. Clin. Invest. 75:667-71 (1985)) and these may be more atherogenic than their unoxidized counterparts. Oxidized low density lipoprotein (LDL) can potentially promote atherogenesis by several mechanisms. First, these modified lipoproteins may be toxic to or alter function of arterial endothelium. Oxidized LDL is cytotoxic to cultured endothelial cells as well as fibroblasts in vitro (Hessler et al., Arteriosclerosis 3(3):215-22 (1983); Yagi, K., Bioessays 1:58-60 (1984)). This altered endothelium may permit diffusion of serum lipids into the subendothelium and/or alter the ability of the endothelium to prevent thrombosis. Second, oxidized LDL chemotactically attracts and immobilizes monocyte/macrophages (Quinn et al., Proc. Natl. Acad. Sci. 82:5949-53 (1985)), some of which are destined to become lipid-laden foam cells within atheromatous plaque (Schaffner et al., Am. J. Pathol. 100:57-73 (1980); Gerrity, R. G., Am. J. Pathol. 103:181-90 (1981)). Finally, oxidized LDL is taken up into foam cells via a scavenger receptor more readily than unoxidized LDL (Fogelman et al., Proc. Natl. Acad. Sci. 77:2214-18 (1980); Goldstein et al., Proc. Natl. Acad. Sci. 76:333-37 (1979)). Thus oxidation of LDL may play an important role in the initiation and propagation of atherosclerosis. Web site: http://www.delphion.com/details?pn=US05871766__ •
Coated active tablet(s) Inventor(s): Barkley; Aaron (Willow Grove, PA), Callahan; Timothy Patrick (Malvern, PA), Flanagan; John (Neshanic Station, NJ), Nicholson; Richard E. (Birdsboro, PA), Smith; Terry L. (Pottstown, PA) Assignee(s): Monsanto Company (St. Louis, MO) Patent Number: 6,485,747 Date filed: October 11, 1999 Abstract: A tablet coating useful for coating an active selected from the group consisting of aspirin, ibuprofen, naproxin sodium, acetaminophen, celecoxib, sildenafil citrate, alendronate sodium, an analgesic in combination with one or more of an antitussive, antihistamine, decongestant and expectorant, oxaprozin, comprising gellan gum along
168 Aspirin
with a process which comprises admixing gellan gum and water under effective shear conditions to prepare an aqueous gellan gum coating composition thereof whereby the aqueous gellan gum coating composition is applied in an adherent fashion to a placebo or a tablet containing an active to form a gellan gum coated placebo or gellan gum coated active. Excerpt(s): This invention relates generally to tablet coating(s) on active drugs and to a method to prepare compositions useful to coat active drugs. More particularly this invention relates to a drug coated with gellan gum, a method to prepare a gellan gum composition useful to coat an active drug, a gellan gum composition useful to coat an active drug(s), and to a method for coating active drugs(s) with gellan gum. In particular this invention relates to an intact active tablet comprising an active ingredient selected from the group consisting of aspirin, naproxen sodium, acetaminophen, ibuprofen, celecoxib, oxaprozin, sildenafil citrate, alendronate sodium, mixtures thereof and the like and optimally an analgesic in combination with one or more of an antihistamine, antitussive, decongestant, and expectorant and mixtures thereof and the like, coated with gellan gum, a method to prepare a gellan gum composition useful to coat one or more of the aforementioned actives, mixtures thereof and the like, and to a method for coating one or more of the aforementioned actives, mixtures thereof and the like, with gellan gum. Tablets are typically used to deliver a pharmacologically effective amount of a therapeutic active (drug) to humans and animals so as to provide medicinal benefit to the human or animal. Typically such therapeutically effective drugs include those drugs that possess and produce desirable drug effects after effective consumption by the human or animal. Effective consumption is achieved by oral or rectal administration to a patient for example. In medicinal uses, one or more coatings is desired on a medicinal tablet in order to obtain one or more of gloss, better appearance, identification, mouthfeel, stability, color, swallowability, improved taste and the like. Web site: http://www.delphion.com/details?pn=US06485747__ •
Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers Inventor(s): Frank-Kollman; Mary Theresa (173 Egrets Way, Richmond Hill, GA 31324) Assignee(s): none reported Patent Number: 6,440,983 Date filed: December 21, 2000 Abstract: The treatment of migraine and/or cluster headaches in human beings in need of such treatment includes oral administration of a composition containing acetaminophen, ibuprofen, caffeine and magnesium as the active ingredients. The inclusion of an additional active ingredient, guaifenesin, further provides treatment for severe sinus headaches. Compositions and methods for alleviating the symptoms of these headache conditions are disclosed. Excerpt(s): The present invention relates broadly to the field of healthcare, and in particular, to the treatment of severe headaches in human beings. More specifically, this invention relates to compositions and methods for providing relief from the symptoms of migraine headaches and/or cluster headaches and/or headaches related to sinus congestion, in affected individuals who also have a low tolerance for aspirin due to digestive disorders. Migraine is a particularly painful headache, which recurs and can be physically debilitating to sufferers. In many respects, cluster headaches are similar to
Patents 169
migraine headaches, and all references herein to migraine and/or migraine headaches shall be considered as also including, and as references to, cluster headaches. There is no single cause or remedy for migraine headaches, and the incidence of migraine appears to be increasing in the general population. Although sufferers, on average, experience only one attack per month, each attack can last between four and seventy-two hours. In some cases, sufferers experience a pre-onset "warning" which may indicate that a migraine is imminent, and which may be termed an "aura." An "aura" is a disruption of brain function characterized by visual disturbances like flashing lights and blurred vision. These "disruptions" occur twenty to thirty minutes before an attack. About twenty percent of migraine suffers experience "aura" symptoms. Other attacks can be preceded by a "prodrome" several hours before the onset of a migraine. These "prodrome" symptoms may include, but are not limited to, fatigue, yawning, sensory sensitivity, mood changes, and food cravings. Prescription medications have previously been developed to alleviate the severity of migraine pain, but prescription migraine medications generally contain some type of narcotic, which, over time, may become addictive. Although over-the-counter remedies also exist, marketed under the EXCEDRIN.RTM. and ADVIL.RTM. brands, the EXCEDRIN.RTM. Migraine Formula contains aspirin, acetaminophen, and caffeine as its active ingredients, while the only active ingredient of the ADVIL.RTM. Migraine product is ibuprofen. Many migraine sufferers cannot take aspirin, due to digestive disorders, such as acid reflux disease, ulcers, and acid indigestion, and for many such sufferers, ibuprofen alone is not sufficient to lessen the pain or to reduce it to a manageable level. It would therefore be desirable to provide a non-prescription remedy which alleviates migraine symptoms in a manner not accomplished by the currently available "over-the-counter" remedies. Web site: http://www.delphion.com/details?pn=US06440983__ •
Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine Inventor(s): Armellino; Joseph (Chester, NJ), Koslo; Randy (West Windsor Township, NJ) Assignee(s): Bristol-Myers Squibb Company (New York, NY) Patent Number: 5,972,916 Date filed: February 10, 1998 Abstract: The invention provides a safe and economical nonprescription combination of acetaminophen, aspirin and caffeine (APAP/ASA/CAF) for use in treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities. The use of the APAP/ASA/CAF combination is also effective in aborting the prodrome phase of a migraine attack. Excerpt(s): The present invention relates generally to compositions and methods used to alleviate the symptoms and pain associated with acute migraine attack. More particularly, the present invention relates to the use of a nonprescription combination of acetaminophen, aspirin and caffeine for treating individuals afflicted with pre-migraine conditions, migraine-associated symptoms and/or migraine pain of mild to severe intensity. An estimated 23 to 25 million Americans--about 18% of women and 6% of men--suffer from migraine pain and migraine-related symptoms.sup.1. Attacks are common, with more than 50% of sufferers experiencing one or more episodes per month.sup.2. Migraine, a heterogeneous disorder, produces a wide spectrum of pain and associated disabilities, both within and among individual sufferers. The spectrum
170 Aspirin
includes mild pain and no disability in approximately 5-15% of migraine attacks, moderate to severe pain and disability in approximately 60-70% of attacks, and incapacitating pain and total disability in the remaining approximately 25-35% of attacks.sup.3,4. Web site: http://www.delphion.com/details?pn=US05972916__ •
Compositions, kits and methods for administration of antilipemic drugs Inventor(s): Kuhrts; Eric H. (Woodside, CA), Morrow; Jason D. (Nashville, TN), Roberts, II; L. Jackson (Nashville, TN) Assignee(s): Lipoprotein Technologies, Inc. (Woodside, CA), Vanderbilt University (Nashville, TN) Patent Number: 5,981,555 Date filed: September 26, 1997 Abstract: The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect. The present method of treating hyperlipemia comprises predosing the patient with a sustained release NSAID or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug at least 2 hours before administering the antilipemic drug. The present compositions and kits for increasing the effectiveness of an anti-platelet aggregating drug contain an NSAID such as aspirin, niacin or a congener thereof, and optionally, a carboxylic acid other than the NSAID, such as citric acid. Excerpt(s): The present invention concerns compositions, kits and methods for administration of antihyperlipidemic (i.e., hypolipemic or antilipemic) drugs, particularly nicotinic acid and its derivatives, which decrease the flushing reaction caused by such drugs. The present invention also concerns compositions, kits and methods for increasing the effectiveness of nonsteroidal anti-inflammatory drugs in inhibiting or preventing platelet aggregation in non-responding patients. Abnormally high levels of circulating lipids (hyperlipidemias) are a major predisposing factor in development of atherosclerosis. Elevated levels of serum cholesterol and cholesteryl esters, which are carried by the beta-lipoprotein or low density lipoprotein (LDL) and lipoprotein (a) (Lp(a)) fractions of serum lipids, are known to be atherogenic. Also implicated in cardiovascular disease are elevated levels of triglycerides, carried mostly in the very low density lipoprotein (VLDL) fraction. Drugs which lower serum lipids (i.e., hypolipemic drugs) frequently are prescribed to retard development of atherosclerotic lesions in individuals exhibiting hyperlipidemias. Many of these drugs are effective when taken regularly, but suffer from poor patient compliance due to unpleasant side effects. Examples of effective but underutilized hypolipemic drugs include the bile acid-binding resins, such as cholestyramine.
Patents 171
Web site: http://www.delphion.com/details?pn=US05981555__ •
Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same Inventor(s): Abbott; John J. (1500 Redfern Dr., Pittsburgh, PA 15241), Heibel; Richard (20 N. Port Royal Dr., Hilton Head Island, SC 29928) Assignee(s): none reported Patent Number: 6,274,170 Date filed: February 18, 1999 Abstract: Compounds comprising multi-vitamins, zinc and an anti-platelet aggregating agent for the treatment of atherosclerotic cardiovascular disease (ASCVD) are disclosed. The compounds are provided in dosage form, and preferably include selected amounts of ascorbic acid, folic acid, vitamin E, vitamin B6 and vitamin B12. The anti-platelet aggregating agent preferably comprises aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment of ASCVD, and possess extended shelf lives. Excerpt(s): The present invention relates to compounds for the prevention and treatment of diseases such as atherosclerotic cardiovascular disease (ASCVD). More particularly, the present invention encompasses a comprehensive approach including the use of antiplatelet aggregating agents in conjunction with certain vitamins and minerals which, in combination, have a positive effect on normalizing elevated homocysteine levels in vivo, and which impact free radicals with the use of anti-oxidants implicated in the initiation of atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in most industrial countries. This disease involves large, medium and small arteries throughout the body. In addition to family history, the atherogenic risk factors are known to include smoking, hypertension, diabetes mellitus, cholesterol abnormalities and homocysteinuria. The presence of each additional risk factor markedly aggravates the potential for development of the disease. Although seemingly diverse, the risk factors all damage the artery wall and effect formation of thrombosis. In the aorta, the largest artery, the artery wall damage may lead to aortic aneurysm or embolism. ASCVD in medium and small arteries can result in sudden occlusion of the vessel or progressive narrowing of the arterial lumen. The symptoms of persons with this disease are dictated by the organs supplied by the effected arteries. Lumenal narrowing of the arteries supplying the heart with blood is called coronary artery disease (CAD). The symptoms include angina, unstable angina, myocardial infarction (MI) and sudden death. Cerebral vascular disease (CVD) symptoms include progressive neural deterioration, transient ischemic attack (TIA), seizures, and cerebral vascular accident (CVA), i.e., stroke. Kidney effects include hypertension, renal infarction and renal failure. Abdominal vascular insufficiency results in abdominal angina and bowel infarction. Peripheral vascular disease (PVD) symptoms include intermittent claudication, gangrene and amputation. Web site: http://www.delphion.com/details?pn=US06274170__
172 Aspirin
•
Dietary supplement and method of treatment for diabetic control Inventor(s): Fine; Stuart A. (Northbrook, IL) Assignee(s): Akesis Pharmaceuticals, Inc. (La Jolla, CA) Patent Number: 5,962,030 Date filed: November 5, 1997 Abstract: A daily nutritional supplement and method of administering it to assist in the metabolism of glucose for patients with diabetes and pre-diabetes is disclosed. The supplement preferably includes anchor components of Chromium Polynicotinate and Picolinate, Vanadyl Sulfate, Vitamin E Natural, Standardized Willow Bark (aspirin), and Magnesium Chloride, Citrate, Fumarate, Malate, Glutorate, and Succinate Complex, Folic Acid, and Alpha-Lipoic Acid. Excerpt(s): The present invention is related to a unique vitamin, mineral, and herbal supplement for the treatment of both type I and II diabetes, and for the prevention of type II diabetes in those individuals with pre-diabetes, or impaired glucose tolerance (IGT). Specifically, the present invention is directed towards a dietary supplement for diabetic control containing a plurality of compounds from the following group: Vanadyl sulfate, Chromium polynicotinate and picolinate, Magnesium chloride, citrate, fumarate, malate, glutorate, and succinate complex, Natural Vitamin E (free 2R, 4'R, 8'R-alpha tocopherol), Standardized Willow Bark (aspirin), Alpha-lipoic acid, and Folic acid. Diabetes has become a leading health care issue in the United States and other industrialized countries, accounting for one seventh of the entire national health care product. The incidence of diagnosed diabetes has increased five-fold in America over the past 35 years, with currently 8 million diagnosed diabetic patients, another estimated 8 to 12 million undiagnosed diabetic individuals, and still an additional 23 million Americans with pre-diabetes, or impaired glucose tolerance (IGT). As the American populace continues its strong trend towards aging, obesity and greater minority representation, the increasing rate of diagnosed diabetes is certain to continue. The tremendous economic and physical toll diabetes extracts from society is, in large part, secondary to both the short and long-term complications of the disease. While there have been great strides made in reducing the short term complications of diabetes, e.g. ketoacidosis, dehydration, and non-ketotic hyperosmolar coma, little, if any, headway has been made in preventing or even minimizing the devastating chronic complications of the disease, e.g. premature atherosclerosis, retinopathy, nephropathy, and neuropathy. Indeed, diabetes has become the leading cause of new cases of blindness in adults in the United States, and now accounts for over a third of all new cases of end-stage renal disease in this country. It is estimated that a diabetic patient's life is shortened by 10 to 15 years, and those years of life are distinguished by a health care tab four times that of a non-diabetic patient. Web site: http://www.delphion.com/details?pn=US05962030__
•
Inhibition of TNF-(.alpha.)-initiated neutrophil response Inventor(s): Serhan; Charles N. (Wellesley, MA) Assignee(s): Brigham and Women's Hopsital (Boston, MA) Patent Number: 6,387,953 Date filed: March 14, 2000
Patents 173
Abstract: The impact of lipoxin A.sub.4 (LXA.sub.4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF.alpha.)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA.sub.4 and ATL analogs each inhibited TNF.alpha.-stimulated superoxide anion generation and IL-1.beta. release by human PMN. Excerpt(s): Lipid and protein mediators of inflammation such as cytokines and chemokines have a profound impact on the formation and actions of each other (Serhan, C. N., J. Z. Haeggstrom, and C. C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147-1158). In particular, the cytokines TNF.alpha. and IL-1.beta. play major roles in inflammation, septic shock and tissue injury. PMN perform a range of well-appreciated specialized functions, including chemotaxis, generation of reactive oxygen species and biosynthesis of potent lipid mediators (Weiss, S. J. 1989. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365376). In this regard, TNF.alpha. stimulates PMN to transcribe and release cytokines such as IL-1.beta., enhances leukotriene biosynthesis, and up-regulates adhesion molecules (Marucha, P. T., R. A. Zeff, and D. L. Kreutzer. 1991. Cytokine-induced IL-1.beta. gene expression in the human polymorphonuclear leukocyte: transcriptional and posttranscriptional regulation by tumor necrosis factor and IL-1. J. Immunol. 147:2603-2608). Since PMN represent approximately 70% of the peripheral blood leukocytes and are in many instances the initial cell type recruited to interstitial sites, they are now considered a significant source of "proinflammatory" cytokines including TNF.alpha. and IL-1.beta. These as well as other PMN-derived cytokines and chemokines can, in turn, affect the course of inflammatory and immune responses (Lloyd, A. R., and J. J. Oppenheim. 1992. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunology Today 13:169-172). In certain clinical settings, including respiratory distress syndrome, myocardial reperfusion injury, gout and rheumatoid arthritis, PMN contribute to ongoing damage of host tissues (Weiss, S. J. 1989. Tissue destruction by neutrophils. N. Engl. J Med. 320:365-376; Hachicha, M., P. H. Naccache, and S. R. McColl. 1995. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein-1 and interleukin-8 by human neutrophils: A possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J. Exp. Med. 182:2019-2025; Hansen, P. R. 1995. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91:1872-1885). Thus, it is of interest to understand the complex relationships between lipid mediators and TNF.alpha.-evoked PMN responses in order to gain insight for new approaches in controlling these events. The present invention pertains to methods for modulating a disease or condition associated with TNF.alpha. initiated polymorphoneutrophil (PMN) inflammation. The methods include administration to a subject, an effective anti-inflammatory amount of a lipoxin analog having the formula described infra, such that the TNF.alpha. initated PMN inflammation is modulated. The present invention also pertains to methods for treating TNF.alpha. initiated polymorphoneutrophil (PMN) inflammation in a subject. The methods include administration of an effective anti-inflammatory amount of a lipoxin analog described infra, such that TNF.alpha. initiated polymorphoneutrophil (PMN) inflammation is treated. Web site: http://www.delphion.com/details?pn=US06387953__
174 Aspirin
•
Method of treating commercial grade products to remove undesirable odors and flavors Inventor(s): Kuhn; Dale F. (Shawnee Mission, KS) Assignee(s): Tillin, Inc. (Shawnee Mission, KS) Patent Number: 6,303,172 Date filed: September 26, 2000 Abstract: A method of treating antimicrobial products, dairy products, pharmaceutical products and other products having offensive tastes or odors to remove the off-odors and off-tastes from the products. The method involves exposing a selected commercial grade product that contains a small amount of free acid impurities to an ammonia gas. The ammonia gas reacts with the free acid impurities to convert the free acids into ammonium salts, thereby reducing or eliminating the off-flavor and off-odor of the product. The products to be treated include antimicrobial products selected from the group consisting of sodium benzoate, calcium benzoate, potassium benzoate, sodium diacetate, paraben, niacin, calcium acetate, calcium diacetate, sodium sorbate, calcium sorbate, potassium sorbate, sodium propionate, calcium propionate, potassium propionate and mixtures thereof; dairy products selected from the group consisting of casein, whey, skim milk powder, and calostrum; pharmaceutical products selected from the group consisting of acetaminiphen, aspirin, ibuprophen, dextromethorphan hydrobromide, guaejenesin, paracetamol, and sodium erythorbate; and various other products selected from the group consisting of butylate hydroxy tolulene, polydextrose powder, sodium acid sulfate, and sodium diacetate. The common characteristic of the commercial grades of each of these products is that they contain a small amount of free acid impurities that react favorably with ammonia gas. Excerpt(s): The present invention relates generally to methods of treating antimicrobial products, dairy products, pharmaceutical products, and other products having offensive odors or tastes to remove the off-odors and off-tastes from the products. The method involves exposing a selected commercial grade product containing a small amount of free acid impurities to an ammonia gas to convert the free acid impurities into ammonium salts, thereby eliminating the offensive odors and/or tastes caused by the free acids. The growth of mold, rope, yeasts and bacteria is a significant problem in packaged or processed foods such as dairy products, margarine, butter, baked goods, fruit and vegetable containing products such as fruit fillings for pies or pastries, and processed meats. The growth of mold, rope, yeasts and bacteria not only significantly reduces the useful shelf life of the product, thus increasing the sellers' direct costs due to stale or moldy products that cannot be sold, but also requires that certain items be refrigerated during shipping and/or at the marketplace, which causes additional indirect expenses for the end seller of the product. Various food preservatives are on the market. However, when used at concentrations that effectively increase shelf life, the prior art food preservatives impart an off-flavor, odor, color and/or texture to the final product that is undesirable. Consequently, a need exists for a food preservative that increases the shelf life of the product while not requiring refrigeration or causing offflavor, color, odor and/or texture. Web site: http://www.delphion.com/details?pn=US06303172__
Patents 175
•
Method of using aspirin to implant an embryo Inventor(s): Macnamee; Michael (Cambridge, GB) Assignee(s): Applied Research Systems ARS Holding N.V. (Curacao, NL) Patent Number: 5,760,024 Date filed: June 23, 1995 Abstract: The invention provides the use of a cyclooxygenase inhibitor such as the nonsteroidal anti-inflammatory agent aspirin in the manufacture of a medicament to enhance perfusion of blood through the mammalian, preferably human, uterus. The enhanced perfusion aids embryo implantation in natural or assisted methods of conception. Excerpt(s): This application is a 371 of PCT/GB93/02657 filed Dec. 24, 1993. The present invention is concerned with human conception and embryo development, in particular embryo implantation into the uterine endometrium. In humans, the inability to conceive often causes considerable distress and frequently adults with fertility problems undergo protracted and expensive courses of treatment in an effort to achieve a successful pregnancy. Unfortunately, the failure rate of such treatment remains high. Web site: http://www.delphion.com/details?pn=US05760024__
•
Methods and compositions for producing weight loss Inventor(s): Kuhrts; Eric H. (P.O. Box 387, 1109 Tannery Creek Rd., Bodega, CA 94922) Assignee(s): none reported Patent Number: 6,475,530 Date filed: October 4, 2000 Abstract: Dislcosed are methods and compositions for producing weight loss in a mammal by administration of a composition containing a weight loss effective amount of a noradrenaline stimulating compound such as ephedrine, mahuang (a plant source of ephedrine alkaloids), citrus aurantium (bitter orange), synephrine, norephedrine, psuedophedrine, a methylxanthine, such as caffeine or guarana, and a botanical COX inhibitor such as resveratrol polygonum cuspidatum, scutellaria baicalensis, turmeric, curcumin, rosmary, green tea, ocimum sanctum (holy basil), or ginger, instead of an NSAID such as aspirin, and optionally a free fatty acid reducing compound. The thermogenic formula is coupled with a growth hormone stimulating formulation containing L-arginine or L-omithine, L-lysine, and a free fatty acid reducing agent such as nicotinic acid. The thermogenic formula would preferably be administered in the daytime, and the growth hormone producing formula at nighttime. The two compositions form a system of AM and PM weight loss strategy for the therapeutic intervention of obesity. Excerpt(s): This invention relates to methods and compositions for producing weight loss in mammals. One of the greatest problems confronting modem society in economically successful countries today is obesity. Unfortunately, obesity brings with it the conditions that are ripe for the more serious disease of diabetes. Among the many possible solutions for treating obesity are formulations of weight loss products that work with some of the basic biochemical processes involved in fat metabolism. This process has been exploited through pharmaceutical intervention at the neurocrine level
176 Aspirin
as well as at the level of fat cells themselves, or the way fat cells metabolize fats in brown adipose tissue. Web site: http://www.delphion.com/details?pn=US06475530__ •
Methods for treating thrombotic disorders Inventor(s): Grinnell; Brian William (Indianapolis, IN), Jakubowski; Joseph Anthony (Indianapolis, IN) Assignee(s): Eli Lilly and Company (Indianapolis, IN) Patent Number: 6,071,514 Date filed: June 3, 1998 Abstract: The present invention provides a method of treatment for patients with a variety of thrombotic disorders including, but not limited to, stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. Said treatment is a combination therapy with human aPC and antiplatelet agents including, but not limited to, aspirin (ASA), clopidogrel, ReoPro.RTM. (abciximab), dipyridamole, ticlopidine and IIb/IIIa receptor antagonists. The synergy will result in the ability to reduce the dosages of the agents used in the combination therapy. Excerpt(s): This invention relates to medical science particularly the treatment of thrombotic disorders with activated human protein C in combination with antiplatelet agents. Protein C is a serine protease and naturally occurring anticoagulant that plays a role in the regulation of hemostasis by inactivating Factors Va and VIIIa in the coagulation cascade. Human protein C circulates as a 2-chain zymogen which is activated in vivo by thrombin and thrombomodulin on phospholipid surfaces resulting in activated protein C (aPC). Blood coagulation is a highly complex process regulated by the balance between pro-coagulant and anticoagulant mechanisms. This balance determines a condition of either normal hemostasis or abnormal pathological thrombus formation leading to events such as stroke, myocardial infarction and venous thrombosis. Two major factors control this balance, the generation of fibrin and the activation and subsequent aggregation of platelets. A critical factor controlling both processes is the generation of the enzyme thrombin, which occurs following activation of the clotting cascade. Thrombin is a pro-coagulant enzyme that aggregates platelets and converts circulating fibrinogen to insoluble fibrin, resulting in the formation of a blood clot. Thrombin also functions as a potent anticoagulant since it activates protein C zymogen to activated protein C, which in turn inhibits the generation of thrombin. Thus, through the feedback regulation of thrombin generation, aPC functions as perhaps the most important down-regulator of blood coagulation resulting in protection against thrombosis. Web site: http://www.delphion.com/details?pn=US06071514__
Patents 177
•
Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid Inventor(s): Cefali; Eugenio A. (Two Oakwood Blvd., Suite 140, Hollywood, FL 33020) Assignee(s): none reported Patent Number: 6,469,035 Date filed: July 31, 1997 Abstract: The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduce the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention, the flush inhibiting agents are administered orally one to four times a day, and preferably one to two times per day, for between about 7 to about 14 days prior to the start of the nicotinic acid therapy. Examples of flush inhibiting agents include nonsteroidal anti-inflammatory agents. Aspirin is a preferred flush inhibiting agent and may be orally administered in daily doses of between about 80 mg to about 1000 mg, and preferably between about 80 mg and about 650 mg, and more preferably between about 80 mg and about 325 mg, during the pretreatment period. Also consistent with the present invention, the pretreatment therapy may be continued during and administered concurrently with the nicotinic acid therapy, in which the nicotinic acid is preferably administered once per day as a single dose during the evening hours or before or at bedtime. The nicotinic acid may be administered alone or in combination with HMG-CoA reductase inhibitors as well as other lipid-altering agents, like cholestyramine and colestipol. Excerpt(s): Hyperlipidemia or an elevation in serum lipids is associated with an increase incidence of cardiovascular disease and atherosclerosis. Specific forms of hyperlipidemia include, for example, hypercholesteremia, familial dysbetalipoproteinemia, diabetic dyslipidemia, nephrotic dyslipidemia and familial combined hyperlipidemia. Hypercholesteremia is characterized by an elevation in serum low density lipoprotein-cholesterol and serum total cholesterol. Low density lipoprotein (LDL-cholesterol) transports cholesterol in the blood. Familial dysbetalipoproteinemia, also known as Type III hyperlipidemia, is characterized by an accumulation of very low density lipoprotein-cholesterol (VLDL-cholesterol) particles called beta-VLDLs in the serum. Also associated with this condition, there is a replacement of normal apolipoprotein E3 with abnormal isoform apolipoprotein E2. Diabetic dyslipidemia is characterized by multiple lipoprotein abnormalities, such as an overproduction of VLDL-cholesterol, abnormal VLDL triglyceride lipolysis, reduced LDL-cholesterol receptor activity and, on occasion, Type III hyperlipidemia. Nephrotic dyslipidemia is difficult to treat and frequently includes hypercholesteremia and hypertriglyceridemia. Familial combined hyperlipidemia is characterized by multiple phenotypes of hyperlipidemia, i.e., Type IIa, IIb, IV, V or hyperapobetalipoproteinemia. It is well known that the likelihood of cardiovascular disease can be decreased, if the serum lipids, and in particular LDL-cholesterol, can be reduced. It is also well known that the progression of atherosclerosis can be retarded or the regression of atherosclerosis can be induced if serum lipids can be lowered. In such cases, individuals diagnosed with hyperlipidemia or hypercholesteremia should consider lipid-lowering therapy to retard the progression or induce the regression of atherosclerosis for purposes of reducing their risk of cardiovascular disease, and in particular coronary artery disease.
178 Aspirin
Web site: http://www.delphion.com/details?pn=US06469035__ •
Modifying an atmosphere with an aqueous composition including sodium bicarbonate and acetylsalicylic acid Inventor(s): Fuller; Peter E. (Woods Cross, UT) Assignee(s): Applied Humidity Technologies (West Valley City, UT) Patent Number: 6,106,775 Date filed: September 23, 1999 Abstract: Evaporation devices and associated methods for introducing humidity into an atmosphere. The evaporation device includes a substantially rigid shell encasing an absorbent material and having a plurality of holes extending therethrough to permit air flow between the exterior and interior of the shell. The absorbent material can be a natural or synthetic sponge capable of absorbing and retaining water. After applying water to the evaporation device, it is placed in an environment to which humidity is to be introduced. Evaporation of water can be enhanced by placing a mixture of aspirin and sodium bicarbonate on the absorbent material. Examples of methods for using the evaporation device include placing the evaporation device in produce bins, produce refrigerators, cheese and meat refrigerators, and containers of dry foods, such as cookies and brown sugar. Excerpt(s): The present invention relates to devices and methods for evaporating water or another liquid into an atmosphere. More specifically, the present invention relates to self-contained devices having a shell enclosing an absorbent material and having holes formed therethrough, whereby moisture can be evaporated into the atmosphere, and further relates to methods for using such self-contained devices to supply the humidity to the atmosphere. Over the years, many systems and devices for introducing water vapor into the air or for elevating and maintaining the humidity level in the air have been developed. Electrically powered humidifying devices, which actively vaporize water or otherwise cause it to be evaporated into the air, are perhaps the most widely used. Although such humidifying devices are capable of adequately introducing water vapor into the air in many environments, there are several disadvantages and limitations associated with them. First, electrically powered humidifying devices are typically relatively complex, with moving parts that induce the flow of air or that actively vaporize water. The cost of manufacturing such humidifying devices frequently precludes them from being used in situations where they would otherwise be beneficial. Likewise, the cost of supplying electrical energy further makes their use impractical in many settings. Web site: http://www.delphion.com/details?pn=US06106775__
•
Multivitamin/vascular occlusion inhibiting composition Inventor(s): Moshyedi; Emil Payman (49 Rutland Rd., West Babylon, NY 11704) Assignee(s): none reported Patent Number: 5,770,215 Date filed: January 6, 1997
Patents 179
Abstract: The present invention relates to a vitamin supplement containing from 5% to 1000% of the RDA of vitamins and a therapeutically effective amount of a vascular occlusion inhibiting compound which is preferably aspirin (acetylsalicylic acid). The vitamins are selected from vitamins A, D; E, K, C, thiamin, riboflavin, niacin, niacinamide, B.sub.6, folate, B.sub.12, biotin, pantothenic acid and mixtures thereof. The composition can be in capsule or tablet form, may further contain minerals, herbal extracts, homeopathics or other therapeutic substances, and finds particular utility with regard to cardiac care patients. Excerpt(s): The instant invention relates generally to compositions for inhibiting vascular occlusion in humans and more specifically to compositions for inhibiting vascular occlusion which further contain nutritional supplements. Compositions for inhibiting platelet aggregation are known in the art. For example, U.S. Pat. No. 5,401,730(Sauvage, L.R. et al., 28 Mar. 1995) discloses a method of treating a patient comprising the administration of a combination of acetylsalicylic acid (aspirin), citric acid and thiamine, optionally in further combination with zinc. U.S. Pat. No. 4,491,574 (Seifter, E., 1Jan. 1985) discloses a therapeutic composition comprising aspirin in combination with vitamin A or a precursor of vitamin A to reduce toxicity and ulcerogenesis. Web site: http://www.delphion.com/details?pn=US05770215__ •
Osteoarthritis-associated inducable isoform of nitric oxide synthetase Inventor(s): Abramson; Steven B. (Rye, NY), Amin; Ashok R. (Union, NJ) Assignee(s): Hospital For Joint Diseases (New York, NY) Patent Number: 5,759,836 Date filed: March 27, 1995 Abstract: An novel isoform of inducible nitric oxide synthase (OA-NOS) has been identified in osteoarthritis-affected articular cartilage. Some properties, including molecular weight, are similar to the constitutive isoform of neuronal nitric oxide synthase (ncnos) while other properties share similarity with the previously identified inducible nitric oxide (iNOS). Acetylating agents, such as aspirin and N-acetylimidazole act on both iNOS and OA-NOS by inhibiting their catalytic activities. A method is provided to screen for acetylating agents that inhibit OA-NOS, and the selective inhibition of OA-NOS by inhibitory agents is determined by comparison to a panel of different isoforms of nitric oxide synthase. Excerpt(s): The present invention relates to a novel inducible nitric oxide synthase, to a method of screening compounds that inhibit the catalytic activity of the novel nitric oxide synthase, as well as to the DNA encoding the novel inducible protein, the expression vector, and host cells containing such DNA and antibodies to such a protein. Nitric oxide (NO), a recently acknowledged multifunctional mediator produced by and acting on various cells, participates in inflammatory and autoimmune-mediated tissue destruction. NO is produced by the ubiquitous enzyme nitric oxide synthase (NOS). Inflammatory processes in vivo inter-regulate the expression and function of both inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (Vane et al., Proc. Natl. Acad. Sci. USA 91:2046-2050, 1994; Salvemini, Proc. Natl. Acad. Sci. USA 90:72407244, 1993; Tetsuka et al., Proc. Natl. Acad. Sci. USA 91, 12168-12172, 1994). Therefore, modulation of NO synthesis and action represents a new approach to the treatment of inflammatory and autoimmune conditions (Schmidt and Walter, Cell 78:919-925, 1994).
180 Aspirin
Human chondrocytes exposed to NO showed inhibition of growth, chemotaxis, and induced apoptosis and cell death (Blanco et al., Arthritis Rheum. 37 (Suppl.): S294, 1994; Clancy et al., Arthritis Rheum. 37 (Suppl. 9): S293, 1994!. Stimulation of chondrocytes with IL-1 in vitro is known to induce oxygen radicals, upregulation of iNOS activity and inhibition of matrix synthesis, such as proteoglycan synthesis, which can be reversed by inhibitors of iNOS (Taskiran et al., Biochem. Biophys. Res. Comm. 200:142-148, 1994). Recent studies have indicated that NO directly modulates the activity of COX-2 through a mechanism independent of cGMP (Salvemini et al., 1993, supra). The effect of NO on COX-2 is dose-dependent. Low levels of NO activate COX. In contrast, large amounts of NO by iNOS can inhibit the induction of COX-2 and suppress the formation of COX metabolites. Salvemini and co-workers have recently demonstrated inhibition of inflammatory response by modulation of NO production in various animal models of inflammation. These in vivo studies again demonstrate the direct role of NO in inflammation and tissue destruction. Web site: http://www.delphion.com/details?pn=US05759836__ •
Stabilized aspirin compositions and method of preparation for oral and topical use Inventor(s): Blahut; Natalie (9302 Miccosukee, Tallahassee, FL 32308) Assignee(s): none reported Patent Number: 6,177,413 Date filed: March 3, 2000 Abstract: Aspirin compositions for oral and topical use are stabilized by reaction with potassium hydroxide. Excerpt(s): This invention relates to using potassium hydroxide, KOH, to stabilize acetylsalicylic acid, ASA, salicylic acid, SA, and any other related composition and ascorbic acid for oral and topical use. U.S. Pat. No. 1,349,207 to Galat discloses the use of alkaline solvents to stabilize aspirin compositions in solution and describes salicylic acid and acetic acid as undesirable byproducts of the breakdown of acetylsalicylic acid (ASA). To avoid this breakdown of ASA, anionic exchange materials are used. Galat articulates the general assumption that, in order to stabilize aspirin, one must begin with ASA. Salicylic acid (SA) is closely related to salicin, the earliest form of aspirin found in white willow bark, meadowsweet and other botanicals. American Indian tribes used it in therapeutic baths and teas, as did early Americans. The botanicals are still sold in certain health food stores and used in the same way. Web site: http://www.delphion.com/details?pn=US06177413__
•
Stable aspirin-containing preparations for external use Inventor(s): Hasegawa; Yuichi (Kakogawa, JP), Hisaichi; Shin-ichi (Kagawa-ken, JP), Kawada; Mitsuhiro (Kagawa-ken, JP), Mizobuchi; Noriko (Kochi, JP) Assignee(s): Teikoku Seiyaku Co., Ltd. (Kagawa-ken, JP) Patent Number: 6,268,355 Date filed: April 26, 1999 Abstract: External preparations containing Aspirin which are stored for a long term and superior in dermal absorbability.The preparations are prepared by mixing Aspirin
Patents 181
together with at least one substance selected from an ester of an organic acid ester having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton. Excerpt(s): The present invention relates to a stable external preparation containing Aspirin (acetyl salicylic acid). More specifically, the present invention relates to a technique to store stably an external preparation containing Aspirin for a long term which is characterized in mixing Aspirin together with at least one substance selected from an ester of an organic acid having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton. Aspirin has been used as an antiinflammatoric antipyretic analgesics from of old. It is in general orally administered in form of tablets, granules and so on. Web site: http://www.delphion.com/details?pn=US06268355__ •
Stable gelatin coated aspirin tablets Inventor(s): Patell; Mahesh (Edison, NJ) Assignee(s): Bristol-Myers Squibb Company (New York, NY) Patent Number: 5,750,145 Date filed: July 28, 1995 Abstract: Gelatin coated pharmaceutical dosage units containing, for example, analgesic compounds, such as aspirin, stabilized with a proteolytic enzyme, such as pepsin, are described. Excerpt(s): This invention pertains to stabilized pharmaceutical compositions, more particularly gelatin coated pharmaceutically active dosage units containing a therapeutically active ingredient which is subject to hydrolysis on storage as a result of moisture in the air or in one or more of the components of the dosage unit. It is especially concerned with the stabilization of analgesics such as gelatin coated aspirin tablets. The stabilizing agent is a proteolytic enzyme. The presently preferred stabilizing agent is pepsin. This proteolytic enzyme has been found to be a useful stabilizing agent at remarkably low concentrations. Aspirin, or salicylic acid acetate is a well known therapeutic agent which has been employed for many years as an analgesic as well as for its antipyretic and anti-inflammatory properties. Web site: http://www.delphion.com/details?pn=US05750145__
•
Suppression of thromboxane levels by percutaneous administration of aspirin Inventor(s): Fitzgerald; Desmond J. (Dublin, IE), Keimowitz; Rudolph M. (La Crosse, WI) Assignee(s): Gundersen Clinic, Ltd. (La Crosse, WI) Patent Number: 5,763,425 Date filed: January 8, 1997 Abstract: A method is disclosed for inducing thromboxane suppression in a mammalian subject by percutaneously administering a pharmaceutical composition containing aspirin. Articles useful for practicing the therapeutic methods of the invention are also disclosed.
182 Aspirin
Excerpt(s): The present invention relates to the use of acetyl salicylic acid (aspirin) as an antithrombotic agent and as an agent to treat other medical conditions benefiting from suppression of thromboxane levels. Particularly, the present invention relates to the percutaneous administration of aspirin for inducing such effects and treating such conditions. With the recognition of the role of antithrombotic agents in clinical medicine, investigators have pursued their efficacy, optimal dose, route of administration and safety. Aspirin has been found to be an effective antithrombotic agent in patients with cerebrovascular disease and ischemic heart disease. Aspirin may also have other antithrombotic applications. Although aspirin has become widely used as an antithrombotic agent, it still exhibits undesirable side effects, including gastrointestinal toxicity which is probably dose related. To induce its suppressive effects, aspirin irreversibly acetylates the enzyme cyclo-oxygenase found in platelets and vascular wall cells ›Burch et al., J. Clin. Invest. 61:314 (1978); Majerus, J. Clin. Invest. 72:1521 (1983); Roth et al., J. Clin. Invest. 56:624 (1975)!. Cyclo-oxygenase converts arachidonic acid to thromboxane-A.sub.2 (TXA.sub.2) in platelets and to prostaglandin-I.sub.2 (PGI.sub.2 or prostacyclin) in vascular walls ›see for example, FitzGerald et al., J. Clin. Invest. 71:676 (1983); Preston et al., N. Engl. J. Med. 304:76 (1981)!. TXA.sub.2 induces platelet aggregation and vasoconstriction, while PGI.sub.2 inhibits platelet aggregation and induces vasodilation. In other words, aspirin can have both an antithrombotic effect (by reducing TXA.sub.2 production) and a thrombogenic effect (by reducing PGI.sub.2 production). As a result, striking an appropriate balance between aspirin's effects on TXA.sub.2 and PGI.sub.2 production has been a goal of aspirin therapy under these circumstances. Web site: http://www.delphion.com/details?pn=US05763425__ •
Synthesis method of nitroxymethylphenyl esters of aspirin derivatives Inventor(s): Del Soldato; Piero (Milan, IT), Garufi; Michele (Milan, IT) Assignee(s): Nicox S.A. (Paris, FR) Patent Number: 6,512,137 Date filed: July 17, 2001 Abstract: The invention describes a method for the synthesis of nitroxymethylphenyl esters of aspirin derivatives. Excerpt(s): The present invention relates to an improved synthesis for obtaining (nitroxymethyl)phenyl esters of aspirin derivatives. These esters have interesting pharmacological and therapeutical properties; specifically they show an improved systemic and local tolerability, at the level of the gastric mucosa (WO 95/030641) and they are more effective as antithrombotic medicines (WO 97/16405). It is known in the prior art that the (nitroxymethyl)phenyl esters of the aspirin derivatives are prepared by reacting (nitroxymethyl)phenol with the aspirin derivative in the acid form (WO 97/16405). Web site: http://www.delphion.com/details?pn=US06512137__
Patents 183
•
System for transdermal delivery of pain relieving substances Inventor(s): Toppo; Frank (8733 Cremonia Dr., Las Vegas, NV 89117) Assignee(s): none reported Patent Number: 5,985,860 Date filed: June 7, 1994 Abstract: Compositions for pain relieving non-steroidal anti-inflammatory drugs and/or medicaments such as ibuprofen, methotrexate, capsaicin, diphenhydramine, aspirin, methyl-nicotinate and other medicaments largely soluble in oil, alcohol, and/or water, are produced for transdermal delivery. The composition is manufactured by admixing an appropriate amount of oil surfactant with an appropriate amount of pharmaceutically approved co-solubilizer alcohol to establish a non aqueous phase. The oil surfactant may be a polyethoxylated oil such as castor oil. The co-solubilizer solubilizer may be isopropyl alcohol or virtually any other alcohols except for methanol. Thereafter, an appropriate amount of distilled water is slowly added to the homogeneous or non-aqueous phase to further reduce viscosity. The final admixture is a clear, oil-continuous solution having a viscosity no greater than 850 centistokes as measured by the VST Hoppler method at 25 degrees Celsius. The composition produced has the capacity to affect the individual surface skin cells (corneocytes) and allow the passage of medicaments to sub-dermal afflicted areas deep within the skin. Excerpt(s): The present invention relates to a composition, and method of manufacture thereof, for transdermal delivery of pain relieving substances directly to afflicted areas of the body. Debilitating diseases such as rheumatoid arthritis and osteoarthritis afflict 37 million people in the United States. The Arthritis Foundation estimates that 10% of the population of the world and 25% of the population of the United States suffer from arthritis to some degree. Fourteen million work days are lost each year in the United States by arthritis victims. Arthritis is a disease symptomized by painful joints stemming from inflammation in the joint region. Arthritis attacks young, middle-aged and old people alike. Due to the severity of this disease a number of nonsteroidal antiinflammatory drugs (NSAIDs) have been developed for the treatment of generalized muscle and joint aches, and for the pain of arthritis. aspirin (acetylsalicylic acid), ibuprofen (2(-isobutylphenyl) propionic acid), methotrexate (N-[4-[(2,4 diamino-6pteridinyl)-methyl]methylamino]benzoyl)-L-glutamic acid), capsaicin (8 methylvanillyl-nonenamide) and diphenhydramine (2-(diphenyl-methoxy)-N,Ndimethylethylamine hydrochloride) are only a few of the medicaments that are available in prescription and over the counter formulations for the alleviation of pain. Web site: http://www.delphion.com/details?pn=US05985860__
•
Tablets or biologically acceptable implants for long-term antiinflammatory drug release Inventor(s): Pinkus; A. George (Robinson, TX) Assignee(s): Baylor University (